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Abstract 
 
This thesis describes a study into the formulation, manufacture and characterisation of 
mini-tablets and inserts for ocular use.  Powder-based mini-tablets were formulated 
using the antibiotic chloramphenicol and a range of polymers.  The effect of powder 
particle size on the quality of the products was investigated and was significant only for 
drug release from polyethylene oxide 8M mini-tablets.  Transition temperature 
microscopy was used to assess drug distribution across the surface of the mini-
tablets.  Good contact of the nano-probe with the mini-tablet surface was the determining 
factor in the quality of the images created, with the residual particle shape after 
compaction playing a significant role. 
 
A novel approach to the manufacture of mini-tablets using 3-D printing was 
investigated.  The fused deposition modelling approach was unsuccessful due to the 
difficulty in producing extrudates of the required polymers.  Stereolithography was used 
to prepare a range of formulations, with polyethylene glycol (PEG) diacrylate as the base 
material and phenylbis (2,4,6-trimethylbenzoyl) phosphine oxide as photoinitiator.  The 
quality of the 3-D printed tablets was variable and dependent on the relative content of 
these two ingredients and the equipment settings.  The 3-D printed mini-tablets showed 
a slow first-order drug release profile, which was increased by the inclusion of pore 
formers such as low molecular weight PEG. 
 
The applicability of the stereolithography approach for 3-D printing of individualised 
ocular inserts was investigated.  A cranial MRI scan of an adult male human was used, 
with permission, to generate a 3-D image of the eye, from which a personalised ocular 
insert was produced.  A matching personalised flow-through dissolution chamber was 
constructed, in order to enable to assess the drug release profile from the 
 ii 
 
inserts.  Similarly to the 3-D printed mini-tablets, the drug release followed a slow first-
order profile, and was increased by the presence of pore formers in the insert. 
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Introduction 
 
1.1  Overview 
 
Ocular diseases have always been one of the common problems faced by patients 
around the world. However, relatively little research has been conducted into advanced 
ocular dosage forms, especially when compared to the amount of work expended on oral 
drug delivery. Most ocular treatments are still developed as liquids and applied as eye 
drops, thus accounting for 90% of the marketed ophthalmic formulations. This is because 
eye drops are easy to be administered and have reasonably good patient compliance 
(Patel et al., 2013a). However, eye drops are generally considered to be an ineffective 
dosage form, with a few major disadvantages such as the low ocular bioavailability of the 
drug due to fast drainage, reflex blinking and lacrimation (Patel et al., 2013a). 
 
Although eye drops are still the most common ocular treatment, some novel and 
advanced dosage forms are being developed, which aim to deliver drugs for a longer 
period of time (extended release), which should enhance patient compliance by reducing 
administration frequency. Two possible formulation strategies that will be studied here 
are mini-tablets and inserts, which will be discussed later in the Chapter. 
 
This Chapter will provide some context for the work conducted in this thesis. Initially, eye 
anatomy and common diseases will be considered. Following that, the manufacturing 
techniques used to prepare the formulations will be considered along with the analytical 
techniques to assess their characteristics and behaviour. Finally, the aims and objectives 
of the thesis will be presented. 
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1.1.1  Eye anatomy 
In order to understand eye diseases, a knowledge of eye anatomy and functions is 
required. Figure 1.1 shows the anatomy of human eye. 
 
 
Figure 1.1  Eye anatomy (James, 2012). 
 
The eye is generally regarding as being composed of two segments. The anterior 
segment is generally regarded as being everything forward from the lens and the 
posterior segment is regarded as being everything behind the lens. Within the anterior 
segment, there are two chambers, named the anterior and posterior chambers. The 
anterior is located between the cornea and the iris while the posterior is the small area 
between the iris, lens and ciliary body. Both chambers are filled with aqueous humour 
(James, 2012). This aqueous humour is partially responsible for maintaining the shape of 
the eyeball. It also has the functions of moisturising and providing nutrients to the 
anterior segment structures of the eye (Rawas-Qalaji and Williams, 2012). Meanwhile, 
vitreous humour (usually just called the vitreous) occupies the bulk of the posterior 
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segment of the eye between the lens and retina (James, 2012). The vitreous is 
composed of 99 % water and contains collagen fibrils and hyaluronan with a gel-like 
consistency (Batterbury et al., 2009). Its function is to provide physical stability to the 
eye, such as its function as a shock absorber, and ensure that the retina remains 
attached at the back of the eye. 
 
The surrounding eye structures also comprises of three main layers which are fibrous, 
vascular and neural. The fibrous layer consists of the sclera and the cornea, the vascular 
layer consists of the choroid, the ciliary body and the iris, and neural layer consists of the 
retina. The sclera's functions are to give the shape of the eyeball, protect the internal 
structure of the eye and to provide a surface for the attachment of ocular muscles, while 
the cornea's function is refraction and transmission of light and protection against ingress 
of materials from the environment. Meanwhile, most of the eye's blood vessels are 
located in the vascular layer. This layer forms the blood-ocular barrier, which controls the 
movement of substances into the eye from the blood and vice versa. For the neural 
layer, the retina converts the focused light into nerve impulses and allows the individual 
to have sight (Rawas-Qalaji and Williams, 2012). 
 
1.1.2  Ocular diseases 
There are a large number of eye diseases in the world but only three of the common 
ocular diseases will be covered in this Chapter. The diseases are conjunctivitis, cataracts 
and glaucoma. Conjunctivitis is the most common ocular disease in the world. 15 % of 
ocular diseases diagnosed in United Kingdom were caused by allergic conjunctivitis, 5 % 
were caused by acute bacterial conjunctivitis and 20 to 30 % were caused by viral 
conjunctivitis (Wormald et al., 2003). Meanwhile, according to the National Eye Institute 
based in United States of America (USA), 2.7 million of Americans have glaucoma and 
another 24 million are affected by cataracts. These numbers are estimated to increase 
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up to 4.3 million and 38.7 million of Americans suffering from glaucoma and cataracts, 
respectively, by year 2030 (NEI, 2014). 
 
1.1.2.1  Conjunctivitis 
"Conjunctivitis" is defined simply as the inflammation of the conjunctiva and is usually as 
a result of surface infection of the conjunctiva. This then leads to dilatation of the 
superficial conjunctival blood vessel, resulting in hyperaemia and oedema of the 
conjunctiva with discharge (Leibowitz 2000), so the patient presents will a red eye and a 
sticky discharge. There are four different types of conjunctivitis: viral, bacterial, 
chlamydial and allergic conjunctivitis, as summarised in Table 1.1. Conjunctivitis is 
treated via repeated topical applications of an anti-infective agent or an anti-allergic 
agent, generally applied in the form of eye drops. 
 
Table 1.1  Summary of four types of conjunctivitis diseases (Leibowitz 2000, James, 
2012). 
Type Cause Treatment 
Viral 
conjunctivitis 
- Viral infection (adenovirus, 
Coxsackie, picornavirus). 
- Self-limiting. 
- Topical antibiotic. 
Bacterial 
conjunctivitis 
- Bacterial infection 
(Staphylococcus, Streptococcus, 
Pneumococcus, Haemophilus). 
- Self-limiting. 
- Topical antibiotic. 
Chlamydial 
conjunctivitis 
- Chlamydia trachomatis. - Tetracycline. 
- Erythromycin. 
- Doxycycline. 
- Azithromycin. 
- Entropion (require surgical 
correction). 
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- Trichiasis (require surgical 
correction). 
Allergic 
conjunctivitis 
- Pollen. 
- Animal dander. 
- Dust. 
- Mast cell stabilisers (cromolyn 
sodium, loxodamide 
tromethamine, nedocromil). 
- Antihistamines (levocabastine 
hydrochloride, antazoline, 
pheniramine, olopatidine). 
 
1.1.2.2  Cataracts 
"Cataracts" is the term used when the lens suffers loss of clarity, which have a 
subsequent effect in the quality of vision. Cataracts normally occur in older patients and 
in this case are referred to as "age-related cataracts". However, cataracts can also be a 
consequence of other ocular or systemic diseases, such as trauma, uveitis, high myopia, 
topical medication and intraocular tumour, or inherited in an autosomal dominant fashion 
(Batterbury et al., 2009, James, 2012). 
 
There are few symptoms that might indicate that the patient has cataracts, such as 
painless loss of vision, glare and a change in refraction. Cataracts also cause amblyopia, 
a failure of visual maturation, in the case of infantile cataracts. This happens because the 
retina is deprived of a formed image during the visual development stage (James, 2012). 
The only treatment currently available for cataracts is through surgery. However, a 
double-blind study performed by Olmedilla et al. (2003) for the period of 2 years on two 
dietary supplements (lutein and α-tocopherol) and placebo found that lutein supplement 
improved visual performance of patients with age-related cataracts. Cataracts are 
removed surgically, so there is no direct pharmaceutical treatment.  However, post-
operative antibiotic cover may be required and would be applied topically. 
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1.1.2.3  Glaucoma 
Glaucoma is caused by the build-up of ocular pressure on the optic nerve head, which 
then damages the optic nerve (James, 2012). Glaucoma can be classified into four 
types: primary open angle, primary closed angle, secondary and congenital glaucoma. 
Table 1.2 shows the difference between the glaucoma types. Glaucoma is treated via 
repeated topical applications of the appropriate agent, generally applied in the form of 
eye drops. 
 
Table 1.2  Summary of four types of glaucoma (James, 2012, Batterbury et al., 2009). 
Type Symptom Treatment 
Primary open angle 
glaucoma 
- Optic disc cupping. 
- Visual field loss. 
- Open anterior chamber 
angle. 
- Raised intraocular 
pressure. 
- Topical (prostaglandin 
derivatives, beta-blockers, 
carbonic anhydrase 
inhibitors, alpha-agonists) 
Primary closed angle 
glaucoma 
- History of headache, 
blurring and coloured 
haloes around bright lights. 
- Unilateral visual loss, red 
eye, cloudy cornea and 
oval pupil. 
- Systemic acetazolamide. 
- Topical pilocarpine. 
- Beta-blockers. 
Secondary glaucoma -May be open or closed 
angle glaucoma. 
- Causes are uveitis, 
aphakia, cataracts and 
retinal ischemia. 
- Topical steroid. 
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Congenital glaucoma - Buphthalmos (eye 
enlargement in infant). 
- Surgical. 
 
1.1.3  Conventional ocular drug delivery 
Most ocular treatments used currently are liquids and applied as eye drops. However, 
there are a few other conventional ocular drug delivery systems used to treat ocular 
diseases, such as emulsions, ointments and suspensions. These conventional ocular 
drug delivery systems have their own advantages and disadvantages regarding their 
ease of application and the therapeutic levels of the drug achieved in the eye, as 
summarised in Table 1.3. 
 
Table 1.3  Summary of advantages and disadvantages of conventional ocular drug 
delivery (Ghate and Edelhauser, 2006, Patel et al., 2013a). 
Ocular drug delivery 
system 
Advantages Disadvantages 
Eye drops - Easy to apply. 
- Reasonable patient 
compliance. 
- Short precorneal residence 
time caused by rapid reflex 
blinking and increased tear 
secretion. 
- Most of the drug is removed 
through the lacrimal drainage 
system and some may be 
spilled onto the cheeks. 
- Repeated application 
necessary. 
Emulsions - Longer precorneal residence 
time. 
- Causes blurred vision. 
- Difficulty in applying an exact 
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- Sustained drug release. dose. 
Ointments - Longer precorneal residence 
time. 
- Sustained drug release. 
- Causes blurred vision. 
- Difficulty in applying an exact 
dose. 
Suspensions - Longer precorneal residence 
time.  
- Sustained drug release. 
- Causes blurred vision. 
- Difficulty in applying an exact 
dose. 
 
There are some serious issues with the current ocular formulations available for the 
treatment of the forward section of the eye, in that it is difficult with all formulations to 
know precisely what dose has been applied to the eye, because of the problems of 
drainage, etc. Although some improvements in retention time have been observed with 
making the formulations more viscous, up to the point of making an ointment, there is a 
consequent issue of blurred vision, which has an obvious impact on the patient's lifestyle.  
For anterior section treatment, implants and devices which target the drug to the back of 
the eye are not suitable, as the drug is delivered to the wrong site, so although a number 
of different devices are under development for posterior-section therapy, there are not 
applicable here.  Hence there is a need for an improved formulation for topical treatment, 
which is easy to use, provides reproducible dosing, has a reliable drug release profile, 
preferably in a once-a-day manner.  In this study, the utility of mini-tablets to provide 
such a formulation is investigated, with particular emphasis on the manufacturing issues 
concerned with this type of formulation. 
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1.2  Formulation and Manufacturing Processes 
 
1.2.1  Tablets 
Tablets are the most prominent pharmaceutical dosage form for drug delivery, occupying 
two-thirds of the global market for pharmaceutical products. They comprise a mixture of 
active pharmaceutical ingredients (API, drugs) and excipients, commonly pressed or 
compacted from a powder into a solid dose (Wu and Seville, 2009). Patients are very 
comfortable with taking tablets orally and they have the advantages of portability and 
stability, particularly when compared to liquid dosage forms. 
 
The first tablet, which was described as a "compressed pill", was produced by William 
Brockeden in June 1844 (Anderson, 2005). The tablet was made by using the tablet 
press that he invented. The invention consisted of three parts: a base which had a 
central pillar with a concave upper surface, a collar that fitted over this and a punch that 
had a concave lower surface which fitted into the top of the collar, as shows in Figure 
1.2. The ingredients were placed in the space above the pillar and the punch then 
inserted and struck with a heavy hammer. 
 
 
Figure 1.2  The press patterned by William Brockeden (Anderson, 2005). 
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Tablet manufacturing equipment has developed significantly since 1844, but still 
essentially uses the same approach of compression of a powder blend between two 
metal punches contained in a die. 
 
The tabletting process is summarised in Figure 1.3 below. The lower punch is fixed at a 
specific position in the die, leaving a void space, which is filled with the powder or 
granule. Pressure is applied by the punches - from the top punch only in the case of a 
single station press and from both punches in the case of a rotary multi-station tablet 
press. Pressure is removed as the top punch is lifted and then lower punch is raised to 
eject the tablet from the die. The weight of the tablet produced is governed by the initial 
position of the lower punch in the die, and the thickness and crushing strength are 
governed by the compression forces applied by the punches. 
 
 
Figure 1.3  A schematic diagram of the tabletting process. 
 
The quality of the powder that is used in the tabletting process is paramount. It must be 
adequately mixed, not subject to segregation and it must flow well to ensure that the 
tablets are of even weight, ensuring good content uniformity and a reproducible clinical 
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effect. The powder can be a simple direct mixture of ingredients or it can be processed 
first, most commonly by wet granulation. 
 
Wet granulation involves the addition of a liquid (with or without binder) to the mixed 
powders, to form a wet mass (Agrawal and Naveen, 2011). The granulation fluid binds 
the powder particles into granules, with the intention of fixing the drug distribution and 
improves the flow characteristics of the product. Direct compression occurs when there 
is no wet granulation process first and the powders are simply mixed and granulated. 
This relies on the excipients flowing well and being compressible as they are, with no 
further treatment. However, direct compression offers the most expeditious method of 
manufacturing tablets because it required the least handling of materials, involves no 
drying step, and thus is the most energy-efficient method. It is also the fastest method of 
tablet production. 
 
As time goes by, people are starting to be concerned about the size of tablets, especially 
for children. There are concerns and uncertainties about the age at which young children 
can safely swallow orally administered solids, such as conventional tablets and capsules 
(Nunn and Williams, 2005). As the result, mini-tablets have been proposed as a novel 
method to overcome those problems. 
 
1.2.1.1  Mini-tablets 
Conventional tablets are usually round and at least 7 mm in diameter, whilst mini-tablets 
are smaller with diameter equal or smaller than 2 to 3 mm (Lennartz and Mielck, 1998). 
These mini-tablets can be filled into hard gelatin capsules for the production of a 
sustained release multiple unit dosage form which has definite advantages over single 
unit dosage forms, such as lower risk of dose dumping, less inter- and intra- subject 
variability, high degree of dispersion in the digestive tract thus minimising the risks of 
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high local drug concentrations (Bechgaard and Nielsen, 1978, Follonier and Doelker, 
1992).  
 
Mini-tablets showed a few advantages compared to irregularly shaped units such as 
granules in subsequent coating steps. This is because mini-tablets can be coated 
reproducibly with less coating material compared to granules due to their constant 
surface area, smooth surface and high mechanical strength (Munday, 1994). Mini-tablets 
can also be an alternative for the pellets because they are easy to be manufactured, and 
the dimensions and weight of the mini-tablets with smooth surface can be controlled (De 
Brabander et al., 2000). 
 
The preparation of mini-tablets is of rising importance in paediatrics due to new 
European regulatory requirements on products for paediatric use. Clinical studies have 
revealed that even children as young as 2 years old are able to swallow mini-tablets of 3 
mm diameter (Thomson et al., 2009). Therefore, rational development of mini-tablets is 
of high importance with particular interest in robust mechanical properties and high drug 
loads. 
 
Recently, Tissen et al. (2011) managed to prepare mini-tablets with a 1 mm diameter on 
a rotary tablet press using three model drugs of different compression characteristics: 
quinine hydrochloride, ibuprofen and spray-dried gentian extract. Depending on the 
individual drug substance, mini-tablets were produced by direct compression or after roll-
compaction/dry granulation. They successfully produced 1 mm mini-tablets by direct 
compression (90% quinine hydrochloride; 90% dried gentian extract) and after roller 
compaction (70% ibuprofen).  
 
Mini-tablets can either be filled into hard capsules or compacted into larger tablets. The 
Chapter 1 
 
 
14 
 
larger tablets will release the mini-tablets as multiple smaller individual dosage forms 
after disintegration. The development of multiple unit dosage forms that integrated into 
tablets is gaining attention compared to hard gelatin capsules because of the higher 
production costs of capsules (Ghebre-Selassie, 1994). Mini-tablets can maintain their 
structure and shape in a more reproducible way once they have been compressed into a 
tablet compared to normal pellets or granules. This is because of their size uniformity, 
regular shape, smooth surface, low porosity and high mechanical strength. 
 
Lopes et al. (2006) have developed a biphasic oral delivery system by compressing mini-
tablets into a tablet dosage form. The compressed mini-tablets showed slight 
deformation and no fragmentation. Because of their physical characteristics, mini-tablets 
tend to keep their integrity after compression, making the fracturing process of these 
subunits more difficult. 
 
1.2.1.2  Ocular mini-tablets 
Most of the treatments of eye involving the usage of drugs in liquid form. This is due to 
their easy administration. However, eye drops are considered to be a fairly primitive and 
ineffective dosage form with considerable disadvantages which are the low bioavailability 
of the eye drops due to fast drainage, reflex blinking and lacrimation. Since eye drops 
need to be applied frequently to maintain the therapeutic drug level, they may cause 
adverse effects. According to Arıcı et al. (2000), long-term use of eye drops leads to 
toxic side effects, cellular damage at the ocular surface and reduction in tear secretion 
function and it is irreversible. This is probably due to the preservatives that are used in 
the preparation of eye drops. 
 
To enhance the amount of active substance reaching the target tissue or exerting a local 
effect in the fornix, the residence time of the drug in the tear film should be lengthened. 
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Various methods were investigated and developed to increase the drug bioavailability by 
prolonging the contact time between drug and corneal-conjunctival epithelium but most 
of them have disadvantages. 
 
One of the strategies is to increase the viscosity of the vehicle by adding viscosity 
modifiers to the formulation. However, only a small improvement of the retention time of 
the drug in the fornix is usually observed (Ludwig and Van Ooteghem, 1992). Highly 
viscous gels and ointments on the other hand provided a sustained contact with the eye 
surface, but caused a sticky sensation and blurring of vision and induced reflex blinking 
due to their irritating properties (Sintzel et al., 1996). 
 
A further approach to optimising ocular dosage forms was the implementation of the 
mucoadhesive concept. Interactions of suitable natural and synthetic polymers with 
mucins were evaluated (Saettone and Salminen, 1995). The use of films or inserts was 
proposed, to allow drug release over a long period of time. Inserts and collagen shields 
were very effective because of less frequent administration and absence of additives. On 
the contrary, insoluble inserts had to be removed manually, as they are not eliminated 
naturally. 
 
To overcome these problems, ocular mini-tablets have been suggested to replace the 
function of eye drops. Recently, ocular ciprofloxacin-containing mini-tablets with diameter 
of 2 mm were developed and optimized, as shown in Figure 1.4 (Weyenberg et al., 
2003, Mortazavi et al., 2010).  
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Figure 1.4  2 mm diameter mini-tablets. 
 
The mini-tablet is placed in the fornix as showed in Figure 1.5. After application of the 
mini-tablet, lacrimation occurred almost immediately. In time, the mini-tablet will be 
slowly dissolved and turn into viscoelastic gel that might cause blurred vision 
(Weyenberg et al., 2003). Compared with the use of films or inserts, there is no need to 
remove the mini-tablets as they will dissolve and be eliminated naturally. 
 
 
Figure 1.5  Dissolved mini-tablets in the fornix (Weyenberg et al., 2004b). 
 
Since the formulation is intended for ocular use, it is important to sterilise the dosage 
form. In studies by Weyenberg et al. (2004a), two sterilisation techniques that are 
suitable for mini-tablets were compared, i.e. gamma-irradiation and dry heat sterilisation. 
They concluded that gamma-irradiation is the most suitable because the properties of 
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gamma-irradiated mini-tablets were the same as the non-sterilised tablets. 
 
Meanwhile, El-Gawad et al. (2012) conducted a study on piroxicam-loaded ocular mini-
tablets investigating the drug release profiles and the permeation across ocular 
membranes to distal sites. The in-vitro and ex-vivo permeation studies were conducted 
using Franz cells, with both biological and synthetic membranes, and porcine eyes, 
respectively. From the study, they concluded that mini-tablets, applied to the fornix area 
at the front of the eye, can be used to provide sustained delivery of the drug to posterior 
eye segments. 
 
All the ocular mini-tablets manufactured in previous studies were made from 
combinations of biodegradable, water soluble and water insoluble excipients. However, 
none of the studies done using water soluble excipients only. Since the mini-tablets will 
be applied onto the eye, formulation using water soluble excipients only should be taken 
into consideration so the whole mini-tablets would dissolve after they come into contact 
with tears. 
 
1.2.2  Hot Melt Extrusion 
Hot melt extrusion (HME) is the process of applying heat and pressure to melt a polymer 
and force it through an orifice in a continuous process. This technique has been used 
widely in plastic, rubber and food industries since 1930s (Rauwendaal, 2001); whereas 
its application has only become popular in the pharmaceutical field in recent years. 
However, HME papers and patents issued worldwide for pharmaceutical systems have 
increased since early 1980s (Repka et al., 2008). 
 
Generally, the extruders consist of single or twin rotating screw inside a stationary 
cylindrical barrel, as shows in Figure 1.6. Single screw extruders are primarily used for 
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melting and conveying polymers to extrude them into continuous shapes, whereas twin 
screw extruders are used for melting and mixing polymers and for devolatilisation 
(Madan and Madan, 2012). Twin screw extruders may either be co-rotating or counter-
rotating. 
 
 
Figure 1.6  Single and twin screw extruder barrel. 
 
The barrel is normally manufactured in sections, which are bolted or clamped together. A 
die is connected to the end of the barrel which will determines the shape of the extruded 
product (Chokshi and Zia, 2004). Figure 1.7 shows a schematic diagram of HME twin 
screw process.  
 
 
Figure 1.7  Hot melt extrusion with twin screw process (Maniruzzaman et al., 2012). 
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The polymers, with or without drug, are fed through a hopper and pumped through a die 
connected to the end of the barrel, by rotating screws under elevated temperature. 
Extruders provide extensive mixing and agitation that causes de-aggregation of the 
suspended particles in the molten polymer resulting in a uniform dispersion (Patel et al., 
2013b). 
 
Since the production of pharmaceutical formulations requires homogeneous and 
consistent mixing of multiple formulation ingredients, a twin screw is preferred as the 
rotation of the intermeshing screws provides better mixing to produce homogeneous 
solid containing finely dispersed API particles, or a solid-solution of API in polymer 
(Chokshi and Zia, 2004). HME offers several benefits over the conventional methods as 
well as some disadvantages which has been summarised in Table 1.4. 
 
Table 1.4  Advantages and disadvantages of HME (Patel et al., 2010, Maniruzzaman et 
al., 2012). 
Advantage Disadvantage 
Increase solubility and bioavailability of 
water insoluble compounds. 
Thermal process (drug/polymer stability). 
Economic continuous process with fewer 
processing steps. 
Flow properties of the polymer are 
essential to processing. 
Solvent-free manufacture. Limited number of available polymers. 
High mixing efficiency which produce 
better content uniformity in extrudates. 
 
Short processing time.  
Easily controlled process parameters.  
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1.2.3  3D Printing 
3D-printing is a technique of making three dimensional objects from a digital file. The 
technique is becoming a popular research technology in pharmaceutical field, including 
research into tablet manufacturing (Khaled et al., 2014, Wang et al., 2016). The 
technique has generated interest within the pharmaceutical field because of its ability to 
fabricate and tailor drug delivery system accurately at a relatively low cost (Jonathan and 
Karim, 2016). Recently, the US Food and Drug Administration (FDA) approved the first 
3D-printed tablets for the treatment of epilepsy (Szczerba, 2015). The FDA approval 
indicates the possibility of 3D-printing becoming one of the important manufacturing 
technique in pharmaceutical field. 
 
The 3D-printing process starts with making the 3D design of the desired object. The 3D 
design is made using computer aided design (CAD) file using a 3D modelling application 
or software. There are a few free 3D modelling applications or software that are currently 
available such as Tinkercad, SketchUp Make, FreeCAD and many more. The 3D design 
can also be created using MRI image (Herrmann et al.) and 3D scanner (Arayici, 2007). 
The 3D design file created using those applications or software is saved in an .STL 
format and then uploaded to the 3D-printer for the printing process. There are several 
types of 3D-printer but the most commonly used are fused deposition modelling (FDM) 
and stereolithography apparatus (SLA) printers.  
 
1.2.3.1  FDM printer 
FDM printer is the most popular 3D-printer in the market because of its cheaper price 
and printing materials, compared to the SLA printers. This technique was developed and 
patented by Crump (1992) and commercialised in 1992 by Stratasys Inc. (Chua et al., 
2003). A thermoplastic filament, such as polylactic acid (PLA) is commonly used in the 
printing process. The filament is heated to its melting point to extrude the filament and 
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ejected through the nozzle attached to the extruder. The nozzle moves in both the 
horizontal and vertical directions while laying down the molten filament layer by layer, to 
create the 3D object. 
 
A few studies have been performed integrating FDM printing with HME. HME was used 
to extrude the polymer which was then used as a filament with the FDM printer (Sandler 
et al., 2014, Goyanes et al., 2015). 
 
1.2.3.2  SLA printer 
The SLA technique is the oldest 3D-printing technique, developed and patented by (Hull, 
1986). The manufacturing of the object is based on the solidification of a liquid resin by 
photopolymerisation, also known as the curing process. Photopolymerisation is a 
process in which light initiates a chain reaction, causing monomers to form polymers. A 
laser is used to cure the photopolymer while shaping it into an object.  
Wang et al. (2016) successfully printed tablets for oral modified-release dosage form 
using different grades of polyethylene glycol diacetate (PEGDA) with paracetamol and 4-
amino-salicylic acid. SLA printing was also used to manufacture scaffolds for 
multicellular tissue (Ovsianikov et al., 2010) and aortic valve (Hockaday et al., 2012). 
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1.3  Analytical Techniques Used In The Study 
 
1.3.1  Dynamic Vapour Sorption 
Dynamic vapour sorption (DVS) is a gravimetric technique for measuring the rate and 
amount of solvent absorbed by a sample, which is crucial information in the 
pharmaceutical field. For pharmaceutical materials, such as excipients, drug formulations 
and packaging films, the propensity for absorbing moisture is recognised as a critical 
factor in determining their storage, stability, processing and application performance 
(Buckton and Darcy, 1995, Bley et al., 2009).  
 
The DVS analyser is based on a vertical nulling microbalance in which the sample and a 
reference are suspended from the weighing mechanism. The humidity level of the 
chamber is then manipulated and the change in mass is measured. Figure 1.8 showed 
the schematic diagram of DVS. 
 
 
Figure 1.8  Schematic diagram of DVS (Sheokand et al., 2014). 
 
1.3.2  Thermogravimetric Analysis 
Thermogravimetric analysis (TGA) is one of the most common techniques used in  
thermal analysis, whereby changes in mass are used to determine the chemical and 
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physical process that happen during a reactant heating process (Craig and Reading, 
2006). This technique can be applied in the pharmaceutical field to determine 
dehydration, water content, chemical decomposition, thermal stability and lifetime of 
materials (Gaisford et al., 2016, Yee, 2013). 
 
Null-point balances are the typical type of mechanism in most of the TGA instruments. 
These often consist of an electromagnetically beam carrying sample and countermass 
which is suspended from the coil of galvanometer (Gaisford et al., 2016). An attached 
shutter that interrupts a light beam focused on a photocell will detect the beam 
movement whereby imbalance is detected. Figure 1.9 summarised the TGA mechanism 
schematically. 
 
 
Figure 1.9  Schematic diagram of a thermobalance (Gaisford et al., 2016; Craig and 
Reading, 2007). 
 
1.3.3  Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) is the most widely used method of thermal 
analysis within the pharmaceutical field. It is a thermoanalytical technique in which the 
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difference in the amount of heat required to increase the temperature of a sample and 
reference is measured as a function of temperature. The technique usually involves a 
linear heating or cooling signal applied to the sample and the subsequent measurement 
of the temperature and the energy associated with a range of thermal events, such as 
the melting, crystallisation, glass transition and decomposition reactions (Craig and 
Reading, 2006). Figure 1.10 shows a schematic diagram of a DSC cell. 
 
 
Figure 1.10  DSC cell schematic diagram. 
 
The two types of DSC systems commonly in use are power-compensation and heat-flux 
(Nicula, 2002). In power-compensation DSC, the specimen (TS) and reference (TR) 
temperatures are controlled independently using separate (identical) ovens as showed in 
Figure 1.11. The temperature difference between the sample and reference is 
maintained to zero by varying the power input to the two furnaces. This energy is then a 
measure of the enthalpy or heat capacity changes in the test specimen S (relative to the 
reference R). 
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Figure 1.11  Power-compensation DSC. 
 
For heat-flux DSC, the test specimen S and reference material R (usually an empty 
sample pan and lid) are enclosed in the same furnace together with a metallic block with 
high thermal conductivity that ensures a good heat-flow path between S and R (Figure 
1.12). The enthalpy or heat capacity changes in the specimen S lead to temperature 
differences relative to R. These results in a certain heat-flow between S and R because 
of the good thermal contact between S and R. The temperature difference T between S 
and R is recorded and further related to the enthalpy change in the specimen using 
calibration experiments. 
 
 
Figure 1.12  Heat-flux DSC cell. 
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The extension of DSC, known as modulated temperature DSC (MTDSC) was then 
introduced by Reading in the early 1990s (Craig and Reading, 2006). In essence, the 
technique is created by combining the application of a perturbation to the heating 
program of a conventional DSC with a mathematical procedure designed to separate 
different types of sample behaviour.  
 
The temperature programme used in a conventional DSC experiment is based on 
following equation: 
 
T=T0+ βt    Eq. 1.1 
 
where T is temperature, T0 is the start temperature, β is the heating rate and t is time 
(Craig and Reading, 2006). Meanwhile, for MTDSC, the separation procedure can be 
described as follow: 
 
dQ
dt
=Cp∙
dT
dt
+ f(t,T)    Eq. 1.2 
 
where Q is the amount of heat evolved, Cp is the heat capacity, T is the absolute 
temperature, t is the time and f(t,T) is some function of time and temperature that 
governs the response associated with the physical or chemical transformation (Craig and 
Reading, 2006). 
 
Equation 1.2 above displays the total heat flow consisting of two contributions; one which 
is heating rate dependent and one which is absolute temperature dependent. The 
relative effect of these two contributions varies depending on the evaluated transition. 
Heating rate dependent contribution usually has larger transitions and the transition can 
be cycled by alternating heating and cooling, which is called "reversing". Meanwhile, 
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absolute temperature dependent contribution is considered as "non-reversing" because it 
cannot be reversed by the cycling process (Gill et al., 1993). 
 
By separating the total heat flow signal into reversing and non-reversing signals, a clear 
transition can be observed. The reversing signal is used to analyse the melting and glass 
transition temperatures while relaxation, crystallisation and curing can be observed from 
the non-reversing signal (Gill et al., 1993, Reading et al., 1994). 
 
1.3.4  Scanning Electron Microscopy 
Scanning electron microscope (SEM) is a powerful magnification tool that utilises 
focussed beam of electrons to obtain information. The electrons are produced by 
tungsten filament, Schottky emitter or tungsten field-emission tip. The energy range of 
the incident electrons normally between 1 and 30 kV  (Egerton, 2011). 
 
To obtain SEM image, a finely focussed of electrons is strike on the sample surface. The 
beam of electrons is scanned across the sample in a raster scan by scan coils. This 
process is repeated until a desired surface area has been scanned. A signal is received 
above the surface from either analog scanning case or digital systems and stored in a 
computer. The signal is then converted to image (Skoog et al., 2007). 
 
1.3.5  Transition Temperature Microscopy 
In this study, transition temperature microscopy is the only thermal scanning probe 
microscopy technique that has been used. However, in order to understand this 
technique, a brief explanation about atomic force microscopy and localised thermal 
analysis are given.  
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1.3.5.1  Atomic force microscopy 
Atomic force microscopy (AFM) is one of the well-established techniques in powder 
technology. The AFM has been used to image the surfaces of various organic crystals 
(Danesh et al., 2000). AFM data is matrix of data points, which enables quantitative 
roughness and height measurements (Luo et al., 2001). The disadvantages of AFM are 
the small measurement area, slow speed and the need for flat samples. 
 
AFM provides a 3D profile of the surface on a nanoscale, by measuring forces between 
a sharp probe (<10 nm) and a surface at very short distance (0.2 to 10 nm probe-sample 
separation). The probe is supported on a flexible cantilever. The AFM tip gently touches 
the surface and records the small force between the probe and the surface. Figure 1.13 
shows AFM diagrams. 
 
 
Figure 1.13  Block diagram of AFM. 
 
The probe is placed on the end of a cantilever. The amount of force between the probe 
and sample is dependent on the spring constant (stiffness) of the cantilever and the 
distance between the probe and the sample surface. This force can be described using 
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Hooke’s Law (Hubbard, 1995):  
 
F = -kx     Eq. 1.3 
 
where F is the force, k is the spring constant and x is for cantilever deflection. If the 
spring constant of cantilever (typically ~ 0.1-1 N/m) is less than sample surface, the 
cantilever bends and the deflection is monitored. 
 
1.3.5.2  Localised thermal analysis 
Localised thermal analysis (LTA) is an extension technique based on AFM principles, 
combined with the MTDSC principle, and was proposed by Hammiche et al. (1996) 
replacing the conventional AFM probe with a thermal probe. This technique allows the 
transition temperature of a sample surface to be locally analysed. The thermal probe 
used is Wollaston wire probe, consisting of 75 µm diameter silver wire containing a 5 µm 
platinum/rhodium core, as shows in Figure 1.14. This probe was chosen because it can 
be used as a detector and highly localised heating source. 
 
 
Figure 1.14  Wollaston wire probe (Craig et al., 2002). 
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An AFM image of the sample is initially obtained and then the probe is placed on the 
sample surface at a desired location. A voltage profile is then applied to the probe which 
heats up the surface of the sample locally, while the system monitors the position of the 
cantilever on the surface. The depth of penetration of the probe into a softened sample 
due to a thermal event is detected and the temperature transition is determined based on 
calibration measurements (Dai et al., 2012). The probe is then manually repositioned to 
another point on the sample's surface and a new LTA measurement made. The AFM 
images and thermal responses can be then correlated to understand spatial distribution 
of materials on a surface. 
 
1.3.5.3  Transition temperature microscopy 
Transition temperature microscopy (TTM) was invented by Kjoller et al. (2012), based on 
the LTA technique. In essence, it is an automated process of obtaining repeated LTA 
measurements in a grid (map) across a sample's surface. 
 
For this technique, a micromachined silicon probe similar to standard AFM silicon probes 
but incorporating a resistive heater at the end of the cantilever is used. The probes have 
a tip radius of less than 30 nm and 3 to 6 µm in height. Analysis by using these probes is 
known as nano thermal analysis (nano-TA) since it can be conducted at the nano scale.  
 
In TTM, a series of nano-TA measurements is performed on a sample surface over a 
grid pattern, generating a map of the measured transition temperatures. By using this 
technique, the API substances and excipients distribution on the sample’s surface can 
thus be assessed. Figure 1.15 showed the summary of TTM mechanism. Studies 
utilising TTM on polymer samples or films have been reported (Qi et al., 2013, Moffat et 
al., 2014).  
 
Chapter 1 
 
 
31 
 
  
 
Figure 1.15  Summary of TTM mechanism (Kjoller et al., 2010). 
 
1.3.6  Ultraviolet/visible Spectrophotometry 
Ultraviolet/visible (UV/Vis) spectrophotometry refers to absorbance or reflectance 
spectroscopy in the ultraviolet (UV) and visible regions. The wavelength range of the UV 
region is between 200 and 400 nm, and is 400 to 800 nm for the visible region, as shows 
in Figure 1.16 (Perkampus et al., 2013). The molecular absorbance in these regions 
arises from the energy transitions that involve the outer orbital or valency electrons 
(Cooper and Negrusz, 2013). 
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Figure 1.16  Ultraviolet and visible spectrum (Owen, 2000). 
 
In general, UV/vis spectrophotometer are equipped with interchangeable tungsten and 
hydrogen or deuterium lamps as source of radiation. A tungsten lamp is able to emit 
wavelength between 350 and 2500 nm while hydrogen and deuterium lamps emitted 
wavelength in the range of 190 – 400 nm (Skoog et al., 2007). There are two type of 
UV/Vis spectrophotometer: single-beam and double-beam. 
 
In single-beam, the light is focussed on the entrance slit of a monochromator. 
Monochromator will acted as filter and selectively transmit a narrow band of light. This 
light then will passed through the sample to the detector (Owen, 2000). The absorbance 
of the light is calculated by comparing the intensity of light reaching the detector between 
reference (blank sample) and sample. Figure 1.17 shows the schematic diagram of the 
single-beam spectrophotometer.  
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Figure 1.17  Schematic diagram of single-beam spectrophotometer (Owen, 2000). 
 
For the double-beam spectrophotometer, the light is split into two beam after it passed 
through the monochromator. One of the beam will passed through the sample while the 
other will passed through the reference (Owen, 2000). Figure 1.18 shows the schematic 
diagram of double-beam spectrophotometer. 
 
 
Figure 1.18  Schematic diagram of double-beam spectrophotometer (Owen, 2000).  
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The Beer-Lambert Law is used to quantify the light absorbance by the sample, which can 
be explained based on the following equation (Watson, 2012): 
 
Absorbance (A) = log
I0
It
 = εbc   Eq. 1.4 
 
where I0 is the intensity of incident radiation, It is the intensity of transmitted radiation, ε is 
the molar absorbance coefficient of the analyte, b is the pathlength of the cell and c is 
the concentration of the analyte. 
 
1.4  Aims and Objectives 
The aim of this study is to investigate the formulation, manufacturing process and 
characterisation of the ocular mini-tablets and inserts prepared using conventional 
manufacturing techniques such tablet compression and unconventional manufacturing 
techniques such as 3D-printing.  
 
Chloramphenicol was used as the model drug here. It is found as eye drops and 
ointments in the current UK market. 0.5 % (w/v) of chloramphenicol is used in eye drops 
with borax, boric acid, phenylmercuric nitrate and water in the formulation. The 
recommended dose is one drop to be applied to the infected eye every 2 hours during 
waking hours for the first 48 hours and then every 4 hours thereafter, with treatment 
continuing for 5 days.  Meanwhile, for the ointments, the drug concentration used is 1.0 
% (w/w) with liquid paraffin, wool fat and yellow soft paraffin as part of the formulation. 
The dosage regimen is to apply about 1 cm of ointment to the affected eye(s) 3 to 4 
times a day for 5 days. 
 
Using chloramphenicol eye-drops as the basis for calculation, with 8 applications per day 
in the first 2 days and an application volume of 50 µL, a total volume of (8 x 50 µL =) 0.4 
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mL per day would be applied.  This equates to (0.40 mL x 0.5 %w/v =) 2 mg drug applied 
per day.  It is usually assumed that only approximately 5 % of a topically applied dose is 
absorbed into the posterior segment of the eye, but in this case the site of action of the 
drug is much closer to the surface, so more is likely to effective, but still some drug is 
likely to be lost due to spillage, drainage and physical removal.  A reasonable estimate 
may be that 25 % of the drug applied reaches its target site and has a clinical effect.  
Hence, of the 2 mg chloramphenicol applied per day, 0.5 mg may be assumed to have a 
clinical effect.  For a once-a-day mini-tablet, therefore, the total dose of chloramphenicol 
would be 0.5 mg.  If the mini-tablet weighs 10 mg, this equates to a concentration of 5 
%w/w. 
 
The target product profile will be a mini-tablet suitable for a once-daily use, with standard 
BP specifications for weight uniformity, content uniformity and friability. There is no BP 
specification for hardness, either in terms of absolute value or range, and the hardness 
value depends on the shape and dimensions of the product as well as the formulation 
and the manufacturing conditions used.  However, in previous mini-tablet studies, the 
hardness values ranged between 0.67 N and 18.64 N (Weyenberg et al., 2003, 
Weyenberg et al., 2005), so it is reasonable to expect values of between 5 and 15 N to 
show a good balance between product resilience and drug release. There is no BP 
specification for thickness, either in terms of absolute value or range, as this is 
dependent on the diameter of the mini-tablets, their formulation and the hardness value.  
However, based on a 2 mm diameter mini-tablet compressed using round, normal 
concave punches and a weight of circa 10 mg, a thickness value of 2 mm would be 
expected.  The drug release profile should ideally be zero-order over the full 24-hour 
period. This product profile is summarised in Table 1.5 below. 
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Table 1.5  Ideal product profile of the chloramphenicol-loaded mini-tablets. 
Attribute Specification detail 
Drug content 5 %w/w = 0.5 mg 
Meets BP specifications for content uniformity 
Weight 10 mg 
Meets BP specifications for weight uniformity 
Hardness 5 to 15 N 
Thickness 2 mm 
Friability Meets BP specifications for friability 
Dissolution profile Zero order over 24 hours, i.e. 4.17 % per hour 
 
The objectives of this study are: 
 
1. To investigate the effect of particle size on the physical characterisation and drug 
release behaviour using the following techniques: dynamic vapour sorption (DVS), 
scanning electron microscopy (SEM), transition temperature microscopy (TTM), 
modified flow-through dissolution apparatus and UV/Vis spectrophotometer. The 
hypothesis is that the smaller polymer particle size will increase the drug release rate 
of the mini-tablets. This is presented in Chapter 3. 
2. To evaluate the ability of TTM to cope with surface of varying smoothness using 
following techniques: modulated temperature differential scanning calorimetry 
(MTDSC), SEM and TTM. The hypothesis is that a smooth surface will give 
measurements of the transition temperature which are more in line with those 
observed by other techniques, while a rough surface is expected to give more 
variable results. This is presented in Chapter 4. 
3. To formulate and manufacture 3D-printed ocular mini-tablets using following 
techniques: MTDSC, hot melt extrusion (HME), 3D design and modelling, 
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stereolithography apparatus (SLA) printer, DVS, materials microscope, SEM, TTM, 
modified flow-through dissolution apparatus and UV/Vis spectrophotometer. The 
hypothesis is that a 3D-printing technique can be used to manufacture ocular mini-
tablets and possibly be considered as one of tablets manufacturing technique. This is 
presented in Chapter 5. 
4. To investigate a novel approaches of modifying ocular flow-through dissolution 
apparatus and ocular inserts customised based on patient eye using 3D-printing 
techniques. This is a continuation study from Chapter 5 using the following 
techniques: MTDSC, 3D design and modelling, fused deposition modelling (FDM) 
printer, stereolithography apparatus (SLA) printer, modified flow-through dissolution 
apparatus and UV/Vis spectrophotometer. The hypothesis is that a 3D-printing 
technique can be used to manufacture any desired shapes. Meanwhile, by designing 
ocular flow-through dissolution based on patient eye, a more accurate in-vitro study 
can be conducted. This is presented in Chapter 6. 
 
 
 
   
 
Chapter 2 
Materials and Methods 
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Materials and Methods 
 
2.1  INTRODUCTION 
 
In this study, several new approaches to ocular therapy were investigated. The products 
were developed, manufactured and tested using a range of techniques. For the 
manufacturing processes, a rotary tablet press, a hot-melt extruder (HME) and 3D-printers 
(fused deposition modelling (FDM) and stereolithography apparatus (SLA) printers) were 
used. Several tests were performed to characterise the physical properties of the products, 
including are weight uniformity, crushing strength, dimensional analysis, friability, vapour 
sorption using dynamic vapour sorption (DVS), and water content by using 
thermogravimetric analysis (TGA). Scanning electron microscopy (SEM) was used to 
capture images of the surface of the samples. 
 
Thermal analytical studies were also conducted on selected samples to measure the 
melting point and/or glass transition temperature (Tg) by using modulated temperature 
differential scanning calorimetry (MTDSC) and transition temperature microscopy (TTM). 
The drug release profile from the products was assessed using a modified flow-through 
dissolution apparatus and spectrophotometric analysis. Mathematical modelling was 
performed on the dissolution profiles using zero-order, first-order and Korsmeyer-Peppas 
kinetics. The difference (f1) and similarity (f2) factors were used to determine the similarity 
or otherwise of the dissolution profiles. 
 
This Chapter provides the background to the various techniques used here, as well as 
details on the materials used in this project. 
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2.2  MATERIALS 
 
2.2.1  Chloramphenicol 
In this study, chloramphenicol was chosen as the model drug. Chloramphenicol has a 
broad spectrum of antibiotic activity and is commonly used to treat for superficial eye 
infections, such as conjunctivitis. Chloramphenicol has severe side-effects, such as 
aplastic anaemia, when given orally, but chloramphenicol eye drops are well tolerated 
(BANFF, 2015). 
 
Figure 2.1 and Table 2.1 show the chemical structure and physico-chemical properties of 
chloramphenicol, respectively. 
 
 
 
Figure 2.1  The chemical structure of chloramphenicol. 
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Table 2.1  Physical and chemical properties of chloramphenicol (PubChem, 2016, 
Laferriere and Marks, 1982). 
Properties Descriptions 
IUPAC name 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl) 
propan-2-yl] acetamide 
Molecular weight 323.13 g/mol 
Molecular formula C11H12Cl2N2O5 
Physical state White to yellowish-white crystalline powder 
Melting point 150.5 – 151.5 °C 
Solubility Soluble in methanol, ethanol, butanol, ethyl acetate, acetone 
and chloroform. 
Slightly soluble in water (2.5 mg/mL) and ether. 
Insoluble in benzene, petroleum ether and vegetable oils. 
Toxicity Induces aplastic anaemia 
Probably carcinogenic to human (Group 2A) 
 
Based on the BNF (2014), the concentration of chloramphenicol in eye drops used in the 
UK is 0.5 % (w/v) while for the eye ointment, the concentration is 1.0 % (w/v). In this study, 
the concentration used in the mini-tablets was 5.0 % (w/w), with the rationale for this 
concentration being discussed in Chapter 1 section 1.4. 
 
2.2.2  Polyethylene glycol  
Polyethylene glycol (PEG) is polyether compound that is widely used in pharmaceutical 
formulations. Figure 2.2 shows the structural formula of PEG.  
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Figure 2.2  The chemical structure of PEG. 
 
PEGs with molecular weights between 200 and 600 g/mol are clear colourless or slightly 
yellowish liquids, while for molecular weights higher than 1000 g/mol, they are solids and 
can be found in white waxy flakes or powders. If the molecular weight is equal to or higher 
than 100,000 g/mol, PEGs are often known as polyethylene oxide (PEO) rather than PEG, 
although chemically they remain the same (Rowe et al., 2009).  
 
PEG (and PEO) are semi-crystalline polymers, which mean they have both crystalline and 
amorphous regions. They have different melting points depending on the molecular weight 
with the higher molecular weights having slightly higher melting points. However, there is 
no difference in the glass transition temperature (Tg), with all molecular weight PEGs and 
PEOs showing a Tg at -60 °C (Törmälä, 1974). Table 2.2 summarises the physico-
chemical properties of PEG. PEG 4000, PEG 6000 and PEO 8,000,000 were used for the 
current study. 
 
Table 2.2  Physical and chemical properties of PEG and PEO (Rowe et al., 2009). 
Properties Descriptions 
Chemical name α-hydro-ω-hydroxypoly(oxy-1,2-ethanediyl) 
Empirical formula HOCH2(CH2OCH2)mCH2OH 
Physical state PEG 200 to 600: Clear, colourless or slightly yellow-coloured 
liquid. 
PEG 1000 to >6000: White or off-white waxy flakes. 
PEG 6000 and above: White powder. 
Chapter 2 
 
 
43 
Melting point PEG 4000: 40 – 48 °C. 
PEG 6000: 55 – 63 °C. 
PEO 8,000,000: 65 – 70 °C. 
Solubility Soluble in water, acetone, dichloromethane, ethanol (95 %) 
and methanol. 
Slightly soluble in aliphatic hydrocarbon and ether. 
Insoluble in fats, fixed oils and mineral oils. 
Toxicity Nontoxic (Included in FDA Inactive Ingredients Database for 
ophthalmic preparations). 
 
PEG is often used as a component in topical formulations, as it is non-irritant topically, and 
cannot be absorbed by the skin (Rowe et al, 2009). Low molecular weight PEGs are 
commonly used as plasticisers in film formulations, with the aim of reducing the glass 
transition temperature (Tg) while increasing the flexibility and durability of the products 
(Rodríguez-Llamazares et al., 2012, Pivsa-Art et al., 2016). High molecular weight PEGs 
have been studied extensively as carriers in solid dispersion products, and they may 
improve the dissolution profile of poorly water-soluble drugs (Craig, 1990). In tabletting 
processes, PEG can be added into the formulation as a binder or lubricant, although this 
use is not common. A binder, also known as an adhesive, act as a glue to ensure that 
granules and tablets can be formed with the required mechanical strength. Meanwhile, 
lubricant is need to reduce the friction between the mixture and the die wall during tablet 
compression and ejection (Aulton and Taylor, 2013). 
 
2.2.3  Microcrystalline cellulose 
Microcrystalline cellulose (MCC) is one of the most widely used polymer in pharmaceutical 
fields. This polymer commonly used as a filler, disintegrant, binder and anti-adherent for 
tablets and as a binder in capsule formulations (Aulton and Taylor, 2013). Figure 2.3 and 
Table 2.3 show the chemical structure formula and physico-chemical properties of MCC, 
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respectively. 
 
Figure 2.3  The chemical structure formula of MCC. 
 
Table 2.3  Physical and chemical properties of MCC (Rowe et al., 2009). 
Properties Descriptions 
Chemical name Cellulose 
Empirical formula (C6H10O5)n 
Physical state White powder composed of porous particles. 
Melting point Char at 260 – 270 °C. 
Solubility Slightly soluble in 5% (w/v) sodium hydroxide solutions. 
Insoluble in water, dilute acids and most organic solvents. 
Toxicity Nontoxic (used in ocular mini-tablets study by El-Gawad et al. 
(2012)). 
 
MCC is considered to be one of the most versatile polymers because of its multi-functional 
properties as an excipient in tabletting process. However, it cannot replace true 
disintegrants and lubricants in a formulation, but it may complement those properties 
(Thoorens et al., 2014). MCC also displays broad chemical compatibility with drugs (Çelik, 
2016). 
 
2.2.4  Hydroxypropyl methylcellulose K4M 
Hydroxypropyl methylcellulose (HPMC), also known as hypromellose, is widely used in 
oral, ophthalmic and topical pharmaceutical formulations. In general, HPMC is an 
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odourless and tasteless white powder. Figure 2.4 shows the structural formulas of HPMC. 
HPMC has a few different grades commercially available. However, in this chapter, only 
HPMC K4M will be discussed since this is the only HPMC grade that has been used in this 
work. 
 
Figure 2.4  The chemical structure formula of HPMC. 
 
HPMC K4M has a nominal molecular weight of 86,000 g/mol and a nominal viscosity of 
4000 mPa.s for a 2 %w/w aqueous solution at 20 °C. This amorphous polymer displays a 
glass transition (Tg) at 186 °C (Rowe et al., 2009, Ma et al., 2013). The glass transition is 
very small and can be quite tricky to measure. McPhillips et al. (1999) were able to 
distinguish the glass transition temperature by using modulated temperature differential 
scanning calorimetry. Table 2.4 summarises the physico-chemical properties of HPMC. 
 
Table 2.4  Physical and chemical properties of HPMC (Rowe et al., 2009, PubChem, 
2016). 
Properties Descriptions 
Chemical name Cellulose hydroxypropyl methyl ether 
Empirical formula C56H108O30 
Physical state White or creamy-white fibrous or granular powder. 
Melting point Browns at 190 – 200 °C; chars at 225 – 230 °C.  
Tg at 170 – 180 °C. 
Solubility Soluble in cold water, mixtures of ethanol and 
dichloromethane, mixtures of methanol and dichloromethane 
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and mixtures of water and alcohol. 
Insoluble in hot water, chloroform, ethanol (95 %), and ether. 
Toxicity Nontoxic (Included in FDA Inactive Ingredients Database for 
ophthalmic preparations). 
 
HPMC is a hydrophilic polymer that can be used as a controlled-release matrix, film-coat 
former and binder for tablets, and a suspending and thickening agent in topical 
formulations (Aulton and Taylor, 2013, Rowe et al., 2009).  
 
2.2.5  Polyvinylpyrrolidone 90F 
Polyvinylpyrrolidone (PVP) is a synthetic polymer consisting of 1-vinyl-2-pyrrolidinone 
repeating groups, with the empirical formula of (C6H9NO)n (Rowe et al., 2009). PVP is 
commonly used as a binder in tablet formulations, either as wet or dry binder (Aulton and 
Taylor, 2013). PVP is a hydrophilic white powder. There are several different grades of 
PVP but for this study, only PVP 90F was used. Figure 2.5 shows the structural formula 
of PVP. 
 
Figure 2.5  The chemical structure of PVP 
 
PVP 90F has one of the highest molecular weights of the PVP grades commercially 
available at the moment, approximately 1,000,000 g/mol. There are several published 
studies using PVP 90F as part of the formulation in film coating for controlled release 
formulations (Fini et al., 2008, Sungthongjeen et al., 2004). This is because PVP 90F can 
be used as a plasticiser to increase the flexibility of the films. All PVP grades are 
characterised based on the relative viscosity in water at 25 °C of a 20 %w/w aqueous 
Chapter 2 
 
 
47 
solution and their K-value. The K-value for PVP 90F was 90, hence the grade name 
(Bühler, 2008). Table 2.5 summarises the physico-chemical properties of PVP. 
 
Table 2.5  Physical and chemical properties of PVP (Rowe et al., 2009, Bühler, 2008). 
Properties Descriptions 
Chemical name 1-Ethenyl- 2-pyrrolidinone homopolymer. 
Empirical formula (C6H9NO)n 
Physical state White or creamy-white powder. 
Melting point Soften at 150 °C. 
Tg at 170 – 180 °C. 
Solubility Soluble in water, acids, chloroform, ethanol (95 %), ketones 
and methanol. 
Insoluble in ether, hydrocarbons and mineral oils. 
Toxicity Nontoxic (Included in FDA Inactive Ingredients Database for 
ophthalmic preparations). 
 
2.2.6  Carbopol 974P 
Carbopol is commonly used in liquid and semi-solid pharmaceutical formulations as a 
rheology modifier. It can also be used as bioadhesive, controlled-release and emulsifying 
agents (Rowe et al., 2009). Carbopol 974 is the only grade used in this study. Figure 2.6 
shows the chemical structure formula of Carbopol. 
 
 
Figure 2.6  The chemical structure formula of Carbopol. 
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Carbopol is a hygroscopic polymer. The polymer can absorb moisture content between 8 
and 10% (w/w) at 25 °C and 50% relative humidity. Carbopol does not dissolve in any 
solvents. This polymer only swell up to a certain extent due to its three-dimensionally 
crosslinked microgels (Rowe et al., 2009). Table 2.6 shows the physico-chemical 
properties of Carbopol. 
 
Table 2.6  Physical and chemical properties of Carbopol (Rowe et al., 2009). 
Properties Descriptions 
Chemical name Carbomer 
Empirical formula (C3H4O2)n 
Physical state White powder. 
Melting point Tg at 100 – 105 °C.  
Decomposition occurs at 260 °C within 30 minutes. 
Solubility Swellable in water, glycerin and 95% of ethanol (after 
neutralisation).  
Toxicity Nontoxic (Included in FDA Inactive Ingredients Database for 
ophthalmic preparations). 
 
Carbopol is used pharmaceutically because it is non-toxic and non-irritant (Rowe et al., 
2009). A study by Weyenberg et al. (2006) on the preparation of ocular mini-tablets by 
manipulating the concentration of Carbopol 974P in the formulations found that the drug 
release rate decreased with the increment of Carbopol 974P. 
 
2.2.7  Sodium stearyl fumarate 
Magnesium stearate is the most widely used as lubricant in tabletting and capsuling 
processes due to its superior lubrication properties. However, there is one drawback with 
magnesium stearate, which is that it is hydrophobic. (Aulton and Taylor, 2013). To 
overcome this problem, sodium stearyl fumarate (SSF) was used in the present work. 
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Figure 2.7 shows the structural formula of SSF and Table 2.7 summarises its physico-
chemical properties. 
 
 
Figure 2.7  The chemical structure of SSF. 
 
Tablet 2.7  Physical and chemical properties of SSF (Rowe et al., 2009). 
Properties Descriptions 
Chemical name 2-butenedioic acid monooctadecyl ester. 
Empirical formula C22H39NaO4 
Physical state White powder. 
Melting point 224 – 245 °C (with decomposition). 
Solubility Soluble in water. 
Slightly soluble in methanol. 
Insoluble in acetone, chloroform and ethanol. 
Toxicity Nontoxic (used in ocular mini-tablets study by Weyenberg et 
al. (2006). 
 
SSF is effective as a lubricant in tablet formulations and affect the disintegration and tensile 
strength of the tablets in the same fashion as magnesium stearate (Hölzer and Sjögren, 
1979). As it is non-toxic, non-irritant and water soluble (Rowe et al., 2009), it is the most 
suitable lubricant for ocular mini-tablets, where aqueous solubility of all ingredients is 
desired. 
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2.2.8  Polyethylene glycol diacrylate 700 
Polyethylene glycol diacrylate (PEGDA) is a photopolymerisable polymer that has been 
widely studied as a base polymer for products made using photopolymerisation process, 
especially hydrogels (Dana et al., 2013, Chan et al., 2010, Cuchiara et al., 2010, Nemir et 
al., 2010). Figure 2.8 and Table 2.8 show the structural formula and the physico-chemical 
properties of PEGDA. In this study, PEGDA 700, with a nominal molecular weight of 700 
g/mol, was chosen as the base polymer for the 3D-printed mini-tablets using the 
stereolithography technique based on a photopolymerisation process. 
 
 
Figure 2.8  The chemical structure of PEGDA. 
 
Table 2.8  Physical and chemical properties of PEGDA (PubChem, 2016). 
Properties Descriptions 
Empirical formula H2C=CHCO(OCH2CH2)nO2CCH=CH2 
Physical state Colourless liquid. 
Melting point 12 – 17 °C. 
Solubility Soluble in water. 
Slightly soluble in benzene, ethanol and ligroin. 
Toxicity Nontoxic. 
 
During the photopolymerisation process, PEGDA monomers and low molecular weight 
PEGDA pre-polymers are mixed with a photoinitiator and exposed to UV light. A free 
radical chain reaction process is induced and leads to the formation of highly crosslinked 
products (Allen, 1996). Figure 2.9 shows the photopolymerisation process of PEGDA. The 
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3D-printer applies this concept by using laser light to cure the photopolymer. The 3D-
printing technique will be explained later. 
 
 
Figure 2.9  Photopolymerisation process of PEGDA (Fei et al., 2012). 
 
2.2.9  Phenylbis (2,4,6-trimethylbenzoyl) phosphine oxide 
Phenylbis (2,4,6-trimethylbenzoyl) phosphine oxide (BAPO) is a common photoinitiator 
used in photopolymerisation. Kenning et al. (2008) in their studies on photoinitiation rate 
comparing four different photoinitiators found that BAPO was the most efficient 
photoinitiator for photoinitiation in thick polymer systems. Figure 2.10 and Table 2.9, 
respectively, show the structural formula and physico-chemical properties of BAPO. In this 
study, BAPO was used as the initiator for the photopolymerisation of PEGDA. 
 
 
Figure 2.10  The chemical structure of BAPO. 
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Table 2.9  Physical and chemical properties of BAPO (PubChem, 2016). 
Properties Descriptions 
IUPAC name [phenyl-(2,4,6-trimethylbenzoyl) phosporyl]-(2,4,6-
trimethylphenyl) methanone 
Empirical formula C26H27O3P 
Physical state Yellowish powder. 
Melting point 131 – 135 °C. 
Solubility Soluble in acetone, acetonitrile, hexanedioldiacrylate and 
toluene. 
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2.3  MANUFACTURING PROCESSES 
 
2.3.1  Mini-tablet manufacturing 
 
In this study, the mini-tablets were prepared by compression using a Riva Piccola rotary 
tablet press (Riva, Argentina) with 2 mm normal concave plain punches, supplied by 
Adamus (Poland), as shown in Figure 2.11. This press is fitted with four B and four D 
stations, although the D stations were blanked off and only the B stations were used. The 
Piccola press was set with a 6 mm cam, allowing a fill depth in the die of approximately 5 
mm. The compression force was fixed at 1.8 ± 0.2 kN for all formulations. Only one set of 
punches was used during the process in order to reduce variability. During the tabletting 
process, the feeder and turret speed were maintained at 15 rpm for the whole batch. No 
pre-compression force was applied in the tabletting process. All punches and die were 
lubricated with food grade lubricant after the tabletting process. 
 
 
 
 
 
 
 
 
 
Figure 2.11  Photograph of a set of the 2 mm normal concave tooling used in this study.  
Top - upper punch, middle - die and bottom - lower punch (courtesy of Dr Joanne 
Peacock).  
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2.3.2  Hot Melt Extrusion 
 
Hot melt extrusion (HME) is a processing technique whereby an intimate mix of materials 
may be obtained, generally on a molecular scale (Repka et al., 2007). It works by melting 
the materials and subsequent mixing them with either a single or twin screw configuration. 
Its use in pharmaceutics has been to prepare products with improved dissolution profiles 
where the drug in question has poor aqueous solubility, or to provide stabilisation for 
amorphous drugs. 
 
In this study, hot melt extrusion was performed using a Process II parallel twin screw 
extruder (Thermo Scientific, USA) with a 2 mm nozzle. The extrusion parameters were 
varied, depending on the specific polymer's transition temperature. The extrusion 
temperature was ranged between 50 and 180 °C with a screw speed at 25 rpm. All eight 
heating zones were kept the same temperature for all experiments. 
 
2.3.3  3D-Printing techniques 
 
3D-printing can be described as the construction of in three dimensions of a material to a 
specific design. There are several different 3D-printing techniques available, with separate 
advantages and disadvantages. In this study, the fused deposition modelling (FDM) and 
stereolithography apparatus (SLA) approaches were both investigated and are described 
below. 
 
2.3.3.1  3D model design 
Before a product can be 3D-printed, it first needs to be designed. There are several 
software packages that can be used to design three dimensional (3D) models for 3D-
printing. The one used here is Tinkercad (2015), a free browser-based 3D design and 
modelling application. Tinkercad allows users to create 3D models based on pre-installed 
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geometric shapes, letters, numbers and symbols and to share their geometric creations. 
Figures 2.12, 2.13, 2.14 and 2.15 show the creation of a series of objects using the 
Tinkercad software. 
 
 
Figure 2.12  Pre-installed geometric shapes, letters, numbers and symbols. 
 
Figure 2.12 shows the pre-installed basic shapes that are available. After deciding on the 
specific shape, it can be dragged to the workplane (the blue grid in the centre of the 
screen). The dimensions of the 3D object selected can be adjusted by clicking the 
"helpers" tab and then choosing "ruler". The object measurement will be shown once the 
"ruler" is used on the workplane, as indicated in Figure 2.13. The object also can be 
rotated to a different angle by clicking the "rotate" symbol on the object and move it around. 
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Figure 2.13  Selected object without (left) and with (right) the "ruler". 
 
Two or more objects can be combined to become one object by placing them together, 
selecting all the objects and clicking the "group" icon, as shown in Figure 2.14. The 
objects' colours will be changed into a single colour, indicating the object already been 
combined. This process can be revered and the objects separated by clicking the 
"ungroup" icon next to the "group" icon. 
 
 
Figure 2.14  3D objects before (left) and after (right) being combined.  
 
In order to make a hole in the object, the size and shape of the hole is chosen as if it were 
part of a second solid object and this is then overlapped with the primary object as if it was 
to be combined as described above. The shape is then turned into a hole once the "hole" 
icon on the "inspector" window is clicked as shown in Figure 2.15. 
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Figure 2.15  A sphere object (left) was turned into hole (right) on a cylinder. 
 
All the 3D-printed models used in this study were designed by applying these basic steps. 
The model was then saved into an .STL file format and sent to the 3D-printer to be printed. 
 
2.3.3.2  3D model based on MRI 
Magnetic resonance imaging (MRI) is a diagnostic imaging technique, commonly used in 
the medical field, which generates an internal image of the body by using strong magnetic 
fields. Since the image obtained from MRI is in 3D, it can be used to generate a model for 
use with a 3D printing technique. In this study, a colleague in the UCL School of Pharmacy 
kindly provided an MRI image of his own head and gave permission for it to be used as a 
model in this work. 
 
InVesalius (2016) was used to analyse the MRI image. The MRI image used was actually 
a combination of several 2D images, called slices, stacked together. These slices were 
imported to InVesalius and a 3D image was constructed, as shown in Figure 2.16. The 
letters in the images indicate the position of the head from different angles while the 
numbers at the bottom left corner indicate the slice number for the images.  
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Figure 2.16  InVesalius software with 3D images from the MRI scan. 
 
There are three anatomical planes that can be viewed from the MRI image: axial, sagittal 
and coronal as shown in Figure 2.17. The axial, or transverse, images are horizontal slices 
through the body, beginning at the bottom and moving through to the top of the body. The 
sagittal images are vertical slices through the body, beginning at the left hand side and 
moving to the right hand side. Finally, the coronal images are vertical slices through the 
body, beginning at the front and moving to the back of the body. 
 
  
Chapter 2 
 
 
59 
 
  
Figure 2.17  Cross-sections of the anatomical planes through the MRI image. 
 
The position of the images were aligned by clicking the "slices' cross intersection" icon, as 
shown in Figure 2.18. The red cross intersection line will appear on all images, pointing 
at the same position across the anatomical planes. The images from each plane were 
scrolled to change the slice image in order to find exactly the same position for all planes. 
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Figure 2.18  MRI images from different anatomical planes with slices' cross intersection 
line. 
 
The dimensions of the eye across the three different planes were measured by clicking 
the "measure distance" icon and "clicking and dragging" the mouse across the eye. The 
measurements were then displayed on the images and at the bottom left corner of the 
software, as shown in Figure 2.19. Three measurements were made for each anatomical 
plane. The 3D eye shape was reconstructed based on the measurements. 
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Figure 2.19  The "Measure distance" icon and measurement of the eye. 
 
2.3.3.3  Printing 3D objects 
There are a few types of 3D-printer available but the most popular on the market, and used 
in this study, are the fused deposition modelling (FDM) and stereolithography apparatus 
(SLA) printers. 
 
2.3.3.3.1  Fused deposition modelling 
FDM printers are the most common 3D-printers in the current market. This technique was 
developed and patented by Crump (1992). The FDM printer uses a thermoplastic filament 
which is heated to its melting point. The molten filament is then ejected as a droplet through 
the nozzle attached to the extruder at a specific site. Following the 3D design generated 
earlier, the position of the nozzle will be moved and another droplet deposited. Hence, it 
will be laid down layer by layer, creating the desired 3D object.  
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In this study, an FDM printer from MakerBot (USA) (Figure 2.20) was used to make 
prototypes of the 3D model designs before the final product design was decided. This 
enabled assessment of the 3D model shape after printing. An advantage of the FDM 
printer is that it is cheaper than the SLA, hence is useful for prototyping designs. The final 
product design, however, was printed by using an SLA printer because this is a more 
accurate printer than the FDM printer. 
 
 
Figure 2.20  The FDM printer used here (supplied by MakerBot). 
 
2.3.3.3.2  Stereolithography apparatus 
The SLA technique is the oldest 3D printing technique, having been patented by (Hull, 
1986). This technique uses the photopolymerisation concept, in which light catalyses the 
production of a polymer from the monomers present in solution. Here, a laser is used to 
cure the photopolymer while shaping it into an object.  
 
In this study, a self-levelling platform 3D printer from Formlabs (USA) was used. This 
printer is from the Formlabs 1+ series, comprised of three important parts: the build 
platform, the resin tank and the optical system, as shown in Figure 2.21.  
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Figure 2.21  SLA printer by Formlabs. 
 
Before the printing process starts, the .STL file of the required 3D designed model is 
uploaded to the computer connected to the printer. The model design is then opened by 
using PreForm software from FormLabs. On the start-up window, the software prompts 
the print setup window to identify the material and layer thickness (resolution) used for the 
printing, as shown in Figure 2.22. 
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Figure 2.22  The print setup window on the SLA printer computer. 
 
There are 7 types of material that can be chosen from the settings. These material types 
are based on resins commercially available from Formlabs (USA). Some of the materials 
have multiple versions that can be identified by reference to the resin bottle. If the resin 
used is not from Formlabs (USA), the material setting can be chosen based on the 
similarity of the polymer used to the properties of the commercialised resins, as 
summarised in Table 2.10. 
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Table 2.10  Materials properties summary (Formlabs, 2016). 
Material Description 
Castable Investment casting, blue colour, slightly softer than standard 
resins before post-curing. 
Flexible Impact resistance, compression, great for ergonomic soft-touch 
grips. 
Black Highly pigmented, our most opaque, high detail resin, great for 
printing small, accurate features. 
Clear Transparency, polishes to near optical clarity, great for internal 
channels and working with light. 
Grey Neutral tone, slight opacity when thin, provides a great base 
colour for painting prints. 
White Neutral tone, slight opacity when thin, great for showing off 
surface finish, photographs easily. 
Tough  Impact resistance, cyclic stress or strain, machining, snap-fits 
and living hinges. 
 
After the material type and layer thickness are chosen, the main window opens. There are 
five icons on the left-side of the main window. The icons are, from top to bottom, "size", 
"orientation", "supports", "layout" and "start a print". The "size" icon is used to change the 
size while the "orientation" icon is used to rotate the model.  
 
Some of the 3D models need support (essentially scaffolding) in order to print them. The 
"supports" function was used to create the support needed, as shows in Figure 2.23. By 
using the support, the shape of the model can to be held in place as it is being printed. 
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Figure 2.23  An example of a support (grey) for the 3D model (blue). 
 
The "layout" function was used to align and create duplicates of the model, as shown in 
Figure 2.25. In this mode, the model can be moved around and aligned, as required. The 
model can be replicated into several individual units, as long as the overall design can fit 
onto the build platform. 
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Figure 2.24  Replicating the model. 
 
The "start a print" icon is clicked once the printing setting is complete. The printing setting 
is then sent to the printer. At this point, the printer has not started the printing process yet, 
as the start button needs to be pressed in order to operate the printer. Before the printing 
process is started, the resin needs to be filled into the resin tank.  
 
During the printing process, the build platform is lowered down and fully submerged within 
the resin tank, close to the bottom surface of the tank. The laser is projected from the 
optical system into the resin tank, following the design of the model and cures 
(polymerises) the resin, layer by layer. The resin tank is lowered down by a spring-loaded 
tank support each time a layer is complete in order to remove the layer from the resin tank 
surface. This process is called "peel" (Lobovsky et al., 2014, Formlabs, 2016).  
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2.4  CHARACTERISATION TECHNIQUES 
 
2.4.1  Physical Characterisation  
Physical characterisation consists of several tests that are performed to determine the 
physical properties of the materials. The mini-tablets were evaluated for uniformity of 
weight, uniformity of content, crushing strength, dimensions, friability, and dissolution and 
swelling behaviours. 
 
2.4.1.1  Uniformity of weight 
The British Pharmacopoeia (BP) uniformity of weight test measures the weight consistency 
of products. Assuming that the initial powder mix is correct, the uniformity of weight is used 
as an initial means of determining whether the products will contain the correct dose of 
drug. The uniformity of weight of tablets is determined by accurately weighting 20 tablets 
individually, using an electrical balance. From the data, the mean weight and deviation 
from the mean can be obtained. Not more than 2 of the individual masses deviate from the 
average mass by more than the percentage deviation shown in Table 2.11 and none 
deviate more than twice that percentage (British Pharmacopoeia, 2015). 
 
Table 2.11  The allowable deviation of individual weight in the BP Uniformity of weight 
test (British Pharmacopeia, 2015). 
Pharmaceutical Form Average Mass Percentage Deviation 
Tablets (uncoated and film-
coated) 
80 mg or less 
 
More than 80 mg and 
less than 250 mg 
 
250 mg or more 
10 
 
7.5 
 
 
5 
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Since the expected weight of 2 mm mini-tablets is less than 80 mg, the allowable 
percentage deviation is 10 %. 
 
2.4.1.2  Uniformity of content 
The British Pharmacopoeia (BP) uniformity of content test measures the content 
consistency of products. The uniformity of content of tablets is determined by accurately 
analysing 10 tablets individually, using an appropriate analytical technique. From the data, 
the mean drug content and deviation from the mean can be obtained. The preparation 
complies with the test if each individual drug content value is between 85 % and 115 % of 
the average content. The preparation fails to comply with the test if more than one 
individual content is outside these limits or if one individual content is outside the limits of 
75 % to 125 % of the average content. If one individual content is outside the limits of 85 
% to 115 % but within the limits of 75 % to 125 %, determine the individual contents of 
another 20 dosage units taken at random. The preparation complies with the test if not 
more than one of the individual contents of the 30 units is outside 85 % to 115 % of the 
average content and none is outside the limits of 75 % to 125 % of the average content 
(British Pharmacopoeia, 2015). 
 
In this work, the uniformity of content was not measured directly in a "stand-alone" manner, 
but was inferred from the results of the dissolution assays.  In this case, where the 
formulation had completely disintegrated and the drug completely dissolved, the total 
amount of drug within the formulation was calculated from the value at full release.  Where 
the drug was not fully released from the formulation, the remaining formulation at the end 
of the dissolution experiment was tested for residual content and the overall total amount 
contained initially calculated.  This method was used as some of the batch sizes, especially 
those of the 3D-printed products, were not large enough to allow for full testing of all 
parameters specified in the BP. 
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2.4.1.3  Mechanical strength 
The mechanical strength of a tablet is associated with the resistance of the solid specimen 
to fracturing and attrition. This means the tablet must be able to stay intact during the 
manufacturing process, packaging, distribution and dispensing before it is administered by 
the patient. The most common tests to determine the mechanical strength of the tablet are 
crushing strength and friability test. 
 
2.4.1.3.1  Crushing strength 
The crushing strength of a tablet is usually determined by applying a force on the tablet 
diametrically and establishing the intensity of the force needed to fracture or break the 
tablet (Aulton and Taylor, 2013). The crushing strength depends on the composition of the 
tablets, the dimensions of the tablet, and the compression forces used to manufacture the 
tablet. Generally, increasing the compression force increases the crushing strength and 
decreases in friability of the tablets. 
 
Due to the small size of the mini-tablets and the low forces that are required to crush them, 
conventional equipment used for larger tablets (e.g. a Schleuniger hardness tester) is not 
sensitive enough. El-Gawad et al (2012) developed a method using a texture analyser 
which allowed smaller forces to be measured accurately and that method was used here. 
A mini-tablet is placed on the fixed platform of the texture analyser and a probe descends 
vertically to the tablet, making contact and continuing to move downwards. The force 
required to break the mini-tablet is then recorded. A TA.XT plus Texture Analyzer (Stable 
Micro Systems, UK) was used with a 11.6 mm diameter Perspex cylinder probe The 
experimental set-up is shown in Figure 2.25 and the experimental parameters listed 
below. Ten individual mini-tablets from each batch were tested. 
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 Texture analyser 
 
 
 Probe 
 
 Mini-tablet placed on plate 
 
 
Figure 2.25 The texture analyser set up used to measure the crushing strength of the 
mini-tablets (photo courtesy of Dr Joanne Peacock). 
 
The instrument parameters for testing the crushing strength of the mini-tablets. 
 
Probe 11 mm diameter cylindrical Perspex probe 
Pre-test speed 1 mm/s 
Test speed 0.1 mm/s  
Post-test speed 1 mm/s 
Compression distance 1 mm 
Trigger force 0.05 N 
 
2.4.1.3.2  Friability 
The reason behind the friability test is to subject the tablet to forces mimicking the 
conditions during handling between its production and administration, such as film-coating 
and packaging. It is important that the tablet is capable of resisting attrition to ensure the 
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correct amount of drug is administered and to maintain the tablet appearance (Aulton and 
Taylor, 2013).  
 
The friability (F) of the mini-tablets was determined following method used by El-Gawad 
et al. (2012) by subjecting 10 tablets weighted together to falling shocks for 100 revolutions 
at 25 rpm in a friabilator. The mini-tablets are dusted off and re-weighed, and the 
percentage friability is calculated, using the following equation: 
 
F(%)= (
P-P'
P
) ×100    Eq. 2.1 
 
where P is the initial weight of 10 mini-tablets and P' is the final weight after the friability 
test (Weyenberg et al., 2003). 
 
2.4.1.4  Sample dimensions 
For the measurement of the mini-tablets dimensions, 10 mini-tablets were chosen 
randomly from each formulation. The dimensions of the mini-tablets were measured using 
a digital calliper. The mean value and standard deviation were then calculated. The digital 
calliper was also used to measure the inserts' dimensions. 10 inserts were randomly 
chosen from each formulation. The width, height, depth and thickness of the inserts were 
measured and the mean and standard deviation were calculated. 
 
The surface area of the inserts was calculated using Netfabb (2016). The software is 
designed to be used to edit, repair and analyse .STL format files. The 3D design file for 
the inserts was opened using this software. The inserts' dimensions are displayed at the 
right bottom corner of the screen with the calculated volume and surface area values, as 
shows in Figure 2.26. 
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Figure 2.26  Dimensions values on the Netfabb software. 
 
The surface areas of the inserts were calculated using this software, by editing the inserts' 
dimension based on the actual width, height and depth measurements in the "scale parts" 
windows. These windows are opened by clicking at the "scale parts" icon, as shown in 
Figure 2.27. The surface area values will be automatically calculated based on the 
measurement values that were changed. 10 surface area measurements were recorded 
and the mean and standard deviation values were calculated. 
 
  
Dimensions values 
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Figure 2.27  "Scale parts" icon and windows. 
 
2.4.1.5  Water/moisture uptake  
The amount of water uptake of the mini-tablets is determined at room temperature, 
gravimetrically. The weight of the mini-tablet is determined at a set of time intervals until 
the weight of tablet remained unchanged or even reduced. The percentage of water uptake 
(W%) is calculate using the following equation: 
 
W(%)= (
Mw-Md
Md
) ×100     Eq. 2.2 
 
where Md  is the initial weight of the dry mini-tablet and Mw is the final weight of the wet 
mini-tablet (Weyenberg et al., 2003). 
 
The water uptake test for mini-tablets that been used previously by other researchers is 
performed by placing a weighed mini-tablet on top of a filter membrane connected to a 
“Scale parts” icon 
“Scale parts” 
windows 
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liquid reservoir on its lower side (Weyenberg et al., 2005, Mortazavi et al., 2010, El-Gawad 
et al., 2012). At certain time intervals, the mini-tablet is then removed, re-weighed and 
replaced on the membrane to continue the experiment. This process is subject to 
experimental errors due to the difficulty of handling the wet mini-tablets. The application of 
dynamic vapour sorption (DVS) was proposed to replace the previous water uptake test. 
 
For the moisture uptake profile of the mini-tablets, the DVS was set at a fixed high humidity 
(95.0 ± 1.0 % RH) and left up to 24 hours. The DVS was set as half-cycle with method 
details as below: 
 
dm/dt (%/min) 0.001 
Incubator (°C) 32.0 
Start RH (%) 95.0 
dm/dt window (min) 5 
Minimum stage time (min) 60 
Maximum stage time (min) 1440 
 
Water vapour was used to control the humidity level in the chamber. The temperature was 
set at 32 ± 1 °C based on previous set up used on the equipment. It is slightly lower than 
eye surface temperature (34 °C) but still closely resembles the temperature. The weight 
changes was recorded every minutes. The system was set to stop recording the readings 
after 24 hours (1440 minutes) of run or until there is no difference in weight changes for 5 
minutes (dm/dt). The test was replicated three times for each formulation.  
 
2.4.2  Thermogravimetric Analysis  
Thermogravimetric analysis (TGA) is a technique whereby the weight of a sample is 
continually measured as it is heated. The weight loss-temperature profile can be used to 
assess the quantity of residual solvents, the presence of volatile materials or the chemical 
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reactions of the materials in air. Here, the water content in selected samples was 
measured by using a Hi-Res TGA 2950 (TA Instruments, USA). The TGA was equilibrated 
at 25 °C, heated up to 110 °C at 10 °C/min and held isothermally for 5 minutes. The 
percentage of water loss was then calculated based on the weight change. 
 
2.4.3  Modulated Temperature Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) is a common thermal analysis technique and has 
been used extensively to characterise pharmaceutical systems. It involves the application 
of a linear heating signal to a sample and a reference (generally a matched empty cell) 
and the measurement of the energy changes over a transition, such as melting or a glass 
transition. Modulated Temperature DSC (MTDSC) is an extension of the conventional 
DSC technique whereby a sinusoidal heating ramp is applied on top of the linear heating 
signal. This allows the measurement signal to be split into two components, the reversing 
and non-reversing signals, which then allows finer resolution of low energy transitions such 
as the glass transition. 
 
In this study, MTDSC was performed using a DSC Q1000 (TA Instruments, USA) over a 
range of temperature, depending on the materials. The instrument was calibrated based 
on the manufacturer's recommendation. The temperature calibration was performed using 
three different materials: indium (melting point 156.6C and heat of fusion 28.57 J/g), tin 
melting point 231.93C and heat of fusion 60.6 J/g) and n-octadecane melting temperature 
28.24C and heat of fusion 238.76 J/g) (values supplied by TA instruments (USA). The 
cell constant was calculated using indium. The heat capacity in the modulated mode was 
calibrated with an aluminium oxide (sapphire) disc. The heating rate was set at 2 
°C/minute, 40 seconds for modulation period and 0.212 °C for the amplitude.  
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The sample was weighed and sealed in a pinholed aluminium pan (Perkin Elmer). 
Pinholed pans were chosen in order to allow the removal of liberated moisture from the 
sample, which might otherwise influence the analysis, especially of the glass transition 
process. A purge gas and carrier gas nitrogen of was used with a flow rate of 50 mL/minute 
and 150 mL/minute, respectively. The sampling interval was set up at every 0.10 second 
per point. An oscillation amplitude of 0.212 °C with a period of 40 seconds was used with 
heating rate at 2 °C/minute. 
 
2.4.4  Scanning Electron Microscopy 
Scanning Electron Microscopy (SEM) is an imaging technique which is used extensively 
to assess the size and surface appearance of samples, both pharmaceutical and non-
pharmaceutical. It is best used for solid samples that are resistant to the treatment with 
gold coating which is required in order to obtain a high quality image. 
 
The surface image of mini-tablets was evaluated by using FEI™ Quanta 200F field 
emission scanning electron microscopy (SEM) (FEI Company, USA). The samples were 
attached directly on the specimen stub using double-sided tape and coated with 25 nm of 
gold under vacuum using a Quorum Q150T Turbo-Pumped Sputter Coater with a film 
thickness monitor unit. All micrographs were taken at acceleration voltage of 5 kV. Several 
images from difference magnifying images were recorded. 
 
2.4.5  Transition Temperature Microscopy 
Transition Temperature Microscopy (TTM) is an automated technique which measures the 
thermal behaviour at specific locations on the surface of a sample. A probe makes contact 
with the sample's surface and is heated, resulting in localised heating in the sample. When 
the sample goes through a thermal transition (e.g. melting or glass transition), the surface 
will soften and the probe will penetrate into the sample. It is this probe deflection which is 
measured by the equipment. By performing multiple measurements over a pre-determined 
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grid, a map of the transitions across the sample can be made, which can then be used to 
assess the distribution of materials across the sample's surface. 
 
The probe needs to be calibrated before any measurements can be made on the sample 
surface. This is carried out by measurement of the transition voltage of calibration samples 
that are homogenous with a range of melting temperatures and exhibits sharp melting 
points. Polycaprolactone, polyethylene and polyethylene terephthalate with melting points 
of 55°C, 116°C and 235°C, respectively, were used as calibration samples. At least three 
measurements were taken for each sample. The calibration was analysed by using 
Analysis Studio software, as shows in Figure 2.28. A quadratic curve was fitted to the data 
to quantify the voltage applied to the probe into temperature. 
 
 
Figure 2.28  Calibration windows from Analysis Studio software. 
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After the calibration was performed, the sample was glued onto the specimen disc and 
placed at the centre of the platform. The TTM head was lowered down carefully and the 
surface image was focussed by using brightfield optical microscope. The probe tip then 
was aligned to the centre of the image. The measurement was carried out over an area of 
100 × 100 µm with 11 × 11 grid of measurements on desired surface areas, as shows in 
Figure 2.29. 
 
 
Figure 2.29  Measurement area of 100 × 100 µm with 11 × 11 grid on the sample 
surface. 
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2.5  DISSOLUTION STUDIES 
 
Dissolution studies play an important role in drug development as a quality control to 
investigate drug release from a dosage form. Dissolution profiling is also used to predict 
how the formulation will perform in-vivo (Fotaki, 2011). There are four different types of 
dissolution test that have been suggested by the British Pharmacopoiea (2015) which are 
the basket apparatus (apparatus 1), the paddle apparatus (apparatus 2), the reciprocating 
cylinder (apparatus 3) and the flow-through cell (apparatus 4). In this chapter, only the 
flow-through cell test will be discussed as this is the only dissolution technique that been 
applied in this current study. 
 
2.5.1  Dissolution Theory 
Dissolution is a process where molecules or ions are transferred from a solid state into 
solution. This process is controlled by the relative affinity between the molecules of the 
solid substance and those of the solvent (Aulton and Taylor, 2013). In other words, it is the 
process of a solute dispersing in a solvent by forming a homogeneous dispersion at 
molecular-level known as a solution (Smith, 2015). There are different types of solutions 
based on combinations of gas, liquid and solid. However, in this chapter, only solid-in-
liquid solution will be discussed as the current studies only focus on dissolution of mini-
tablets (solid) in dissolution media (liquid). 
 
In general, the solid-in-liquid dissolution is the movement from the largest form to 
molecularly dispersed form with no or few steps in the middle of the process as shows in 
Figure 2.30. The intermediate process that might occur is disintegration and 
deaggregation process. 
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Figure 2.30  Solid-in-liquid dissolution process (Smith, 2015). 
 
The rate of drug diffusion can be described by Fick's Law of Diffusion. The law states that 
the rate of change in concentration of dissolved material with time is directly proportional 
to the concentration difference between the two sides of the diffusion layer (Aulton and 
Taylor, 2013) as shown below: 
 
dC
dt
= k∆C    Eq. 2.3 
 
where C is the concentration of solute in solution at any point and at time (t), k is the rate 
constant and ΔC is the difference in concentration of solution at the solid surface and the 
bulk of the solution. 
 
2.5.2  Preparation of Dissolution Media 
Acidic solutions, buffers, surfactants and combination of surfactants with acid or buffers 
are common dissolution media used for dissolution studies. Meanwhile, for in-vitro and in-
vivo correlation studies, media with bile salts and other relevant physiologically based 
ingredients are used (Fotaki et al., 2013). These media, also known as simulated biological 
fluids, are often used to give a better understanding of the release mechanisms in living 
organisms. 
 
Chapter 2 
 
 
82 
For ocular treatment, simulated tear fluid (STF) is used as the dissolution medium. This 
medium consists of sodium bicarbonate 0.2% (w/w), calcium chloride 0.008% (w/w) and 
sodium chloride 0.67% (w/w) at pH 7.4. (Marques et al., 2011). This formulation of STF is 
commonly used in in-vitro studies of drug release from ocular formulations (e.g. El-Gawad 
et al, 2012), and hence was used here for consistency, but it must be noted that this 
formulation replicates only the mineral content and pH of biological tears, and not any 
protein or lipid content that may be expected to be present. 
 
2.5.3  Dissolution Method 
The drug release profile of the mini-tablets was assessed by using a modified flow-through 
dissolution apparatus, based on the flow-through cell (apparatus 4) guideline from the 
British Pharmacopoiea (2015). The flow-through dissolution apparatus used was courtesy 
of Professor Steve Brocchini's group. A casket with a 200 µL chamber was connected to 
the peristaltic pump and flowed with dissolution medium at 34 °C at the rate of 50 
µL/minute, as shown in Figure 2.31. The samples were taken every 1 hour and filtered 
through a 0.45 µm membrane filter. The drug release was quantified 
spectrophotometrically at 278 nm. At least three replicates were made for each 
formulation. 
 
 
Figure 2.31  Diagram of modified flow-through dissolution apparatus. 
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2.5.4  Ultraviolet/visible Spectrophotometer 
Ultraviolet/visible (UV/Vis) spectrophotometry refers to absorbance or reflectance 
spectroscopy in the ultraviolet (UV) and visible regions. The wavelength range of the UV 
region is between 200 and 400 nm, and is 400 to 800 nm for the visible region (Perkampus 
et al., 2013). The molecular absorbance in these regions arises from the energy transitions 
that involve the outer orbital or valency electrons (Cooper and Negrusz, 2013). The Beer-
Lambert Law is used to quantify the light absorbance by a solution, which can be explained 
based on the following equation (Watson, 2012): 
 
Absorbance (A) = log
I0
It
 = εbc   Eq. 2.4 
 
where I0 is the intensity of incident radiation, It is the intensity of transmitted radiation, ε is 
the molar absorbance coefficient of the analyte, b is the pathlength of the cell and c is the 
concentration of the analyte. A Jenway 6305 uv/vis spectrophotometer (UK) was used to 
quantify chloramphenicol content from the samples. Each sample was scanned at 278 nm 
wavelength, maximum absorbance (λmax) for chloramphenicol (Tuerk et al., 2006, 
Hummert et al., 1995).  
 
A calibration curve graph was constructed by plotting absorbance at 278 nm against 
chloramphenicol standard concentrations at 0.05, 0.025, 0.01, 0.005 and 0.001 mg/mL. 
The standard concentrations were prepared from a stock solution which was the highest 
standard concentration. The stock solution was made by accurately weighing 
chloramphenicol and making a solution in STF in a 100 mL volumetric flask.  
The standard solutions were then prepared by diluting the stock solution into lower 
concentration standards solutions based on following equation: 
 
M1V1 = M2V2    Eq. 2.5 
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where M1 and M2 indicate initial and final concentration, while V1 and V2 is the initial and 
final volume, respectively. 
 
Three separate sets of calibration standard solutions were prepared and analysed.  Figure 
2.32 and Table 2.12 shows the data for individual replicates, and Figure 2.33 and Table 
2.13 shows the overall mean responses. 
 
 
Figure 2.32  Calibration curve of the absorbance of chloramphenicol in STF at 278 nm 
(mean  SD, n=3 for each replicate set of solutions). 
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Table 2.12  Absorbance of chloramphenicol in STF at 278 nm - individual readings from 
the three replicate sets of standards. 
Conc. 
(mg/mL) 
UV Absorbance (ABS) Mean 
(ABS) 
SD 
1 2 3 
0.05 
1.347 1.347 1.348 1.347 0.001 
1.345 1.346 1.346 1.346 0.001 
1.350 1.350 1.350 1.350 0.000 
0.025 
0.681 0.682 0.680 0.681 0.001 
0.681 0.681 0.679 0.680 0.001 
0.679 0.680 0.680 0.680 0.001 
0.01 
0.279 0.279 0.278 0.279 0.001 
0.279 
0.278 
0.277 
0.276 
0.278 
0.275 
0.278 
0.276 
0.001 
0.002 
0.005 
0.148 0.145 0.145 0.146 0.002 
0.146 0.147 0.146 0.146 0.001 
0.146 0.144 0.145 0.145 0.001 
0.001 
0.040 0.038 0.040 0.039 0.001 
0.038 0.039 0.037 0.038 0.001 
0.037 0.039 0.040 0.039 0.002 
 
 
Figure 2.33  Calibration curve of the absorbance of chloramphenicol in STF at 278 nm 
(overall mean  SD, n=3). 
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Table 2.13  Absorbance of chloramphenicol in STF at 278 nm - overall mean values  for 
each concentration. 
Conc. 
(mg/mL) 
UV Absorbance (ABS) Mean 
(ABS) 
SD 
1 2 3 
0.050 1.347 1.346 1.350 1.348 0.002 
0.025 0.681 0.680 0.680 0.680 0.001 
0.010 0.279 0.278 0.276 0.278 0.002 
0.005 0.146 0.146 0.145 0.146 0.001 
0.001 0.039 0.038 0.039 0.039 0.001 
 
The regression value (r2) is a value between 1.0 and -1.0 where a 1.0 value indicates that 
all points lie on straight line with no scatter with positive gradient, while -1.0 gives the same 
information but negative gradient. A zero value means there is no connection between the 
set of data. The calibration curves for each replicate in Figure 2.32 were overlapping with 
each other, suggesting the results are reproducible. The error bars for all graphs could not 
be seen because they are too small. 
 
2.6  MATHEMATICAL MODELLING 
 
2.6.1  Zero Order Kinetics 
Zero order kinetics is the rate of a deposition, dissolution or drug release process that 
takes place at a constant rate independent of the reactants' concentration. This constant 
rate of drug release is usually the most desirable for controlled-release pharmaceutical 
products, as a constant input of drug into the body is achieved (Aulton and Taylor, 2013). 
Zero order kinetics can be calculated by using equation below: 
 
Qt = Q0 + k0t     Eq. 2.6  
 
where Qt is the amount of drug dissolved in time (t), Q0 is the initial amount of drug in the 
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solution (usually 0 for a dissolution test) and k0 is the release rate kinetic constant 
expressed in units of concentration/time. With zero order kinetics, the drug release profiles 
are usually analysed up to 85 % of drug release (Costa and Sousa Lobo, 2001). 
 
2.6.2  First Order Kinetics 
First order kinetics describe a process that depends on the concentration of only one 
reactant. Most of the drug release profiles of conventional formulations follow first order 
kinetics (Aulton and Taylor, 2013). First order kinetics can be expressed by using following 
equation: 
 
ln Ct = ln C0 + k1t   Eq. 2.7 
 
For first-order release kinetics, C0 is the amount of drug in the formulation at the start of 
the dissolution experiment (usually taken to be 100 %), Ct is the amount of drug remaining 
in the formulation at time t during the dissolution experiment, and k1 is the first-order 
release rate kinetic constant expressed in units of time-1. As with zero order, first order 
processes are usually analysed up to 85 % of drug release (Costa and Sousa Lobo, 2001). 
 
2.6.3  Korsmeyer-Peppas Model 
The Korsmeyer-Peppas Model was developed by Korsmeyer et al. (1983) to statistically 
determine the mechanisms of solute release from porous hydrophilic polymers. The model 
can be used to analyse Fickian and non-Fickian release profile. Below is the Korsmeyer-
Peppas model equation: 
 
Mt
M∞
=kKPt
n
    Eq. 2.8 
 
where Mt / M∞ is the fraction of drug release at time t, kKP is a kinetic constant characteristic 
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of the drug/polymer system, t is the release time and n is an exponent which characterizes 
the mechanism of release. 
 
The values were analysed from the first 60 % of the fractional release. This is because the 
fractional release profile is nearly constant within this period (Korsmeyer et al., 1983, 
Ritger and Peppas, 1987). Korsmeyer et al. (1983) suggested that the n value can be used 
to characterise the different release mechanisms; n equal to 0.5 for Fickian diffusion, 
higher than 0.5 but lower than 1.0 for anomalous (non-Fickian) diffusion and equal to 1.0 
for Case II transport (zero order release). However, according to Ritger and Peppas 
(1987), in case of a cylindrical swellable polymer, n value should be 0.45 instead of 0.5 
and 0.89 instead of 1.0. Table 2.13 showed the summary of diffusional exponent 
mechanisms for cylindrical sample. 
 
Table 2.14  Diffusional exponent mechanism for cylindrical sample (Ritger and Peppas, 
1987, Costa and Sousa Lobo, 2001). 
Diffusional exponent (n) Drug release mechanism Time-dependence of 
solute release rate 
0.45 Fickian diffusion t-0.5 
0.45 < n < 0.89 
Anomalous (non-Fickian) 
diffusion 
tn-1 
0.89 Case II transport Zero order release 
n > 0.89 Super Case II transport tn-1 
 
2.6.4  Fit Factors 
Fit factors were determined by using two equations to compare the dissolution profiles 
between two formulations. These equations were proposed by Moore and Flanner (1996). 
The equations were difference factor (f1) and similarity factor (f2). 
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The difference factor (f1) measures the percentage error between two curves over all time 
points: 
 
f1=
∑ |Rj−Tj|
n
j=1
∑ Rj
n
j=1
×100    Eq. 2.9 
 
where n is the sampling number, Rj and Tj are the percentage dissolved of the reference 
and test products respectively at each time point j. The percentage error is zero when the 
test and drug reference profiles are identical and increases proportionally with the 
dissimilarity between the two dissolution profiles. 
 
Similarity between two drug products can be defined by f2 taking values between 50 and 
100, where f2 equals 100 for identical dissolution profiles. The similarity factor f2 is defined 
as a logarithmic reciprocal square root transformation of one plus the average squared 
differences of drug percentage dissolved between the test and the reference products. An 
average difference of 10% at all measured time point results in f2 value of 50 (Anderson et 
al., 1998, Khan et al., 2013). The value of f2 can be calculated as follows: 
 
f2=50× log {[1+
1
n
∑ wj|Rj −Tj|
2n
j=1 ]
-0.5
} ×100  Eq. 2.10 
 
where Rj and Tj represent the average percentage of drug dissolved from the mini-tablets 
measured at the jth time point of the reference and the test preparations respectively. n is 
the number of the time points tested (n is considered in the calculations as not more than 
one measurement after 85% of drug released in the preparation) and wj is an optional 
weight factor. 
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The Effect of Particle Size on the Physical Characteristics and Drug-release 
Behaviour of Chloramphenicol-loaded Mini-tablets for Ocular Use 
 
3.1  INTRODUCTION 
 
Ocular drug delivery is challenging because of the inherent difficulty of accessing the target 
sites, especially those in the posterior segment of the eye. The natural defense 
mechanisms, such as the constant turnover of the tear film on the surface of the eye and 
the blink reflex, reduce the amount of drug that is therapeutically available after surface 
administration. Eye drops have continued to be used as the main vehicle for ocular therapy 
due to their perceived patient acceptance, despite the disadvantages of fast removal and 
low overall drug bioavailability. 
 
One of the potential methods of improving the retention time at the site of administration 
and hence promoting the efficiency of drug therapy is ocular mini-tablets. Mini-tablets have 
a diameter of around 2 to 3 mm or smaller (Lennartz and Mielck, 1998) and a total weight 
of circa 6 to 21 mg in range (Stoltenberg and Breitkreutz, 2011, Thomson et al., 2009). 
They can be inserted into the eye fornix, where they will hydrate and release the drug into 
the surface ocular fluid (Weyenberg et al., 2006). 
 
Formulation and production of mini-tablets is similar to conventionally-sized tablets, but 
there are specific issues related to the control of the particle size distribution of the 
component powders that are much more significant for mini-tablets than larger tablets. 
During the manufacturing process, if the particle size is too large, only a few particles can 
fit in the die, which is likely to result in uneven mini-tablet weight and consequently poor 
content uniformity of the active drug. However, if the particle size is too small, the powder 
will pass through the gap between the die and punch, as shown in Figure 3.1. In most 
tablet formulations the drug has the smallest particle size compared to the excipients and 
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therefore is more likely to be lost in this way, resulting in low drug loading in the final 
product. 
 
 
 
 
 
 
 (a) (b) 
Figure 3.1 Schematic of (a) large particles in the die; and (b) the gap between the punch 
and the die (die clearance). 
 
Particle size is also inversely correlated with surface area, in that the smaller the particle 
size of the drug, the larger the total surface area and vice versa. Depending on the 
aqueous solubility of the drug, altering the particle size distribution may subsequently 
affect the drug release profile of the mini-tablets. Less attention is usually focused on the 
effect on the overall product behaviour of the particle size distribution of the excipients 
used, such as their mixing and flow properties. 
 
This work investigates the effect of excipient particle size on the physical behaviour and 
drug release characteristics of mini-tablets for intended for ocular use. Chloramphenicol, 
an antibiotic routinely used to treat surface ocular infections, was used here as the model 
drug. The formulations studied were direct compression mixtures in order to ensure that it 
was the primary particle size distribution that was being studied. 
 
  
DIE 
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3.2  METHODOLOGY 
 
3.2.1  Materials 
 
Hydroxypropyl methylcellulose K4M (HPMC) was obtained from The DOW Chemical 
Company, USA. Polyethylene glycol 6000 (PEG 6K) was obtained from Clariant GmbH, 
Germany. Microcrystalline cellulose (Avicel PH101) (MCC) was provided by FMC 
BioPolymer, UK. Polyvinylpyrrolidone 90F (Kollidon 90F) (PVP 90F) was provided by 
BASF The Chemical Company, Germany. Polyethylene oxide 8,000,000 (PEO 8M), 
chloramphenicol, sodium bicarbonate and calcium chloride were obtained from Sigma 
Aldrich, U.K. Sodium chloride was obtained from Fluka Chemie GmbH, Germany. Sodium 
stearyl fumarate (SSF) was obtained from Tokyo Chemical Industry, Japan. Carbopol 
974P was provided by Lubrizol, USA. 
 
3.2.2  Methods 
 
3.2.2.1  Manufacture of the mini-tablets 
A range of mini-tablets was prepared using two general formulae. Formula 1 consisted of 
chloramphenicol 5 %w/w, Carbopol 974P 15 %w/w, SSF 2 %w/w and polymer 78 %w/w. 
For Formula 2, chloramphenicol 5 %w/w, SSF 2 %w/w and polymer 93 %w/w were used. 
For Formula 1, HPMC, PEG 6K and MCC were used. These polymers were selected to 
give a range of dissolution profiles in the final formulations. The addition of Carbopol 974P 
in the formulation was to increase the viscosity of the dissolving mini-tablets in the 
dissolution medium and possibly influence the dispersion of MCC which is a water 
insoluble polymer. 5 %w/w of chloramphenicol was used in the formulation, as explained 
in Chapter 1, because the ocular mini-tablets is a slow-release system that needs to be 
applied once a day, unlike eye drops that need to be reapplied several times a day. The 
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Carbopol 974P percentage (15 %) was chosen based on a previous study done by 
Weyenberg et al. (2006). The percentage of SSF (2 %) in the formulation is commonly 
used in tableting process (Aulton and Taylor, 2013). Meanwhile, HPMC, PEG 6K, PVP 
90F and PEO 8M were used for Formula 2. Carbopol 974P was removed because all 
polymers used in the in this formulation were water soluble polymers. For each polymer, 
two sieve fractions were assessed: 125 to 180 µm and 180 to 250 µm. The powders 
(except the lubricant) were mixed using a Turbula mixer for 10 minutes, and then lubricated 
with SSF in the same mixer for another 5 minutes. Mini-tablets were prepared by 
compression using an instrumented 4 station Riva Piccola rotary tablet press (Riva, 
Argentina) with 2 mm normal concave plain punches (B tooling) at a compression force of 
1.8 ± 0.2 kN. Only one set of tooling was used during the process.  For each formulation, 
one batch of circa 100 mini-tablets was manufactured. 
 
3.2.2.2  Physical characterisation of the mini-tablets 
 
3.2.2.2.1  Weight uniformity 
The weight uniformity of the mini-tablets was assessed following the British 
Pharmacopoiea (2015) method. Twenty tablets from each formulation were weighed 
individually and the mean and standard deviation were determined. 
 
3.2.2.2.2  Measurement of mini-tablet dimensions 
Ten tablets were selected randomly from each batch and their thickness (curved surface 
to curved surface) was measured using a digital calliper (Mitotoyo, Japan). The diameter 
was assumed to be constant at 2 mm, as this was determined by the use of the 2 mm 
punches. 
 
3.2.2.2.3  Friability  
The friability or F(%) of the mini-tablets were assessed as described in Chapter 2. Ten 
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tablets were weighed as a unit and placed in the drum of a friability tester (Copley 
Scientific, UK). The drum was rotated for 100 revolutions at 25 rpm. Any loose dust from 
the tablets was removed and the tablets then re-weighed as a unit to calculate the % 
friability using following equation: 
 
F(%)= (
P-P'
P
)×100 Eq. 3.1 
 
where P is the initial weight and P' is the final weight of the tablets. 
 
3.2.2.2.4  Crushing strength 
The crushing strength of ten randomly-selected mini-tablets was assessed using a TA.TX2 
texture analyser (Stable Microsystems Ltd, UK) following the method of El-Gawad et al. 
(2012) and as described in detail in Chapter 2. 
 
3.2.2.2.5  Moisture uptake 
The moisture uptake profile of the mini-tablets was measured over 24 hours using a 
dynamic vapour sorption (DVS) method (Surface Measurement Systems, UK) at fixed high 
humidity (95 ± 1 % RH) as described in detail in Chapter 2. This method was proposed to 
replace water uptake tests that have been used previously by other researchers 
(Weyenberg et al., 2005, Mortazavi et al., 2010, El-Gawad et al., 2012). The test was 
replicated at least three times for each formulation.  
 
3.2.2.2.6  Surface analysis 
The surface quality of the mini-tablets was evaluated by using FEI™ Quanta 200F field 
emission scanning electron microscopy (SEM) (FEI Company, USA). The samples were 
coated with 25 nm of gold under vacuum condition using a Quorum Q150T Turbo-Pumped 
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Sputter Coater with a film thickness monitor unit, as explained in more detail in Chapter 
2. 
 
The transition temperature of the mini-tablet's surface was mapped by using a VESTA 
instrument supplied by Anasys Instruments (USA), which is equipped with an AN-200 
Therma-Lever™ micromachined silicon probe. The measurement was carried out over an 
area of 100 × 100 µm with 11 × 11 grid of measurements. Further details on this technique 
are explained in Chapter 2. 
 
3.2.2.3  Drug release profile 
The drug release profile of the mini-tablets was assessed using a modified flow-through 
dissolution apparatus with chamber size 200 µL and flow rate 50 µL/minute as described 
fully in Chapter 2. The dissolution medium used was simulated tear fluid (STF), consisting 
of an aqueous solution of sodium bicarbonate 0.2 %w/w, calcium chloride 0.008 %w/w 
and sodium chloride 0.67 %w/w at pH 7.4 (Marques et al., 2011). The outflow of the 
apparatus was collected in 1-hour time blocks, such that 3 mL of sample was available for 
analysis at each time point. The drug content in these samples was quantified 
spectrophotometrically at 278 nm. The study continued for 9 hours, measuring the amount 
released every hour. For samples which had reached maximum drug release at 9 hours, 
no further analysis was performed and the 9-hour cumulative amount released was taken 
to be the 100 % level and used to calculate the percentage drug release at each of the 
earlier timepoints. However, for those samples whereby drug release was not complete at 
9 hours, the total amount of drug in the mini-tablet was estimated by reference to the drug 
content of a random sample of mini-tablets from the same batch. This was measured by 
dissolving a mini-tablet in STF and making the solution up to 10 mL with STF, and 
measuring the drug content spectrophotometrically at 278 nm. It was not possible to collect 
the residual tablet from the flow-through dissolution chamber in order to assess the 
undissolved drug content, as it had formed a viscous gel during the dissolution process, 
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making extraction and quantification difficult. At least three replicates were performed for 
each formulation. 
 
3.2.2.4  Mathematical modelling of the dissolution profiles 
The dissolution profiles generated in this study were analysed by fitting them to the zero 
order, first order and Korsmeyer-Peppas kinetic equations. Additionally, the dissolution 
profiles were compared holistically using the f1 difference and f2 similarity factors. The 
mathematical analysis is described in Chapter 2. 
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3.3.  RESULTS AND DISCUSSION 
 
3.3.1  Physical characterisation of Formula 1 mini-tablets 
 
The purpose of physical characterisation is to determine the physical properties of the 
mini-tablets and, in this case, to assess whether there was any systematic variation in 
these properties with the sieve fraction of the predominant polymer used in the formulation. 
Table 3.1 shows a summary of all the physical characterisation data except the moisture 
uptake profile. 
 
Table 3.1 Summary of physical properties of Formula 1 mini-tablets (mean  SD). 
Polymer Sieve 
Fraction 
(µm) 
Weight 
(mg) 
(n=20) 
Thickness 
(mm) 
(n=10) 
Friability 
(%) 
(n=3) 
Crushing 
Strength 
(N) (n=10) 
HPMC 125-180 8.85 ± 1.26 2.59 ± 0.18 0.04 ± 0.07 35.2 ± 18.6 
HPMC 180-250 9.22 ± 0.59 2.66 ± 0.21 0.04 ± 0.07 38.4 ± 15.6 
PEG 6K 125-180 9.65 ± 0.67 2.70 ± 0.08 n/a 26.6 ± 2.6 
PEG 6K 180-250 11.10 ± 0.62 3.04 ± 0.19 n/a 27.6 ± 1.2 
MCC 125-180 8.70 ± 1.41 2.21 ± 0.49 0.30 ± 0.27 18.7 ± 15.2 
MCC 180-250 8.34 ± 1.15 2.23 ± 0.44 0.41 ± 0.10 24.2 ± 20.7 
* n/a = Not applicable. 
 
The details of the studies regarding the physical characterisations are discussed in 
following sections. 
 
3.3.1.1  Weight uniformity 
The weight of the mini-tablets ranged between 8.34 ± 1.15 mg for the HPMC 125-180 µm 
sieve fraction and 11.10 ± 0.62 mg for the PG 6K 180-250 µm sieve fraction as shown in 
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Table 3.1. The British Pharmacopoeia (2015) specification for weight variation for solid 
products with nominal weight less than 80 mg is that a maximum of two of the twenty 
tablets tested have weights which are more than 10 % different from the mean value and 
that no tablets have weights that deviate by more than 20 % from the mean. Additionally, 
the BP specifies that for products with weights less than 40 mg, the test for weight 
uniformity does not apply and the test for content uniformity should apply instead. 
However, as the product weight variability is a good measure of the effectiveness of a 
formulation and a process in combination, this test was used here with the above 
specifications being applied. Table 3.2 shows the weight measurements of twenty mini-
tablets randomly chosen from each formulation. Black type denotes tablets that directly 
passed the above specification (i.e. tablets with weights showing less than 10 % deviation 
from the mean), red type denotes tablets that show between 10 and 20 % deviation from 
the mean value, and blue type denotes tablets that show greater than 20 % deviation from 
the mean value. 
 
Inspection of the data shows that only the batch of mini-tablets based on the PEG 6K 180-
250 µm sieve fraction passed the weight uniformity test, with 1 tablet showing greater than 
10 % deviation from the mean. Its counterpart batch failed, with 3 tablets showing between 
10 and 20 % deviation from the mean. These two batches of mini-tablets were also 
statistically different in terms of actual weight (p < 0.05). Mini-tablet batches made from 
the other two polymers were inherently more variable in terms of the individual tablets' 
weights, but showed no statistical difference in weight between sieve fractions (p > 0.05). 
Overall, for all three polymers, mini-tablets made from the smaller particle size powders 
showed greater variability than those from the larger particle size powders, as 
demonstrated by the RSD values. 
 
  
Chapter 3 
 
 
100 
Table 3.2  Weight uniformity data for Formula 1 mini-tablets. 
Mini-
tablets 
HPMC 
125-180 
µm (mg) 
HPMC 
180-250 
µm (mg) 
PEG 6K 
125-180 
µm (mg) 
PEG 6K 
180-250 
µm (mg) 
MCC 
125-180 
µm (mg) 
MCC 
180-250 
µm (mg) 
1 7.64 9.03 9.87 11.70 8.88 9.61 
2 9.98 9.84 9.24 11.87 11.46 7.99 
3 7.02 8.60 10.15 11.62 7.70 9.00 
4 8.18 9.07 10.58 11.71 9.30 9.30 
5 9.82 10.10 9.99 10.67 7.35 9.39 
6 7.13 8.96 10.00 10.89 8.21 8.47 
7 8.14 8.99 10.76 11.40 7.89 8.62 
8 9.21 8.09 9.29 10.81 8.18 8.22 
9 8.00 9.33 9.55 10.78 11.20 10.42 
10 8.56 10.14 10.27 11.60 8.20 7.88 
11 9.70 8.73 9.92 11.75 7.30 6.07 
12 7.71 9.21 9.16 10.87 9.83 9.59 
13 10.21 9.52 8.49 10.96 8.50 6.81 
14 11.15 8.98 8.38 10.00 8.14 8.77 
15 7.97 8.23 10.26 10.79 7.65 6.36 
16 7.12 8.96 9.09 11.18 11.35 8.26 
17 10.42 9.59 9.44 12.00 6.33 7.71 
18 10.44 9.31 10.29 11.17 9.74 7.96 
19 9.42 9.49 9.41 9.70 7.77 9.23 
20 9.20 10.22 8.79 10.47 9.12 7.09 
Mean (mg) 8.85 9.22 9.65 11.10 8.71 8.34 
SD (mg) 1.26 0.59 0.67 0.62 1.41 1.14 
RSD (%) 14.26 6.35 6.95 5.60 16.24 13.73 
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3.3.1.2  Thickness 
There are no pharmacopoeial specifications for the thickness of tablets, either the actual 
value or its uniformity. However, it is a vital attribute to control as it can potentially affect 
the accuracy of packing of tablets into blisters or tubes. It is also indirectly related to the 
crushing strength of a tablet. Table 3.3 shows the thickness measurements of ten mini-
tablets randomly chosen from each formulation. 
 
Table 3.3  Thickness data for Formula 1 mini-tablets. 
Mini-
tablets 
HPMC 
125-180 
µm (mm) 
HPMC 
180-250 
µm (mm) 
PEG 6K 
125-180 
µm (mm) 
PEG 6K 
180-250 
µm (mm) 
MCC 
125-180 
µm (mm) 
MCC 
180-250 
µm (mm) 
1 2.62 2.70 2.75 3.39 2.83 2.88 
2 2.67 2.67 2.77 3.00 2.87 1.85 
3 2.81 2.78 2.83 3.08 2.32 2.09 
4 2.63 2.95 2.66 3.02 1.88 2.02 
5 2.62 2.44 2.67 2.62 1.87 2.83 
6 2.64 2.83 2.63 3.13 2.94 1.94 
7 2.86 2.95 2.64 3.00 1.71 2.14 
8 2.34 2.45 2.79 3.11 1.88 2.85 
9 2.33 2.44 2.65 3.06 1.90 1.87 
10 2.42 2.43 2.63 2.96 1.85 1.86 
Mean (mm) 2.59 2.66 2.70 3.04 2.21 2.23 
SD (mm) 0.18 0.21 0.08 0.19 0.49 0.44 
RSD (%) 6.95 7.98 2.78 6.25 22.29 19.65 
 
The measured thickness values ranged from 2.21 ± 0.49 mm for the MCC 125-180 µm 
sieve fraction to 3.04 ± 0.19 mm for the PG 6K 180-250 µm sieve fraction. No difference 
was observed in the thickness of the tablets based on the two sieve fractions of MCC nor 
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of HPMC (p > 0.05). A statistically significant difference (p < 0.05) was observed between 
the mini-tablets based on the two sieve fractions of PEG 6K. The variation within each 
batch was quite considerable and far greater than would be expected for tablets of 
conventional size, where an RSD value for thickness of 1 to 2 % is normal. As thickness 
is also directly related to the weight of the tablet, if the compression force is kept constant, 
these results are not surprising, given the weight variability results described above. 
 
3.3.1.3  Crushing strength 
In common with tablet thickness, there are no specific pharmacopoeial specifications for 
the values of the crushing strength of tablets and the measured value is dependent on the 
size and shape of the tablet as well as the formulation and the compression parameters 
used. However, it is vital that a correct value of the crushing strength is obtained: too low 
and the tablet will be very delicate and unable to withstand further processing or transport; 
too high and the dissolution profile may be adversely affected. In previous studies, the 
hardness values ranged between 0.67 N and 18.64 N (Weyenberg et al., 2003, 
Weyenberg et al., 2005), so 5 to 15 N was chosen as a target value here, as described in 
Chapter 1. Table 3.4 shows the crushing strength measurements of ten mini-tablets 
randomly picked from each formulation. 
 
HPMC mini-tablets showed the highest crushing strength values followed by PEG 6K and 
MCC mini-tablets respectively, for both sieve fractions. However, HPMC and MCC mini-
tablets displayed great variability in their crushing strength. Although crushing strength 
values tend to be more variable than those of other physical characteristics (such as weight 
variability or thickness), this high variability is unacceptable for any pharmaceutical 
formulation because tablets show consistent behaviour in all aspects (Aulton and Taylor, 
2013). A difference in the crushing strength may also affect the drug release profile, in that 
the higher the crushing strength, generally the slower the drug release (Weyenberg et al., 
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2005), although the relationship should be established for each individual formulation. 
Typically, RSD values for tablet weights are in the order of 1 to 2 %, whereas those for 
thickness tend to be less than 1 % and RSD values for the hardness measurements of the 
same tablets tend to be in the order of 10 %.  Several of the individual hardness results 
for the HPMC and MCC mini-tablets were extremely low. Although the individual tablet 
weights were not recorded prior to the crushing strength test, the tablets with the lowest 
crushing strength values were observed to be smaller than some of their counterparts from 
the same batch, so are likely to have lower resistance to crushing. This observation, taken 
together with the overall variability of the results for these batches of mini-tablets, 
suggested that these individual results were somewhat anomalous, so although they did 
not meet the usual statistical requirements for assessment of outliers (where the individual 
values should be more than 3 standard deviations from the mean), the summary data were 
re-calculated without these data points.  If the very low results (less than 10 N) are 
removed from the calculations, the results are more consistent, with greater similarities 
seen between the two batches made from the same material. 
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Table 3.4  Crushing strength data for Formula 1 mini-tablets. 
Mini-
tablets 
HPMC 
125-180 
µm (N) 
HPMC 
180-250 
µm (N) 
PEG 6K 
125-180 
µm (N) 
PEG 6K 
180-250 
µm (N) 
MCC 
125-180 
µm (N) 
MCC 
180-250 
µm (N) 
1 3.3 58.2 24.5 27.3 15.2 29.8 
2 47.6 24.9 30.6 28.4 5.4 54.6 
3 25.2 20.7 26.4 28.7 9.2 28.9 
4 46.7 34.7 22.4 25.0 29.7 2.5 
5 50.4 48.5 25.8 27.0 37.9 2.6 
6 4.2 58.2 23.8 29.3 39.1 37.9 
7 56.5 26.1 29.3 28.3 4.7 56.8 
8 35.5 28.3 27.9 27.3 3.6 10.3 
9 40.5 26.2 26.1 27.2 6.0 3.8 
10 42.4 58.2 29.0 28.0 36.2 15.0 
Mean (N) 35.2 38.4 26.6 27.6 18.7 24.2 
SD (N) 18.6 15.6 2.6 1.2 15.2 20.7 
RSD (%) 52.88 40.62 9.85 4.36 81.23 85.50 
Mean (N) 43.1 38.4 26.6 27.6 31.6 33.3 
SD (N) 9.7 15.6 2.62 1.2 9.9 17.9 
RSD (%) 22.4 40.6 9.85 4.36 31.2 53.7 
 
NB The very low results were removed from the calculations in the second set of summary 
statistics. 
 
3.3.1.4  Friability 
For the friability test, the maximum loss of mass after the test should not exceed 1.0 % of 
the initial mass (British Pharmacopoeia, 2015). The friability values were all well within the 
acceptable range as shown in Table 3.5.  
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Table 3.5  Friability data for Formula 1 mini-tablets. 
Mini-tablets Initial 
(mg) 
Final 
(mg) 
Difference 
(mg) 
Difference 
(%) 
Mean 
(%) 
SD 
HPMC  
125-180 µm 
80.3 80.3 0.0 0.00 0.04 0.07 
81.8 81.8 0.0 0.00   
77.6 77.5 0.1 0.13   
HPMC  
180-250 µm 
88.1 88.1 0.0 0.00 0.04 0.07 
96.2 96.2 0.0 0.00   
86.6 86.5 0.1 0.12   
PEG 6K 
125-180 µm 
97.8 97.8 0.0 0.00 0.00 0.00 
98.6 98.6 0.0 0.00   
99.3 99.3 0.0 0.00   
PEG 6K  
180-250 µm 
113.5 113.5 0.0 0.00 0.00 0.00 
114.0 114.0 0.0 0.00   
107.1 107.1 0.0 0.00   
MCC  
125-180 µm 
60.7 60.6 0.1 0.16 0.30 0.27 
76.8 76.6 0.1 0.13   
65.5 65.1 0.4 0.61   
MCC  
180-250 µm 
67.4 67.2 0.2 0.30 0.41 0.10 
65.2 64.9 0.3 0.46   
63.6 63.3 0.3 0.48   
 
HPMC and PEG 6K mini-tablets showed very similar friability profiles for both their 
component sieve fractions. However, there was a notable difference in the values for MCC 
mini-tablets between the sieve fractions, with MCC mini-tablets prepared from the smaller 
sieve fraction displaying a higher friability compared to their counterparts. 
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3.3.1.5  Moisture uptake 
The most common method used in the literature for assessing moisture/water uptake is by 
placing the mini-tablet on top of a membrane or glass filter which is connected on the lower 
side to a reservoir and then measuring the weight gain of the mini-tablets over time 
(Weyenberg et al., 2005, Mortazavi et al., 2010, El-Gawad et al., 2012). This technique 
has a drawback which is that the mini-tablet needs to be repeatedly removed from the 
membrane for it to be re-weighed and replaced again on top of the membrane. During the 
transferring process, some of the mini-tablet part might stick on the forceps which will 
reduce the actual weight and make the test less accurate. Additionally, as the water uptake 
increases over time, the mini-tablets can become less rigid and so more difficult to 
manipulate, again introducing errors into the measurement. By using DVS, these 
drawbacks can be prevented since the mini-tablet will stay in the chamber and the weight 
change data will be collected automatically by the computer. 
 
Figure 3.2 illustrates the moisture uptake of the mini-tablets over a 24-hour period. PEG 
6K mini-tablets absorbed moisture the most followed by the HPMC and MCC mini-tablets 
respectively. From the graph, it can be concluded that the mini-tablets made from the 
larger sieve fractions of PEG 6K and HPMC absorbed more moisture compared with their 
counterparts. There was no difference in the behaviour of the two batches of mini-tablets 
prepared from MCC. 
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Figure 3.2  Moisture uptake profiles of Formula 1 mini-tablets (mean ± SD, n=3). 
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MCC mini-tablets showed smaller weight changes and identical profiles for both sieve 
fractions because MCC is not a water-soluble or hydrophilic polymer, so it does not absorb 
much moisture/water. HPMC and PEG 6K mini-tablets (both sieve fractions) were 
completely dissolved at the end of the studies. However, MCC mini-tablets were still intact 
because of their hydrophobic properties. 
 
3.3.1.6  General discussion for the Formula 1 mini-tablets 
There was a high degree of variability in the weight of the mini-tablets produced from 
Formula 1 as shown in Table 3.2 above. This variability probably hides any difference 
that may exist between the two particle size distributions of the polymers. However, the 
extent of this variability was unexpected and so was further investigated. Ultimately, the 
cause of the observed variable weight of the mini-tablets was not an intrinsic property of 
the powders, but the lowering cam equipped on the tablet press as shown in Figure 3.3. 
 
         
Figure 3.3  The lowering cam from the tablet press. 
 
During the tableting process, after the die is filled with the powder at the feeder section, 
the lower punch will be drawn down by the lowering cam, creating a gap at the top of the 
die, with the intention of preventing the powder in the die from spillage on rotation. Due to 
this action, some of the powder slipped downwards through the gap that was then created 
between the die and the punch, reducing the amount of powder in the die. This problem 
only occurs with dies with small diameter cores (e.g. 2 mm), reflecting smaller diameter 
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tablets, due to their shape. The smaller-diameter dies are not symmetrical and have wider 
openings at the bottom side than the top side (shown in Figure 3.4) while for the dies with 
larger diameter cores (e.g. 7 mm), the opening is the same size on both sides. In the case 
of the punches with the 2 mm diameter cores, the width of the gap on the underside is 10 
mm. 
 
  
 (a) (b) 
Figure 3.4  (a) Top and (b) bottom opening of 2 mm diameter die. 
 
During the tabletting operation, when the punch is drawn down as described above, a 2 
mm diameter punch tip will slide down from the 2 mm diameter opening to the 10 mm 
diameter opening, creating a gap into which particle will fall, causing the powder loss which 
ultimately results in tablet weights which are lower and more variable than would be 
expected. Logically, smaller particles would be expected to show greater movement 
through the gaps, and indeed the smaller particle size powders produced greater variability 
in tablet weight than their larger particle size counterparts, as indicated by the relevant 
RSD values. To overcome the problem, the lowering cam was removed from the tablet 
press machine, so that the lower punch was not pulled down during the compression cycle 
and powder was not lost in the gap between the lower punch and the die. 
 
Further tests for mini-tablets from Formula 1 were not conducted as most of the mini-
tablets did not pass the physical characterisation tests, only the PEG 6K mini-tablets. 
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Formula 2 was suggested to replace Formula 1 where MCC is replaced with PVP 90F 
and PEO 8M, and Carbopol 974P is removed from formulation. MCC is replaced with other 
polymers because it did not dissolve in water. And since all the polymers chosen for 
Formula 2 are water soluble, there was no need to add Carbopol 974P in the formulation 
since this polymer was initially added to Formula 1 formulations to act as a viscosity-
raising agent which can increase the water sorption and prolong drug release, as 
suggested by Weyenberg et al. (2006). 
 
3.3.2  Physical characterisation of Formula 2 mini-tablets 
 
Table 3.6 summarises all the physical characterisation data for the Formula 2 mini-tablets 
except vapour sorption, performed as described for the Formula 1 mini-tablets. 
 
Table 3.6 Summary of the physical properties of Formula 2 mini-tablets (mean  SD) 
Polymer Sieve 
Fraction 
(µm) 
Weight 
(mg) 
(n=20) 
Thickness 
(mm) 
(n=10) 
Friability 
(%) 
(n=3) 
Crushing 
Strength 
(N) (n=10) 
HPMC 125-180 6.26 ± 0.34 1.89 ± 0.03 0.22 ± 0.01 12.43 ± 1.74 
HPMC 180-250 6.20 ± 0.21 1.91 ± 0.04 0.16 ± 0.06 17.11 ± 2.55 
PEG 6K 125-180 5.50 ± 0.35 1.58 ± 0.04 0.48 ± 0.04 8.24 ± 1.29 
PEG 6K 180-250 9.75 ± 0.29 2.79 ± 0.04 0.34 ± 0.07 12.10 ± 1.38 
PEO 8M 125-180 6.97 ± 0.08 2.22 ± 0.01 0.03 ± 0.01 43.18 ± 1.44 
PEO 8M 180-250 7.40 ± 0.09 2.33 ± 0.02 0.05 ± 0.02 40.07 ± 2.06 
PVP 90F 125-180 7.84 ± 0.07 2.43 ± 0.01 1.44 ± 0.25 5.84 ± 0.59 
PVP 90F 180-250 7.43 ± 0.10 2.34 ± 0.02 9.92 ± 0.69 5.64 ± 0.99 
 
Each of the characterisation studies is discussed in detail in the following sections. 
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3.3.2.1  Weight uniformity 
The weight of the mini-tablets ranged between 5.50 ± 0.35 mg for the PEG 6K 125-180 
µm sieve fraction and 9.75 ± 0.29 mg for the PG 6K 180-250 µm sieve fraction, as shown 
in Table 3.6. Table 3.7 shows the weight measurements of twenty mini-tablets randomly 
chosen from each formulation. As before, black type denotes tablets that directly passed 
the BP specification, red type denotes tablets that show between 10 and 20 % deviation 
from the mean value, and blue type denotes tablets that show greater than 20 % deviation 
from the mean value.  
 
Both mini-tablet batches based on PVP 90F and both mini-tablets batches based on PEO 
8M directly passed the BP specification, with all individual readings being within 10 % of 
the relevant mean value. All four of these batches showed excellent reproducibility, with 
very low RSD values of circa 1 %. For both polymers, there was a slight but statistically 
significant difference (p < 0.05) in the mean weight between the two sieve fractions: the 
PEO 8M mini-tablets showed a higher weight with the larger size fraction, whereas the 
PVP 90F showed the opposite effect. The HPMC-based mini-tablets passed the BP 
specifications, the larger size fraction batch directly with all values being within 10 % of the 
mean value, and the smaller size fraction batch with one value being approximately 83 % 
of the mean value. There was no difference between the weights of the mini-tablets from 
the two sieve fractions of HPMC (p > 0.05). The PEG 6K mini-tablets showed the greatest 
difference in weight between the size fractions, which was surprisingly large compared to 
the other results.  
 
The variability of the mini-tablets from the smaller particle size powder was much greater 
than from the larger particle size polymer, and included one tablet which fell outside of the 
limits of the 20 % deviation from the mean. The HPMC and PEG 6K mini-tablets in 
Formula 2 were lower compared to both mini-tablets in Formula 1. This is possibly 
because of the removal of Carbopol 974P from the formulation. These results suggest that 
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the removal of the lowering cam on the tablet press had an overall beneficial effect on the 
reproducibility of the tablet weight, but there was an additional small effect attributable to 
the powders themselves.  
 
Table 3.7  Weight uniformity data for Formula 2 mini-tablets. 
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1 6.59 6.06 6.10 9.79 7.16 7.35 7.71 7.38 
2 6.73 6.55 5.70 9.96 6.93 7.32 7.73 7.28 
3 6.20 6.41 5.49 9.84 6.97 7.44 7.72 7.22 
4 6.31 6.22 5.12 9.53 6.95 7.58 7.76 7.34 
5 6.25 6.08 5.63 8.97 6.93 7.42 7.87 7.57 
6 5.22 6.18 5.64 10.09 7.00 7.28 7.86 7.41 
7 6.33 6.34 5.24 9.74 7.02 7.29 7.74 7.31 
8 6.42 6.28 5.43 9.97 6.98 7.34 7.84 7.49 
9 6.05 6.00 4.67 9.54 7.02 7.41 7.86 7.35 
10 6.31 6.03 5.40 9.74 6.97 7.39 7.89 7.49 
11 6.46 6.12 5.61 9.87 7.03 7.40 7.83 7.58 
12 6.55 6.19 5.91 9.89 6.95 7.55 7.91 7.55 
13 6.30 6.07 5.65 9.89 7.02 7.52 7.86 7.43 
14 6.64 6.11 6.04 9.95 7.01 7.36 7.83 7.50 
15 6.36 6.14 5.15 10.08 6.86 7.56 7.82 7.46 
16 5.95 5.71 5.43 9.79 7.02 7.37 7.85 7.42 
17 5.80 6.26 5.71 9.76 7.03 7.37 7.96 7.42 
18 6.30 6.68 5.36 9.68 6.92 7.42 7.85 7.36 
19 5.98 6.41 4.98 9.09 6.85 7.42 7.92 7.49 
20 6.46 6.09 5.76 9.91 6.80 7.23 7.89 7.57 
Mean (mg) 6.26 6.20 5.50 9.75 6.97 7.40 7.84 7.43 
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SD (mg) 0.34 0.21 0.35 0.29 0.08 0.09 0.07 0.10 
RSD (%) 5.44 3.44 6.43 2.96 1.13 1.27 0.89 1.37 
 
3.3.2.2  Thickness 
The thickness data are shown in Table 3.8. The measured thickness values ranged from 
1.89 ± 0.03 mg for the HPMC 125-180 µm sieve fraction to 2.79 ± 0.19 mg for the PEG 6K 
180-250 µm sieve fraction.  
 
Table 3.8  Thickness data for Formula 2 mini-tablets. 
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1 1.90 1.95 1.60 2.81 2.20 2.34 2.42 2.32 
2 1.93 1.90 1.54 2.73 2.21 2.35 2.45 2.33 
3 1.84 1.85 1.61 2.82 2.21 2.34 2.43 2.34 
4 1.86 1.88 1.53 2.72 2.20 2.33 2.44 2.34 
5 1.86 1.87 1.54 2.82 2.24 2.30 2.45 2.36 
6 1.90 1.90 1.63 2.78 2.23 2.32 2.43 2.36 
7 1.91 1.91 1.63 2.77 2.20 2.32 2.42 2.33 
8 1.93 1.94 1.57 2.80 2.22 2.31 2.44 2.37 
9 1.88 1.96 1.60 2.81 2.23 2.30 2.43 2.34 
10 1.91 1.89 1.52 2.82 2.22 2.34 2.43 2.33 
Mean (mm) 1.89 1.91 1.58 2.79 2.22 2.33 2.43 2.34 
SD (mm) 0.03 0.04 0.04 0.04 0.01 0.02 0.01 0.02 
RSD (%) 1.63 1.87 2.67 1.34 0.65 0.77 0.44 0.69 
 
All batches showed an acceptable (in some cases, very acceptable) level of variation as 
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demonstrated by the RSD values, although the variability for the PEG 6K 180-250 µm 
sieve fraction was a little on the high side, with an RSD of 2.67 %. No difference was 
observed in the thickness of the tablets based on the two sieve fractions of HPMC. A 
statistically significant difference (p < 0.05) was observed between the mini-tablets based 
on the two sieve fractions of PEO 8M and PVP 90F. Mini-tablets based on PEG 6K 
appeared to be anomalous here, with the larger particle size of the polymer giving rise to 
much thicker tablets than the smaller particle size. 
 
3.3.2.3  Crushing strength 
The crushing strength results showed a very wide range of values from 5.64  0.99 N to 
43.18  1.44 N, as shown in Table 3.9. The lowest value of crushing strength was from 
PVP 90F mini-tablets (from both sieve fractions) followed by the PEG 6K, HPMC and PEO 
8M mini-tablets, in that order. Previous published studies on mini-tablets showed values 
of hardness ranging between 0.67 N and 18.64 N (Weyenberg et al., 2003, Weyenberg et 
al., 2005). 
 
PEO 8M mini-tablets from both sieve fractions have the highest crushing strength and 
showed very different behaviour compared to the rest of the mini-tablets, because they 
were just deformed instead of breaking. However, the endpoint recorded was actually the 
force registered at the end of the probe's fixed-distance travel, rather than the force at 
breaking as for the other mini-tablets. Hence, although the measurements for the PEO 
mini-tablets were consistent with low RSD values at 3.34 % and 5.14 % for the smaller 
and larger sieve fractions, respectively, the data should not be over-interpreted. 
 
The rest of mini-tablets showed conventional breaking behaviour. No difference (P > 0.05) 
was observed in the crushing strength of the two PVP 90F batches, but the mini-tablet 
batches based on HPMC and PEG 6K both showed statistically significant differences (p 
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< 0.01), with the larger particle size fraction leading to increased crushing strength. This is 
counter-intuitive, as it would be expected that the smaller particle size fraction would lead 
to increased contact between the particles, hence increased binding and greater 
resistance to crushing. All of these batches displayed crushing strength RSD values higher 
than 10 %. Even though there is no standard suggested by the British Pharmacopoeia, 
and values of this magnitude are reasonably common among tablet formulations, the 
crushing strength should be kept consistent to avoid any change in the dissolution 
behaviour of the tablets. 
 
Table 3.9 Crushing strength data of Formula 2 mini-tablets. 
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1 10.64 14.31 8.93 11.96 44.50 36.29 5.85 4.90 
2 16.36 20.94 8.15 11.46 43.96 39.03 6.21 7.40 
3 12.76 16.13 7.67 12.15 42.56 38.93 5.33 5.89 
4 10.90 17.56 7.56 15.00 46.34 41.06 5.77 4.98 
5 11.15 19.95 7.01 11.32 41.41 40.13 5.82 6.10 
6 13.97 14.29 7.99 12.09 43.35 43.06 6.57 5.54 
7 12.97 15.68 10.09 12.86 42.06 41.15 6.53 4.69 
8 11.91 14.19 8.47 10.38 42.05 39.82 5.71 4.62 
9 11.13 19.79 6.18 10.48 42.82 42.81 6.06 5.12 
10 12.55 18.23 10.35 13.33 42.77 38.38 4.55 7.15 
Mean (N) 12.43 17.11 8.24 12.10 43.18 40.07 5.84 5.64 
SD (N) 1.74 2.55 1.29 1.38 1.44 2.06 0.59 0.99 
RSD (%) 14.03 14.93 15.67 11.38 3.34 5.14 10.09 17.58 
* Red = Values relating to deformation rather than breaking. 
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3.3.2.4  Friability 
The friability data are shown in Table 3.10. 
 
Table 3.10  Friability data for Formula 2 mini-tablets. 
Polymer Initial 
(mg) 
Final 
(mg) 
Difference 
(mg) 
Difference 
(%) 
Mean 
(%) 
SD 
HPMC 
125-180 µm 
65.34 65.19 0.15 0.23 0.22 0.01 
63.26 63.13 0.13 0.21   
65.04 64.89 0.15 0.23   
HPMC 
180-250 µm 
61.19 61.13 0.06 0.10 0.16 0.06 
63.95 63.85 0.1 0.16   
62.60 62.46 0.14 0.22   
PEG 6K 
125-180 µm 
54.16 53.92 0.24 0.44 0.48 0.04 
53.35 53.10 0.25 0.47   
53.53 53.25 0.28 0.52   
PEG 6K 
180-250 µm 
98.36 97.95 0.41 0.42 0.34 0.07 
97.93 97.65 0.28 0.29   
97.38 97.08 0.3 0.31   
PEO 8M 
125-180 µm 
69.55 69.53 0.02 0.03 0.03 0.01 
69.79 69.76 0.03 0.04   
69.09 69.08 0.01 0.01   
PEO 8M 
180-250 µm 
73.70 73.66 0.04 0.05 0.05 0.02 
73.45 73.41 0.04 0.05   
73.74 73.72 0.02 0.03   
PVP 90F 
125-180 µm 
84.23 83.21 1.02 1.21 1.44 0.25 
83.65 82.22 1.43 1.71   
84.13 82.94 1.19 1.41   
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PVP 90F 
180-250 µm 
77.15 69.97 7.18 9.31 9.92 0.69 
79.78 71.97 7.81 9.79   
79.19 70.74 8.45 10.67   
 
For this friability test, a higher accuracy balance was used, compared to the previous 
study. The balance used in this study can measure up to 5 decimal points in grams (equal 
to 2 decimal points in milligrams) while the balance used in previous study could measure 
only up to 4 decimal points in grams. With this balance, smaller changes in weight could 
be determined more accurately. From Table 3.9, it can be seen that all of the mini-tablets 
pass the friability test specification except PVP 90F mini-tablets for both sieve fractions. 
The percentage losses of PVP 90F (125-180 µm) and PVP 90F (180-250 µm) were 1.44 
± 0.25 % and 9.92 ± 0.69 %, respectively, higher that the limit set by British Pharmacopoiea 
(2015), which is not more than 1.0 % weight loss. 
 
As would be expected, there was a general relationship between the crushing strength 
data and the friability results, in that a higher crushing strength results in a lower friability. 
The mini-tablets need to be able to withstand handling and transport from the 
manufacturing process to administration by patient. If the weight of the mini-tablets 
decreases during that period, the dose of the drug taken by the patient will be decreased 
commensurately, which might affect the therapeutic outcome (Aulton and Taylor, 2013). 
 
3.3.2.5  Moisture uptake 
 
Figure 3.5 illustrates the moisture uptake of the mini-tablets over a 24-hour period. The 
highest weight change after 24 hours was for the PEO 8M (125-150 µm) mini-tablets at 
approximately 130 % weight increase from the initial weight while the lowest weight gain 
was for the PVP 90F (180-250 µm) mini-tablets at approximately 40 % weight increase 
from the initial weight. PEG 6K and PEO 8M mini-tablets were completely dissolved at the 
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end of the studies while mini-tablets based on HPMC and PVP 90F absorbed water and 
swelled. 
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Figure 3.5  Moisture uptake of Formula 2 mini-tablets (mean ± SD, n=3). 
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For the HPMC and PVP 90F formulations, there are only limited differences in the weight 
changes between the two size fractions. All of these batches absorbed between 40 and 
50 % of moisture compared to their initial weights, with the bulk of the weight changes 
occurring within the first 3 hours and plateauing thereafter. However, for PEG 6K and PEO 
8M formulations, the differences in moisture uptake are obvious where smaller sieve 
fraction mini-tablets are able to absorb more moisture compared to the larger sieve fraction 
mini-tablets. For both these polymers, the smaller sieve fractions absorbed circa 130 % of 
moisture compared to their initial weights while for the larger sieve fraction, they only 
absorbed circa 100 % moisture. Interestingly, the larger particle size batches appeared to 
be reaching a plateau at the end of the experiment after 24 hours study, whereas the 
smaller particle size batches still seem to be gaining moisture and had not yet reached a 
plateau when the experiment was terminated after 24 hours. 
 
3.3.2.6  Scanning electron microscopy 
All mini-tablets were smooth and shiny to the naked eye, but were scanned with SEM to 
observe the surface topography in more detail. The SEM images are shown in Figure 3.6. 
There was no obvious difference in the microscopic appearance of the mini-tablets 
prepared from the two sieve fractions of the same polymer, although there were some 
differences between formulations using different polymers. PEG 6K mini-tablets showed 
the smoothest surface compared with the other mini-tablets while PEO 8M and HPMC 
mini-tablets' surfaces were relatively smooth with visible cracks. PVP 90F mini-tablets, 
however, showed very rough surfaces and looked very fragile. These images help to 
explain the reason why PVP 90F mini-tablets did not pass the friability test and have low 
crushing strength values. 
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Figure 3.6  SEM images of Formula 2 mini-tablets. 
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3.3.2.7  Transition temperature microscopy 
The surface of the mini-tablets was analysed by using temperature transition microscopy 
(TTM). This technique is effectively an automated gathering of multiple local thermal 
analytical measurements taken over a grid pattern, measuring the thermal transition at 
each point. TTM is useful in assessing the distribution of materials across a surface. In this 
case, the selected area was 100 × 100 µm with 11 × 11 grid points. The background to 
the TTM technique is described in Chapter 2. 
 
During the TTM study on the mini-tablets' surface, a few things captured the attention. 
Other than the PEG 6K mini-tablets, the mini-tablets displayed irregular results where they 
did not show the expected transition temperature behaviour. Further investigations into 
this phenomenon were conducted and are discussed in Chapter 4. 
 
3.3.2.8  General discussion for the Formula 2 mini-tablets 
From the physical characterisation tests, it can be concluded that most of the Formula 2 
mini-tablet formulations complied with the standards that have been specified by BP for 
the weight uniformity and friability, the exception being the PVP 90F mini-tablets for both 
sieve fractions. PVP 90F mini-tablets did not pass the friability test as they exceeded the 
maximum limit which is 1.0 % of total weight loss (1.44 % for 125-180 µm sieve fraction 
and 9.92 % for 180-250 µm sieve fraction). The SEM images of these mini-tablets indicate 
that the PVP 90F mini-tablets are fairly loosely compacted which would lead to weak 
tablets. This problem could possibly be overcome by increasing the compression force 
during manufacture to provide a tougher tablet. However, the maximum force that can be 
applied using the 2 mm mini-tablet punches is 2.0 kN (in order to prevent damage to the 
punches themselves) and that was already within the force range which was used in this 
study (1.8 ± 0.2 kN). To exceed that compression force, larger punches would be needed, 
as the maximum tolerated force increases with increasing punch diameter, in a more than 
linear fashion. However, the larger punches would obviously produce larger tablets, which 
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would not be useful as ocular drug delivery systems. Overall, this means that the PVP 
90F-based mini-tablet formulation cannot be included as potential formulation for ocular 
mini-tablets for this study. However, the dissolution test for this formulation was still 
performed so as to see the release profile by all the mini-tablets.  
 
3.3.3  Drug release profile 
 
For the dissolution studies, a modified flow-through dissolution apparatus was used, as 
described in Chapter 2. This was following the suggestion put forward by Brown et al. 
(2011) on dissolution methodology suitable for granules, since the size of the mini-tablets 
made here is approximately the same as the size of granules. The mini-tablet was inserted 
into a 200 µL chamber of the flow-through dissolution apparatus and ran with STF at a 
rate of 50 µL/minute. Samples were taken every hour up to 9 hours and 
spectrophotometrically quantified at 278 nm. Figure 3.7 showed the release profiles of all 
the mini-tablets. 
 
Chloramphenicol in the mini-tablets prepared from both sieve fractions of PVP 90F and 
PEG 6K was completely released within 8 hours. At the end of the dissolution experiment, 
all of these tablets had completely dissolved leaving no residue. More than 85 % of the 
chloramphenicol contained in HPMC mini-tablets (both sieve fractions) and PEO 8M (180-
250 µm sieve fraction) mini-tablets had been released when the dissolution experiment 
was terminated after 9 hours. However, only 60% of the chloramphenicol in PEO 8M (125-
180 µm sieve fraction) mini-tablets had been released at the 9 hours timepoint. 
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Figure 3.7  Drug release profiles of chloramphenicol-loaded Formula 2 mini-tablets (mean ± SD, n=3). 
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From Figure 3.7, the drug release rate for all formulations can be described as in the 
following descending order: PEG 6K 180-250 µm > PEG 6K 125-180 µm = PVP 90F 125-
180 µm = PVP 90F 180-250 µm > HPMC 125-180 µm = HPMC 180-250 µm > PEO 8M 
180-250 µm > PEO 8M 125-180 µm. The graph also suggests that all formulations 
displayed nearly identical drug release profiles compared to their counterpart sieve 
fraction, except for PEO 8M formulation which showed distinctly different release profiles. 
This observation will be investigated by using the fit factors. 
 
3.3.3.1  Mathematical modelling of the release profiles 
Three mathematical models were applied to analyse the drug release profiles of mini-
tablets. The models are zero order kinetics, first order kinetics and the Korsmeyer-Peppas 
equation. Zero order and first order kinetics were analysed up to approximately 85 % drug 
release profile while the Korsmeyer-Peppas equation was analysed up to approximately 
60 % of drug release. Table 3.11 shows the coefficient of determination (r2), the release 
rate constants (k0, k1 and kKP) and the diffusional exponent (n) values for the release 
profiles. The best fit to the data is highlighted in green text. 
 
Based on the fitting results, PEG 6K and PVP 90F mini-tablets (both sieve fractions) 
showed a better fit to zero order kinetics (green text) than first order kinetics, although the 
r2 values are still quite low and indicate an imperfect fit to the profile. These mini-tablets 
could not be analysed with the Korsmeyer-Peppas equation because only 2 values were 
under 60 % of fractional drug release. This is because their release rates were too fast at 
the early timepoints of the dissolution test. Meanwhile HPMC and PEO 8M mini-tablets 
displayed better fits to the Korsmeyer-Peppas equation. However, HPMC mini-tablets for 
both sieve fractions were analysed with only 3 values since only these values were under 
60 % of fractional release. Zero order kinetics was the second best fit for HPMC mini- 
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Table 3.11  Mathematical modelling parameters for drug release from chloramphenicol-loaded Formula 2 mini-tablets. 
 
Polymer Sieve 
Fraction (µm) 
Zero order First order Korsmeyer-Peppas 
 r2 k0 r2 k1 r2 kKP n 
HPMC 125-180  0.9908 17.9140 0.9966 0.1686 0.9864 10.0543 1.2064 
HPMC 180-250 0.9959 18.9290 0.9887 0.2574 0.9752 12.3320 1.2154 
PEG 6K 125-180 0.9930 23.8810 0.9214 0.5667 0.9957 26.0157 0.9109 
PEG 6K 180-250 0.9895 29.7600 0.9409 0.7524 0.9948 32.2140 0.8793 
PEO 8M 125-180  0.9908 7.1756 0.9939 0.1026 0.9951 7.9741 0.9533 
PEO 8M 180-250 0.9840 11.989 0.9663 0.2063 0.9913 14.8070 0.8412 
PVP 90F 125-180 0.9902 20.7380 0.9491 0.4805 0.9848 16.4233 1.2180 
PVP 90F 180-250 0.9869 20.6930 0.9565 0.4386 0.9730 21.8784 0.9200 
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-tablets if the Korsmeyer-Peppas equation is disregarded from the results because the 
lack of points to be analysed. PEO 8M mini-tablets on the other hand can be fit with zero 
order kinetics as well since the r2 values for both sieve fractions are close to 1.0 (0.9936 
and 0.9847 for smaller and larger sieve fraction, respectively). 
 
Although it is generally recommended that the Korsmeyer-Peppas equation is only used 
for the first 60 % of drug release (Korsmeyer et al., 1983, Ritger and Peppas, 1987) and 
there are only two or three data points in the mean values with less than 60 % drug release, 
if higher release quotients are studied, then the data suggest that the Korsmeyer-Peppas 
model is a better fit for the dissolution profile for most of these mini-tablet formulations. If 
the exponent n is then considered, then either it is very close to 1 (e.g. for the PEO mini-
tablets), which is effectively zero-order kinetics, or it is greater than 1, which indicates a 
Super Case II transport situation, which is usually due to erosion. For the specific 
formulations and dissolution test procedure studied here, approximate zero-order kinetics 
may be expected for the PVP, PEG and PEO formulations as these are water-soluble 
polymers and would be expected to dissolve over time releasing the drug. The zero-order 
control factor would be the constant flow rate of the STF over the tablet surface in the 
dissolution chamber, effectively providing a constant sink for dissolution of the polymer. 
For the HPMC mini-tablets, the conditions would be slightly different, as larger HPMC 
tablets (e.g. 10 mm diameter) are known to release the drug via a combination of hydration, 
gel formation, erosion and diffusion. A similar process here would result in the dissolution 
profiles seen in the current study. 
 
3.3.3.2  Fit factors  
The fit factors were used to determine the difference or similarity between two drug release 
profiles from the same formulation but manufactured using different sieve fractions of the 
polymer. The two factors that are commonly used are the difference factor (f1) and 
similarity factor (f2), as described in Chapter 2. Table 3.12 shows the difference factor and 
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similarity factor of drug release profiles for chloramphenicol-loaded Formula 2 mini-
tablets. 
 
Table 3.12  Difference factor and similarity factor for drug release profiles between sieve 
fractions of Formula 2 mini-tablets. 
Formulation Difference Factor (f1) Similarity Factor (f2) 
HPMC 4 78 
PVP 90F 5 72 
PEG 6K 13 52 
PEO 8M 53 34 
 
Drug release profiles are considered identical if the value of the difference factor is close 
to 0. Meanwhile, for the similarity factor, the drug release profiles are generally considered 
identical if the values are between 50 and 100 (Anderson et al., 1998). HPMC and PVP 
90F mini-tablet formulations showed very low difference factor values of 5 or less and 
similarity factor values of greater than 50. These values indicated that drug release profiles 
between the two sieve fractions from those formulations can be considered to be identical. 
Based on the similarity factor value, drug release profiles for the PEG 6K mini-tablet 
formulations would be considered as identical (f2 = 52). However, this value of f2 just barely 
passes the benchmark for similarity and therefore it would be better to consider this result 
as inconclusive or borderline. For the PEO mini-tablets formulation, the fit factors clearly 
indicate that the drug release profiles are different between the sieve fractions. 
 
3.3.3.3  Content uniformity assessment 
The total release values (100 % release) of the drug from the mini-tablets were used to 
estimate the content uniformity of the mini-tablets, as shown in Table 3.13. The mean drug 
content in the mini-tablets ranged between 0.25 and 0.56 µg with a loading average of 
3.41 to 6.30 %, calculated using the mean mini-tablet weight. The target values for these 
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attributes were 0.5 mg and 5 %, respectively.  According to BP specifications, the 
formulations would be considered uniform if not more than 1 individual drug content value 
were outside the limit of 85 to 115 % and none outside 70 to 130 % of the average content, 
although this specification relates to data from a greater number (10) of tablets tested than 
was the case here (3). The red type indicates the values that deviated outside the range 
of 85 to 115 % but within the 70 to 130 % range compared to the average for both the 
actual content and drug loading. Blue type indicates the values that deviated outside of 
the range of 70 to 130 %. Based on the limited data available, all mini-tablets based on 
HPMC, PEG 6K and PVP would pass the BP specification when compared to the mean 
value of the actual drug content, as all measured values were within the 85 to 115 % range.  
Mini-tablets based on PEO 8M showed greater variability and would most likely fail the BP 
content uniformity test, as several values fell into the secondary range, i.e. outside 85 to 
115 % but within 70 to 130 %. 
 
In terms of the drug loading, the target value was 5 % w/w, and only three batches of mini-
tablets were close to this: PEO 8M both sieve fractions, although the variability discussed 
above must be remembered, and PVP 125 to 180 µm sieve fraction.  The PVP 180 to 250 
µm sieve fraction mini-tablets were sub-potent and the mini-tablets based on HPMC and 
PEG 6K were super-potent.  These results probably reflect mixing and segregation issues. 
 
 
Chapter 3 
 
 
130 
Table 3.13  Content uniformity of chloramphenicol-loaded Formula 2 mini-tablets based on the weight and percentage of drug in mini-tablets. 
Polymer Weight (µg) 
(Mean ± SD) 
Drug content 
(µg) 
Mean (µg) SD (µg) Drug content 
(%) 
Mean (%) SD (%) 
HPMC  
125-180 µm 
6.26 ± 0.34 0.39 0.39 0.02 6.23 6.18 0.24 
 0.37   5.91   
 0.40   6.39   
HPMC  
180-250 µm 
6.20 ± 0.21 0.41 0.38 0.03 6.61 6.18 0.49 
 0.35   5.65   
 0.39   6.29   
PEG 6000  
125-180 µm 
5.50 ± 0.35 0.38 0.35 0.03 6.91 6.30 0.56 
 0.32   5.82   
 0.34   6.18   
PEG 6000  
180-250 µm 
9.75 ± 0.29 0.57 0.56 0.03 5.84 5.78 0.31 
 0.53   5.44   
 0.59   6.05   
PEO 8M  
125-180 µm 
6.97 ± 0.08 0.40 0.38 0.09 5.74 5.40 1.25 
 0.28   4.02   
 0.45   6.46   
PEO 8M  
180-250 µm 
7.40 ± 0.09 0.42 0.38 0.06 5.68 5.18 0.74 
 0.32   4.32   
 0.41   5.54   
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PVP 90F  
125-180 µm 
7.84 ± 0.07 0.37 0.39 0.02 4.72 5.02 0.27 
 0.41   5.23   
 0.40   5.10   
PVP 90F  
180-250 µm 
7.43 ± 0.10 0.24 0.25 0.03 3.23 3.41 0.43 
 0.23   3.10   
 0.29   3.90   
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3.3.3.4  Correlation between drug release and vapour sorption 
The drug release and vapour sorption profiles displayed similar patterns. This suggested 
that there might be a correlation between these two profiles which could help explain the 
drug release patterns. To verify this hypothesis, a correlation graph was plotted to 
determine if there is any relationship between these two profiles (Figure 3.8). The 
correlation graph was plotted out using the same time points up to 9 hours in both 
percentage of weight changes in the vapour sorption profiles and drug release in the 
dissolution profiles, or until to the point where either weight changes plateaued or the 
release profile reached 90 % of maximum. 
 
All p values obtained are smaller than 0.05. According to Seltman (2015), there are 
significant correlation between two profiles if the p value is smaller than 0.05. It can be 
deduced that the more water/vapour been absorbed, the greater the amount of drug 
been released. The vapour sorption-drug release correlation graphs give some indication 
into the potential drug release mechanisms from the mini-tablets. There is a clear linear 
relationship between water uptake and drug release from the PEO and PEG-based mini-
tablets, beginning at the start of the experiments. The gradient of these correlation 
graphs reflects the ease and speed of dissolution of the polymer, i.e. the lower molecular 
weight PEG will dissolve faster than the higher molecular weight PEO (the chemistry of 
these two materials is the same), leading to faster drug dissolution. Both PVP-based and 
HPMC-based mini-tablets also show a linear relationship between water absorption and 
drug release, but both appeared to require a lag period, where the outer layer of the mini-
tablet is hydrated, before drug release starts. This is well-known for larger HPMC matrix 
tablets, where the external surface forms a gel into which the drug will dissolve and 
through which the drug will diffuse to be released into the bulk external phase. It would 
be interesting to repeat this experiment, but measuring the drug release at much earlier 
timepoints, to fully investigate this hydration phenomenon. The vapour sorption-drug 
release correlation graphs show very little difference between mini-tablets made from the 
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two sieve fractions of HPMC and PVP 90F, slight differences for the PEG 6K formulations 
and greater differences between the PEO 8M formulations, which agrees with the results 
of the fit factor analysis above. 
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Drug release vs vapour sorption
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Drug release vs vapour sorption
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Figure 3.8  Correlation graphs between drug release and vapour sorption. 
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3.4  GENERAL DISCUSSION 
 
The purpose of this study was to examine the influence of particle size of the predominant 
formulation ingredient on the behaviour of mini-tablets, in terms of ease of manufacture, 
pharmaceutical quality of the product and drug release behaviour. The mini-tablets here 
were specifically designed to be used in ocular drug delivery to provide a sustained 
release of the drug locally after administration. Hence, the dissolution profile required 
here was one of prolonged release, rather than an immediate release profile as would 
be the case for oral drug delivery. All other parameters describing the quality of a 
pharmaceutical product, such as weight uniformity and physical strength, would be the 
same irrespective of the route of delivery and desired drug release rate. 
 
It was possible to make mini-tablets of all the various formulations studied here. It is 
important to note that the tablet tooling used here has a slightly different configuration 
for very small diameter punches and die cores, which can lead to loss of small particle 
size powder during compression, which consequent effects on product quality attributes 
such as weight uniformity and crushing strength. The small diameter punches are very 
delicate, with their maximum tolerated compression pressure being very low at 2 kN, 
which potentially leads to issues with materials that do not compact very well and would 
normally require a higher compression force. In this study, Formula 2 mini-tablets based 
on PVP 90F were very fragile and this polymer would not be recommended as the main 
component of a direct compression mini-tablet formulation for this reason. PVP is usually 
used in tablet formulations as a binder in wet granulation processes, rather than as a 
diluent or compression aid. The three other polymers (i.e. PEG 6K, PEO 8M and HPMC) 
all produced high quality mini-tablets from both sieve fractions. The most obvious 
difference between the mini-tablets made from the different polymers was in the crushing 
strength values, with the PEO 8M-based mini-tablets showing the highest values and a 
different deformation / fracture behaviour to the other formulations. Although there were 
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differences in the weight, thickness and friability values between the batches, these 
differences are more subtle than the crushing strength values. Similarly, some 
differences were observed between matching pairs of mini-tablet formulations, which 
although statistically significant, would be controllable by manipulation of the settings on 
the tablet press. The most significant quality issue was the weight difference between 
the mini-tablets based on the two sieve fractions of PEG 6K, which was unexpected. 
 
The various formulations showed quite different water absorption and drug release 
profiles. In terms of water absorption, the mini-tablets based on PEG 6K and PEO 8M 
behaved similarly, as would be expected as they are chemically similar, with only the 
molecular weight of the polymer being different. Conversely, the mini-tablets based on 
HPMC and PVP 90F behaved similarly, with less total water uptake than the PEG 6K or 
PEO 8M formulations. Drug release seemed to be directly correlated with water uptake 
for all formulations, with some subtle differences being observed in the necessity of a lag 
phase for hydration of the polymer before drug release started, as in the case of the 
HPMC-based mini-tablets, or the dissolution appearing to start as soon as the 
experiment begun, as in the case with the PEG 6K formulations. In most cases, at least 
85 % of chloramphenicol was released from the formulation when the dissolution 
experiment was terminated after 9 hours, the one exception being the mini-tablets based 
on PEO 8M 125-180 µm. During the dissolution process, it was observed that the 
samples collected from PEO 8M mini-tablets formulations were highly viscous solutions. 
According to (Cheong et al. (1992)), the higher the solution viscosity, the more resistant 
it is to diffusion of drugs and a high viscosity solution surrounding a drug-loaded matrix 
will retard the drug release from that matrix. This is the most likely explanation for why 
the PEO 8M mini-tablets release profiles were the slowest. The differences between the 
mini-tablets based on PEO 8M is interesting to note that the smaller sieve fraction mini-
tablets showed a slower profile than the larger particle size mini-tablets. The dissolution 
profiles of the PEO mini-tablets were best described by zero-order kinetics, supporting 
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the hypothesis that the dissolution is controlled by diffusion through the external viscous 
solution, whereas the other mini-tablets were better described by either a first order 
process or the Korsmeyer-Peppas model, the correlation values (r2) being very similar in 
most cases. However, the Korsmeyer-Peppas model only uses the first 60 % 
(approximately) of drug release, and most drug release profiles look zero-order if only a 
few points are studied, so there is a danger of misinterpreting the data if the kinetic 
models are followed too slavishly, rather than observing the whole of the drug release 
profile. Based on the calculated difference factor (f1) and similarity factor (f2) values, it 
appears that all the mini-tablets formulations have similar drug release profiles for both 
sieve fractions, except the PEO 8M mini-tablets formulations which were quite different. 
However, PEG 6K just barely passed the benchmark for the similarity factor, so it would 
be better to regard this as a borderline case. 
 
Table 3.14 below summarises whether the Formula 2 mini-tablet batches would pass 
the initial target specifications presented in Chapter 1 and whether they would be 
considered for further development. 
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Table 3.14  Summary of the analytical tests of Formula 2 mini-tablets in comparison to the initial target values. 
 
Attribute Target HPMC PEG 6K PEO 8M PVP 90F 
125-180 
(µm) 
180-250 
(µm) 
125-180 
(µm) 
180-250 
(µm) 
125-180 
(µm) 
180-250 
(µm) 
125-180 
(µm) 
180-250 
(µm) 
Drug content 5 %w/w 
= 0.5 mg 
No No No No Possibly Possibly No Yes 
 Meets BP 
specifications 
for content 
uniformity 
Yes Yes Yes Yes No No Yes Yes 
Weight 10 mg No No No Yes No No No No 
 Meets BP 
specifications 
for weight 
uniformity 
Yes Yes No Yes Yes Yes Yes Yes 
Hardness 5 to 15 N Yes No Yes Yes No No No No 
Thickness 2 mm Yes Yes No No No No No No 
Friability Meets BP 
specifications 
for friability 
Yes Yes Yes Yes Yes Yes No No 
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Dissolution 
profile 
Zero order No No Yes Yes No No Yes Yes 
 24 hours 
release, i.e. 
4.17 % per 
hour 
No No No No No No No No 
Development 
potential 
 Possibly Possibly Possibly Possibly No No Possibly Possibly 
Comments  Dissolution 
profile 
needs to be 
altered. 
Drug 
loading 
needs to be 
increased 
to account 
for low 
weight. 
Dissolution 
profile 
needs to 
be altered. 
Drug 
loading 
needs to 
be 
increased 
to account 
for low 
weight. 
Dissolution 
profile 
needs to 
be 
extended. 
Drug 
loading 
needs to 
be 
increased 
to account 
for low 
weight. 
Dissolution 
profile 
needs to 
be 
extended. 
Drug 
loading 
needs to 
be 
increased 
to account 
for low 
weight. 
  Dissolution 
profile 
needs to 
be 
extended. 
Hardness 
needs to 
be 
improved. 
Dissolution 
profile 
needs to 
be 
extended. 
Hardness 
needs to 
be 
improved. 
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3.5  CONCLUSIONS 
 
This study investigated the effect of polymer particle size on the physical behaviour and 
drug release characteristics of slow-release mini-tablets for ocular use. As this study was 
exploratory only, it was performed with one batch of each formulation of mini-tablets only. 
PVP 90F was found to be unsuitable as the major component in such a formulation, as 
the product was too friable, whereas all other formulations produced high quality mini-
tablets. Mini-tablets composed of PEG 6K and PEO 8M, which have similar structural 
formulae, showed intriguing results. For both polymers, mini-tablets based on the smaller 
particle size absorbed more moisture and released the drug slower than their 
counterparts, with the similarity and difference factors clearly showing that the two 
batches of PEO 8M mini-tablets were significantly different in their dissolution profiles 
and the two batches of PEG 6K mini-tablets being of marginal similarity. HPMC and PVP 
90F mini-tablets, on the other hand, did not show any significant differences in term of 
moisture uptake and drug release profiles between the formulations based on the two 
particle sizes. 
 
Overall, the results suggest that the particle size of the polymer used to prepare the mini-
tablets has limited effect on the physical quality of the product, but may have a significant 
effect on its drug dissolution profile as suggested by PEO 8M mini-tablets. This feature 
needs to be borne in mind when designing mini-tablet formulations using a direct 
compression method. 
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Nano-scale Surface Analysis of Direct Compression Mini-tablets Using Transition 
Temperature Microscopy 
 
4.1  INTRODUCTION 
 
In the pharmaceutical field, it is important to ascertain the distribution of materials within 
a product, in order to understand its behaviour. In tabletting, distribution of materials can 
potentially affect the uniformity of content, mechanical strength, disintegration speed, 
and the drug release profile of the tablets. It could be argued that these potential effects 
are more pronounced or important for tablets with break-bars, as the quality control 
attributes such as content uniformity and dissolution profile are tested at the level of the 
split tablet as well as on the whole tablet. Similarly, any issue with distribution is likely to 
be more significant with mini-tablets than conventional-sized tablets, as fewer particles 
are required for each individual mini-tablet. 
 
Scanning electron microscopy (SEM) is commonly used to analyse the surface of 
pharmaceutical products, including mini-tablets (Weyenberg et al., 2006, El-Gawad et 
al., 2012). However, this technique is capable only of providing topographical images of 
the surface and, while this is important and can provide evidence of distribution of 
materials across a surface, such as crystals on the surface of a film, it does not allow 
investigation of the chemical state of the drug, i.e. whether it is amorphous or crystalline 
or exists as a particular polymorph. On the other hand, bulk thermal analysis such as 
differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA), which are 
able to measure thermal transitions and therefore to distinguish different physical states, 
analyse an entire sample and therefore provide only an overall average evaluation of the 
product, rather than allowing assessment of the distribution of particular materials 
through or across the sample.(Craig and Reading, 2006). 
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To overcome the limitation of the techniques described above, Hammiche et al. (1996) 
proposed a combination technique called localised thermal analysis (LTA). By heating 
the sample locally with a thermal probe, any thermal transitions at that point can be 
measured and associated with a particular component. Moving the probe and performing 
the experiment at a different location can give information on the spatial distribution of 
materials across a sample's surface. In LTA, the probe is made of a 75 µm diameter 
silver wire containing a platinum/rhodium core about 5 µm in diameter. Due to the 
(relatively) large size of the probe, resolution is possible only on the several micron scale 
and hence analysis using these probes is known as micro-thermal analysis (µTA). More 
recently, a much smaller micromachined silicon probe was developed, which is made of 
highly doped silicon that has a high electrical resistance just above the tips. This allows 
the probe to be heated when an electrical current is applied (Dai et al., 2012). Analysis 
by using these probes is known as nano-thermal analysis (nano-TA) since it can be 
performed at the nano scale. 
 
An extension of the LTA technique is known as transition temperature microscopy 
(TTM). In TTM, a series of nano-TA measurements is performed on a sample surface 
over a grid pattern, generating a map of the measured transition temperatures. By using 
this technique, the distribution of materials on the sample's surface can be assessed. 
Studies utilising TTM on polymer samples or films have been reported in the literature. 
For example, Qi et al. (2013) prepared films using a spin-coating technique to evaluate 
the properties of the films under different humidity levels. Meanwhile Moffat et al. (2014) 
produced flat extrudates using a hot melt extrusion (HME) technique to study phase 
separation in HME drug dispersions. Both studies utilised TTM to analyse the materials 
distribution on the surface of the samples. All of the samples used in these studies have 
an inherently smooth and flat surface. 
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In Chapter 3, TTM was used in an attempt to examine the distribution of the drug 
chloramphenicol across the sample of the mini-tablets. However, the results were 
inconclusive, variable and did not appear to follow the expected pattern and one possible 
explanation is that the surface of the sample is too rough. Here, the surface of the 
compressed powder mini-tablets similar to those prepared in Chapter 3 is investigated to 
assess the ability of TTM to cope with surfaces of varying smoothness. A range of mono-
component mini-tablets was prepared using the following polymers: hydroxypropyl 
methylcellulose (HPMC), polyethylene glycol (PEG) 6000 and polyvinylpyrrolidone 90F 
(Kollidon 90F), each with two sieve fractions: 125 to 180 µm and 180 to 250 µm. 
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4.2  METHODOLOGY 
 
4.2.1  Materials 
 
Hydroxypropyl methylcellulose K4M (HPMC) was purchased from The DOW Chemical 
Company, USA. Polyethylene glycol 6000 (PEG 6K) was purchased from Clariant 
GmbH, Germany. Polyvinylpyrrolidone 90F (Kollidon 90F) (PVP 90F) was provided by 
BASF The Chemical Company, Germany. 
 
4.2.2  Methods 
 
4.2.2.1  Manufacture of mini-tablets 
Mono-component mini-tablets of three different polymers (HPMC, PEG 6K and PVP 
90F), were prepared by compression using an instrumented 4 station on a Riva Piccola 
rotary tablet press (Riva, Argentina) fitted with 2 mm normal concave tooling (B tooling) 
at a compression force of 1.8 ± 0.2 kN. Only one set of punches was used during the 
process. For each polymer, two sieve fractions were assessed: 125 to 180 µm and 180 
to 250 µm. 
 
4.2.2.2  Modulated temperature differential scanning calorimetry  
Modulated temperature differential scanning calorimetry (MTDSC) was performed using 
a DSC Q1000 (TA Instruments, USA). Calibration was performed as explained in 
Chapter 2. Powder polymers samples of between 4 and 6 mg were weighed and sealed 
in pinholed aluminium pans (supplied by Perkin-Elmer). Nitrogen was used as both 
carrier and purge gas, with flow rates of 140 and 50 mL/minute, respectively. The 
temperature was equilibrated at 0 °C and held isothermally for 1 minute. The sampling 
interval was 0.10 second per point. An oscillation amplitude of 0.212 °C with a period of 
40 seconds was used with an underlying heating rate at 2 °C/minute. The end point 
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temperatures for HPMC, PEG 6K and PVP 90F were 225 °C, 100 °C and 200 °C 
respectively. All studies were repeated at least three times. 
 
4.2.2.3  Film preparation 
2 g of each of the polymers used in 4.2.2.1 were dissolved in 10 mL distilled water and 
allowed to stand until a clear gel was formed. This gel was then spread on a Petri dish 
and allowed to evaporate at 60 °C. The thin film formed was then used for the surface 
analysis. 
 
4.2.2.4  Scanning electron microscopy 
Surface images of the mini-tablets and films were acquired using an FEI™ Quanta 200F 
field emission scanning electron microscopy (SEM) (FEI Company, USA). The samples 
were coated with 25 nm of gold under vacuum using a Quorum Q150T Turbo-Pumped 
Sputter Coater with a film thickness monitor unit. More details are given in Chapter 2. 
 
4.2.2.5  Transition temperature microscopy mapping 
The transition temperature at specific sites on the mini-tablet's and film's surfaces was 
mapped by using a VESTA instrument supplied by Anasys Instruments (USA), which is 
equipped with an AN-200 Therma-Lever™ micromachined silicon probe. The 
measurement was carried out over an area of 100 × 100 µm with an 11 × 11 grid of 
readings. A temperature ramp of 10 °C/second was used over a temperature range of 25 
°C to 250 °C or until the equipment detected that the probe had penetrated through the 
sample.  Further details on this technique are given in Chapter 2. 
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4.3  RESULTS AND DISCUSSION 
 
4.3.1  MTDSC analysis 
 
MTDSC was used to measure the thermal behaviour, i.e. the melting point and/or glass 
transition temperature (Tg), of the specific batches of all three polymers studied here. 
 
4.3.1.1  HPMC 
A representative MTDSC trace for HPMC is shown in Figure 4.1. The large endotherm 
centred around 80 °C is thought to be due to loss of adsorbed water. A similar finding 
was also reported by McPhillips et al. (1999) in their study on HPMC E4M premium. 
 
 
Figure 4.1  A representative MTDSC trace of HPMC. 
 
The current MTDSC data suggest that HPMC's glass transition temperature (Tg) is 
189.47 ± 4.80 °C. This result is slightly higher that reported by Siepmann and Peppas 
(2001) at 184 °C for the same grade (HPMC K4M) and significantly higher than reported 
by McPhillips et al. (1999), which was at 161.9 °C for HPMC E4M premium. According to 
Rowe et al. (2009), the Tg values for HPMC of all grades were generally between 170 °C 
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and 190 °C. The current MTDSC runs also indicate that HPMC has a subtle and low 
energy glass transition, making detection difficult, in agreement with the results of 
McPhillips et al. (1999). 
 
4.3.1.2  PVP 90F 
A representative MTDSC trace for PVP 90F is shown in Figure 4.2. The large 
endotherm centred around 80 °C, similar to that observed with HPMC, is also probably 
due to loss of adsorbed water. 
 
 
Figure 4.2  A representative MTDSC trace of PVP 90F. 
 
Unlike HPMC, PVP 90F displayed a distinct glass transition. The MTDSC data 
suggested that the Tg is 178.35 ± 0.15 °C, in agreement with data from BASF, the 
manufacturer of this polymer who quoted a value of 178 °C. (Bühler, 2008). 
 
4.3.1.3  PEG 6K 
PEG 6K is a semi-crystalline polymer, which mean it contains both amorphous and 
crystalline regions. Since the reported Tg of PEG 6K is 259 K (-14.15 °C) (Verhoeven et 
al., 1989), the glass transition behaviour of PEG 6K was not analysed here. As the Tg of 
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PEG 6K is below room temperature, the temperature at which the surface analysis is 
conducted, the polymer will already have passed through the glass transition and will be 
in the rubbery state when these experiments will be performed. 
 
A representative MTDSC trace for PEG 6K is shown in Figure 4.3. According to Rowe et 
al. (2009), the melting point of PEG 6K is within the range of 55 to 63 °C, which agrees 
with the results obtained here of 59.30 ± 1.38 °C.  
 
 
Figure 4.3  A representative MTDSC trace of PEG 6K. 
 
Double melting peaks were also clearly observed in Figure 4.3 and all repetition runs. It 
is recognised that cooling molten PEG at different rates will lead to differences in the 
relative amorphous / crystalline balance and the presence of different crystalline folded 
states, all of which will lead to different observed melting behaviours (Craig and Newton, 
1991). The double melting peak observed here is probably a consequence of the original 
manufacturing method used to prepare this sample of PEG 6K. 
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4.3.2  SEM images of mini-tablets 
 
The top (cap) and side (band) surfaces of representative samples of each mini-tablet 
formulation (made from both sieve fractions of the polymers) were scanned with SEM to 
obtain topographical images and allow comparison with the matching TTM maps. 
 
4.3.2.1  SEM images of HPMC mini-tablets 
Figure 4.4 shows representative SEM images of HPMC mini-tablets. From the SEM 
images, it can be seen that the top (cap) surfaces of HPMC mini-tablets are generally 
smooth for both sieve fractions. Individual particles were not clearly visible on any 
surface. 
 
 
 
 
 
 
 1(a) 1(b) 
 
 
 
 
 
 
 2(a) 2(b) 
Figure 4.4  SEM images of (1) HPMC 125-180 µm mini-tablet and (2) HPMC 180-250 
µm mini-tablet taken on the cap (a) and the band (b). 
 
Chapter 4 
 
153 
The side (band) of the mini-tablets appeared to be more layered instead of compressed. 
This is because the compression force from the punches is applied on the top and 
bottom of the mini-tablet while there is no force applied from the side of the mini-tablet. 
Due to this, the surface of the tablet's cap is slightly smoother than that of the band. 
There are visible cracks that can be observed in the band of the mini-tablets made from 
both particle sizes of the polymer. These cracks can be up to a few hundred µm long and 
approximately 30 µm wide and were particularly apparent for the mini-tablets made with 
the larger particle size polymer. 
 
4.3.2.2  SEM images of PVP 90F mini-tablets 
SEM images for PVP 90F mini-tablets suggested that their surfaces were the roughest 
and most cracked compared to the mini-tablets prepared from the other polymers, as 
shown in Figure 4.5. In contrast to the HPMC mini-tablets, individual particles are clearly 
visible in all images of the PVP 90F mini-tablets, indicating that the particles did not 
completely fuse during compression. There was no obvious difference in the images of 
the mini-tablets prepared from the two particle size distributions of the polymer. 
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 1(a) 1(b) 
 
 
 
 
 
 
 2(a) 2(b) 
Figure 4.5  SEM images of (1) PVP 90F 125-180 µm mini-tablet and (2) PVP 90F 180-
250 µm mini-tablet taken on the cap (a) and the band (b). 
 
4.3.2.3  SEM images of PEG 6K mini-tablets 
From the SEM images, PEG 6K mini-tablets showed the smoothest surface compared to 
mini-tablets prepared from the other polymers, as shown in Figure 4.6. There is no 
significant different in the smoothness of the surfaces between mini-tablets made from 
the two sieve fractions or between the cap and band surfaces. This is most likely to be 
due to some degree of surface melting during the compression process, as it is well 
known that the temperature of tablets during compression can reach approximately 
60C, which is similar to the melting point of PEG 6K. This would then lead to the fusing 
of individual particles and a smoother appearance. 
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 1(a) 1(b) 
 
 
 
 
 
 
 2(a) 2(b) 
Figure 4.6  SEM images of (1) PEG 6K 125-180 µm mini-tablet and (2) PEG 6K 180-250 
µm mini-tablet taken on the cap (a) and the band (b). 
 
4.3.3  Transition Temperature Microscopy mapping on mini-tablets 
 
Transition temperature microscopy (TTM) mapping is used to make early prediction on 
the distribution uniformity of drug and excipients by measuring the distribution uniformity 
of all the materials on the surface of the samples based on their transition temperature. 
The distribution uniformity of the materials is crucial because it may affect the drug 
dosage, the physical properties or the dissolution profiles. 
 
Based on the British Pharmacopoiea (2015), the drug content uniformity is assessed by 
chemical assay of the whole tablet (or mini-tablet in this study). However, this is an 
averaging test where it takes the whole of the tablet and assesses what is present in the 
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whole of the tablet. It is very good for checking the dose of the drug, but does not provide 
any further information. For example, it does not give information about the physical 
state of the drug (e.g. whether it is in the amorphous or crystalline state) or whether it is 
evenly distributed throughout the bulk of the tablet or associated with particular regions. 
The spatial distribution tests will give some physical characterisation data, which may 
help explain physical stability, chemical reactivity or dissolution profiles. They may also 
help understand the mixing, flow and segregation process of the powder (i.e. if the 
surface has a different profile to the original formulation, it may indicate that there is a 
lack of mixing). If there is more drug on the surface of the mini-tablet than the bulk, it 
may suggest that it may degrade more quickly than expected if the drug is sensitive to 
oxidation or light-induced degradation. As mini-tablets have a greater surface area to 
volume ratio than larger tablets, a different chemical stability profile may possibly be 
expected, even from the same formulation. 
 
In term of comparability to the other surface techniques, such as Raman spectroscopy, it 
is just a different analytical approach. Some compounds will be easier to detect by 
Raman while others are easier to detect by DSC, which is the measurement technique 
adopted by TTM.  
 
TTM mapping was performed on the top (cap) and side (band) surfaces of representative 
samples of each mini-tablet formulation (made from both sieve fractions of the 
polymers). Each of the 121 readings in the 11 × 11 grid was analysed by the TTM 
software and allocated a colour representing the measured transition temperature 
according to the colour-temperature scale used (seen on the side bar of the images), 
using the "colourise" function of the software. The grid was then filled in with the colours 
to give a visual impression of the distribution of measured transition temperatures across 
the sample's surface. The data in this section are presented as the coloured grid and as 
a histogram of transition temperatures measured for each sample. On the colour-
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temperature scale used here, purple/blue represent low temperature transitions (25 to 
circa 75 °C) and orange/red represent the high temperature transitions (circa 225 to 250 
°C). For ease of comparison, the temperature scale (x axis) of the histograms has been 
kept constant for all samples. The mono-component mini-tablets were prepared for this 
study to eliminate the possibility of misinterpreting the results if several materials were 
used. The results obtained from the TTM should be representive of the transition 
temperature from those particular polymers only. 
 
4.3.3.1  TTM analysis of HPMC mini-tablets 
The TTM images for HPMC mini-tablets were variable, with a range of apparent 
transition temperatures being displayed, as shown in Figure 4.7. Based on the MTDSC 
data generated here, the expected colouration of the grid is green/yellow representing a 
transition at approximately 190 °C. 
 
Mini-tablet TTM Map Histogram 
HPMC 125-180 µm 
(cap) 
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HPMC 125-180 µm 
(band) 
 
 
HPMC 180-250 µm 
(cap) 
 
 
   
HPMC 180-250 µm 
(band) 
 
 
 
Figure 4.7  TTM maps and transition temperature histograms of HPMC mini-tablets. 
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The TTM results for the mini-tablets prepared from the two particle size distributions 
seem to be consistently different. HPMC 125-180 µm mini-tablets showed observed 
transition temperatures on TTM of between 150 and 250 °C, with a maximum occurrence 
at circa 200 °C, while for the HPMC 180-250 µm mini-tablets, the observed TTM 
transition temperatures were between 120 and 160 °C with no values near to 200 °C. 
The results from the smaller particle-size mini-tablets seemed to be in better agreement 
with the expected values than those from the larger particle-size mini-tablets. Both the 
histogram and coloured images also showed 0 °C temperature transition values for all 
samples. This cannot be correct as the probe's heating range is between 25 and 250 °C 
and hence a 0 °C reading should not be possible. Overall, approximately half the 
individual readings were incorrect based on the MTDSC data discussed earlier. 
 
4.3.3.2  TTM analysis of PVP 90F mini-tablets 
According to the MTDSC data generated earlier, the expected thermal transition of PVP 
90F occurs at circa 180 °C, so the TTM grid for the PVP 90F mini-tablets would be 
expected to show a uniform green colouration. However, the TTM maps and histograms 
in Figure 4.8 were variable, with a range of apparent transition temperatures being 
displayed. Readings at 0 °C were observed, similarly to the HPMC mini-tablets. Unlike 
the HPMC mini-tablet, however, there are no obvious peaks in the histogram that would 
relate to the Tg observed on MTDSC and transition temperatures were detected across 
the full experimental temperature range of 25 °C to 250 °C. Again, approximately half the 
individual readings were incorrect based on the MTDSC data discussed earlier. The TTM 
maps of the mini-tablet's band (side) were significantly poorer than those taken from the 
top (cap) of the mini-tablets. 
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Mini-tablet TTM Map Histogram 
PVP 90F 125-180 µm 
(cap) 
 
 
PVP 90F 125-180 µm 
(band) 
 
 
PVP 90F 180-250 µm 
(cap) 
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PVP 90F 180-250 µm 
(band) 
 
 
 
Figure 4.8  TTM maps and transition temperature histograms of PVP 90F mini-tablets. 
 
4.3.3.3  TTM analysis of PEG 6K mini-tablets 
Figure 4.9 shows the TTM maps and histograms for the PEG 6K mini-tablets. These 
were very reproducible, giving a predominant purple colouration and a value for the 
melting point of PEG 6K of circa 31 to 34 °C. There was no difference in the TTM results 
from any of the samples studied, indicating that neither the particle size of the polymer 
nor the position on the mini-tablet surface had an effect on the measured transition. 
 
Mini-tablet TTM Map Histogram 
PEG 6K 125-180 µm 
(cap) 
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PEG 6K 125-180 µm 
(band) 
 
 
PEG 6K 180-250 µm 
(cap) 
 
 
PEG 6K 180-250 µm 
(band) 
 
 
 
Figure 4.9  TTM maps and transition temperature histograms of PEG 6K mini-tablets. 
 
From the TTM histograms, it is suggested that the melting point of the PEG 6K tablet is 
around 31 to 34 °C. Although the temperature of transition shows consistency, it is lower 
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that the melting point obtained from MTDSC, which is 59.30 ± 1.38 °C. Such differences 
have been seen before when comparing (MT)DSC and LTA data and is usually more 
apparent with low molecular weight compounds than large molecular weight polymers. 
These differences are thought to arise from pre-melting or surface melting phenomenon 
during contact of the sample with the heating probe over small surface areas. The 
heated surface area starts to melt during the heating process before the probe reaches 
the bulk melting temperature. This causes local disorder and the generation of thin film of 
liquid on the surface of the material, through which the probe sinks. It is this probe 
movement that is detected by the instrument (Zhang et al., 2009). 
 
Unfortunately, a number of 0 °C readings were still observed for the PEG 6K mini-
tablets. However, at less than 10 readings from 121 points, this is a much lower 
incidence than was seen with the HPMC or PVP 90F mini-tablets. 
 
4.3.4  Further investigations into the TTM surface analysis of the mini-tablets 
 
The TTM results for the mini-tablets were unexpected in that they showed much greater 
variability in the measured temperature of transition than would be anticipated. The SEM 
images of the HPMC, PVP 90F and PEG 6K mini-tablets were compared with the results 
obtained from the TTM analysis to determine whether the smoothness of the mini-tablets' 
surface had affected the TTM readings. 
 
The PEG 6K mini-tablets showed smooth surfaces (both cap and band), which was 
reflected in the more consistent TTM results. HPMC and PVP 90F mini-tablets showed 
much rougher surfaces, with cracks being visible on the surface of the HPMC mini-
tablets and individual original particles being observable on the surface of the PVP 90F 
mini-tablets. The TTM results for these samples were much more varied. Hence, there 
seems to be a relationship between the quality of the TTM data and the surface 
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roughness (or smoothness) of the mini-tablets. Ultimately, the quality of TTM data is 
dependent on good contact of the probe with the sample surface and this aspect was 
explored in more detail. 
 
There are three possible ways of the probe making contact with the sample surface, as 
shown in Figure 4.10. 
 
 
 (a) (b) (c) 
Figure 4.10  Three possible ways of the probe contacting the sample surface. 
 
Theoretically, while running a TTM experiment, the probe will be lowered down and 
landed directly on the surface, making full contact (Figure 4.10a). The probe is then 
heated and the surface softens at the melting point or glass transition temperature (Tg) of 
the sample. Probe movement through the softened or molten surface will lead to a 
measurement reflecting the true nature of the material under study. However, there are 
two other possible ways of the probe making contact with the sample's surface. If the 
probe lands on the edge of a particle due to the cracked surface (Figure 4.10b), it will 
make only partial contact which will potentially result in a variable reading as the probe 
slides down the particle surface during the experiment. If the probe lands between two 
particles (Figure 4.10c), it will make no contact at all and therefore will not be able to 
detect any temperature of transition, resulting in a "0 °C" reading (Figure 4.11). 
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Figure 4.11  An example of a 0 °C reading from TTM. 
 
It is thought that the both the "partial contact" and "no contact" modes occurred during 
the TTM experiments on the HPMC and PVP 90F mini-tablets. This happened because 
of the very small size of the probe (<30 nm), when compared with the size of the crack 
on the surface of the compressed tablet, as illustrated in Figure 4.12. Hence, the probe 
could quite easily slip down the gap between neighbouring particles on the sample 
surface, leading to a "no contact" experiment and a 0 °C reading. Equally, it is possible 
that a "partial contact" is made with the probe and the edge of the particle, leading to the 
probe moving during the experiment and variable results. Overall, therefore, the TTM 
maps showed a variable transition temperature, even for mono-component systems such 
as were studied here. 
 
 
 
 
 
 
 
 
Chapter 4 
 
166 
 
 
 
 
 
 
 
 (a) (b) 
Figure 4.12  Comparison between (a) the tip radius of the probe (AnasysInstuments) 
and (b) the gap between neighbouring particles on the HPMC (125-180 µm) mini-tablet 
surface. 
 
Another potential issue with the TTM experiment is the ability of the "colourise" function 
to correct assign a colour to a profile based on the temperature-colour scale being used. 
Hence, the TTM maps were investigated in detail to compare the colourise images with 
the actual readings. A TTM result from the HPMC 125-180 µm mini-tablets (band) was 
chosen for this analysis because this TTM image contained the full range of colours of 
the temperature-colour scale. Each of the individual readings in this grid was assessed 
manually to determine the endpoint temperature and to assign an appropriate colour to it 
based on the temperature-colour scale. This colour was then compared to that assigned 
by the software. Figure 4.13 shows a range of individual pixels assigned various 
different colours by the "colourise" software, highlighted by a cross (+), on the TTM grid 
with their corresponding probe deflection graphs. 
< 30 nm 
± 15 µm 
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(a) 
 
 
(b) 
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(c) 
 
 
(d) 
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(e) 
 
(f) 
 
Figure 4.13  Comparison between individual TTM pixels with actual readings of probe 
deflection. (a) = red colour, (b) = yellow colour, (c) = green colour, (d) = pale blue colour, 
(e) = dark blue colour, and (f) = purple colour 
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Based on the results shown in Figure 4.13, it can be concluded that the colours 
represented in the image tallied with the actual readings, except when poor contact 
seems to have been made between the probe and the sample, and the probe deflection 
graph is a straight line with no obvious endpoint. In this case, the software seems to 
assign either the maximum temperature and a red colouration, or the minimum 
temperature and a purple colouration. This suggests that the software is working well 
and the image produced can be trusted, for the intermediate values but not for the 
extreme values. It is recommended that the individual probe deflection traces are 
examined in these cases to assess the true results. Ultimately, these "odd" results are 
probably a combination of the probe landing awkwardly on the junctions between 
particles or sliding into a gap between particles, and a processing issue for a "non-
results" with the "colourise" software. 
 
One of the concerns about using the TTM technique on the surface of a tablet or mini-
tablet is the shape of the tablet itself. Reported studies utilising TTM have been on 
polymer films (Qi et al., 2013, Moffat et al., 2014), which have a naturally flat surface. 
However, the shape of the cap of the tablet is convex while the band of the tablet is 
cylindrical, i.e. both are curved from the perspective of the probe. From the results 
presented earlier, it would appear that the shape of the sample does not affect the 
efficiency of a TTM reading as long as the probe makes proper contact with the surface. 
 
Up to this point, a few questions still have not been answered regarding the TTM 
analysis on the surface of the mini-tablets. Even though visible cracks can be seen on 
the HPMC mini-tablets surface on the SEM image, although not to the naked eye, the 
surface is still smooth in general. To confirm whether the variable TTM readings were 
entirely due to the rough areas and cracks on the surface or if there is another 
contributory factor, TTM analysis was performed on the surface of films made from each 
of the three polymers individually. 
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4.3.5  Transition temperature mapping on polymer films 
 
Each of the three polymer films was prepared using the solvent-cast technique. The films 
were analysed by TTM with the same measurement parameters as the mini-tablets. 
 
4.3.5.1  TTM analysis of HPMC films 
The TTM map and histogram for HPMC films in Figure 4.14 showed that 90 out of 121 
of the readings were 0 °C readings, with the rest showing the maximum transition 
temperature. 
 
 
 
 
 
 
 
 (a) (b) 
Figure 4.14  TTM map and transition temperature histogram of HPMC films. 
 
TTM analysis on HPMC films therefore displayed a similar but more extreme pattern as 
seen with the HPMC mini-tablets. Neither sample showed a distinct transition 
temperature. Since the film surface is smooth and does not have cracks, it is impossible 
to say that the readings obtained from its TTM analysis were due to improper contact 
between the probe and sample, although this is unlikely given the smooth nature of the 
film's surface. Figure 4.15 shows the individual probe deflection graphs for this TTM 
measurement, suggesting that a proper contact was established on each point, but also 
that the endpoint could not be determined as the probe keeps heating until it reaches the 
maximum experimental temperature of 250 °C. 
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Figure 4.15  Individual TTM probe deflection graphs for an HPMC film. 
 
The probable explanation behind this behaviour is that HPMC has a weak and indistinct 
glass transition. McPhillips et al. (1999) faced a few difficulties while trying to measure Tg 
of HPMC films using MTDSC, although ultimately they were able to measure it. A large 
sample size is usually required in order to overcome the issues of measuring a weak 
transition. In the case of TTM, each point in the measurement will test a very small 
amount of HPMC which may make it almost impossible to measure the Tg. 
 
4.3.5.2  TTM analysis of PVP 90F films 
Based on the TTM map and histogram for PVP 90F mini-tablets, no obvious pattern of 
transition could be observed. However, PVP 90F films showed a consistent value of the 
transition temperature, as shown in Figure 4.16. 
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 (a) (b) 
Figure 4.16  TTM map and transition temperature histogram of PVP 90F films. 
 
The Tg measured using MTDSC for the sample of PVP 90F used here is 178.35 ± 0.15 
°C. However, the Tg obtained from TTM analysis of the PVP 90F film is 186 °C. The Tg 
values observed with thermal probe movement measurement, such as TTM, and other 
thermal measurements, such as (MT)DSC, can differ by up to 20 °C (Royall et al, 2001). 
This is due to the probe measuring the softening process of the polymer, rather than its 
actual Tg point (Craig et al., 2002). Hence, the TTM results on the PVP 90F film, with its 
smooth surface, good probe contact and consistent probe deflection, support the earlier 
hypothesis that the reason why the measured transition temperature on the surface of 
PVP 90F mini-tablets was variable was due to the improper contact of the probe on the 
mini-tablet surface.  
 
4.3.5.3  TTM analysis of PEG 6K films 
The results of TTM analysis on PEG 6K films, shown in Figure 4.17, were similar to 
those of PEG 6K mini-tablets described earlier, as expected, since the surfaces of the 
mini-tablets are as smooth as that of the films. This means there is no difference in 
transition temperature between the films and the mini-tablets. 
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 (a) (b) 
Figure 4.17  TTM map and transition temperature histogram of PEG 6K films. 
 
4.4  GENERAL DISCUSSION 
 
This study sought to understand the factors behind the variable results obtained on the 
TTM mapping of the drug-loaded mini-tablets seen in Chapter 3. TTM maps generated 
on the surface of samples of the multi-component drug-loaded mini-tablets did not show 
the expected distribution of components or a reproducible pattern of transitions and one 
possible explanation was that the surface of the mini-tablets was too rough for the 
technique. A range of mono-component mini-tablets was made and tested to examine 
this. SEM images showed that the surfaces of PEG 6K tablets were smooth, due to the 
tabletting process generating transient temperatures higher than the melting point of 
PEG 6K. The TTM maps of PEG 6K mini-tablets showed reproducible results, with a 
sensible value of the melting point of PEG 6K. However, mini-tablets based on both 
HPMC and PVP 90F were rough, with individual particles being seen and gaps between 
these particles also being observed. It is thought that as the TTM probe is very small (30 
nm), it can easily slip down the side of a particle or into the gap between particles, 
leading to incomplete or no contact, ultimately resulting in variable and misleading 
reasons. A comparative study on films prepared from the same polymers supported the 
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view that the good probe-sample contact was vital in generating reliable data and that 
the rougher the surface, the less reliable the data generated. 
 
One conclusion from this study would be that a visual surface image should be taken 
before a TTM study is conducted, to ensure that the probe is landed correctly on a 
particle, rather than in a gap or on the side of a particle. This is possible with the micro-
thermal analysis equipment, as this is based on an atomic force microscope (AFM), with 
the AFM probe being replaced by the thermal probe. Hence, it is possible to obtain both 
an AFM image and a thermal image of the same point on the sample's surface. 
Unfortunately, the TTM equipment (Vesta, Anasys Instruments, USA) is based on a light 
microscope rather than an AFM, hence the visual image resolution is not sufficient to 
land the TTM nano-probe in a sufficiently controlled manner. 
 
As this particular study was undertaken to help interpret the unexpected TTM results 
from Chapter 3, and used mono-component mini-tablets only, it cannot be used as a 
comparator with the analytical results of the chloramphenicol-loaded mini-tablets.  If the 
surface of the chloramphenicol-loaded mini-tablets can be made to be smooth enough 
then it would be possible to perform TTM analysis on these tablets and then the results 
could be compared to the conventional chemical analysis, such as that conducted for the 
drug content uniformity assessment. 
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4.5  CONCLUSIONS 
 
TTM can be used to measure the component distribution on the surface of a tablet. 
However, it is vital to ascertain that the surface is as smooth as possible and that the 
probe is positioned in the centre of a particle, rather than its edge or in a gap between 
particles. It is recommended that a topographical image of the sample's surface be 
acquired prior to TTM analysis to aid in the interpretation of the results and ideally the 
components used should all have distinct temperature transitions to enable clear 
differentiation between them. 
 
 
   
 
Chapter 5 
Manufacturing Ocular Mini-tablets Using 
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Manufacturing Ocular Mini-tablets Using 3D-printing 
 
5.1  INTRODUCTION 
 
In Chapter 3, a conventional manufacturing process of direct compression of a powder 
blend was used to prepare a range of ocular mini-tablets. There are many advantages of 
using this approach, not least the extensive knowledge within the pharmaceutical 
industry on tabletting techniques and tabletting machinery. However, there are also 
potential disadvantages of this approach, such as the need to apply compaction 
pressures which are too high for tablet punches to withstand and the requirement for the 
powders to exhibit excellent mixing and flow characteristics. 
 
A novel approach studied in this Chapter is to use 3D-printing techniques in order to 
prepare mini-tablets. In recent years, 3D-printing has become popular in a range of 
scientific and artistic endeavours and has started to gain popularity in the pharmaceutical 
field, as it has the potential to allow bespoke design and manufacture of products, which 
is not so easy to achieve with conventional manufacturing paradigms (Jonathan and 
Karim, 2016). To date, there are only a few publications examining the potential for 3D-
printing of tablets and they concentrate on conventional, large-sized tablets (Khaled et 
al., 2014, Wang et al., 2016). Here, the utility of the 3D-printing approach for the 
manufacture of mini-tablets is explored. 
 
There are a few types of 3D-printer available, but the most popular in the market are 
fused deposition modelling (FDM) and stereolithography apparatus (SLA) printers. An 
FDM printer works by heating and extruding filaments and building the object layer by 
layer. Several studies have been conducted using an FDM printer combined with hot 
melt extrusion (HME) technique to manufacture films and tablets. For example, Sandler 
et al. (2014) used HME to prepare drug-loaded extrudates which they then used to 3D-
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print with an FDM printer devices which resembled indwelling catheters. A similar 
approach was adopted by Goyanes et al. (2015) in their preparation of large tablets of 
different geometrical shapes in order to study the drug release profile. 
 
Meanwhile, an SLA printer uses a photopolymerisation process, in which light catalyses 
the production of a polymer from a solution of monomer, and uses a laser to cure 
(polymerise) the photopolymer while shaping it into an object. The SLA technique is also 
the oldest 3D-printing technique, patented by (Hull, 1986). One common photopolymer 
used in the SLA approach is polyethylene glycol diacrylate (PEGDA). Hahn et al. (2006a) 
and Hahn et al. (2006b) used PEGDA with a standard laser jet printer to print hydrogel 
films. The hydrogel films were used in cell behaviour studies. PEGDA has also been 
used with a laser printer to manufacture scaffolds for multicellular tissue (Ovsianikov et 
al., 2010) and aortic valves (Hockaday et al., 2012). The polymer was chosen for those 
published studies because of its biocompatible properties. 
  
In this chapter, 3D-printing techniques have been used to manufacture ocular mini-
tablets. The desired shape of the 3D-printed mini-tablets was the same as that used in 
Chapter 3 for the compressed powder mini-tablets and was chosen to allow direct 
comparison to the previous study. The physical properties of the 3D-printed tablets and 
their corresponding dissolution profiles were characterised to investigate the potential of 
using this technique as tabletting process. 
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5.2  METHODOLOGY 
 
5.2.1  Materials 
 
Hydroxypropyl methylcellulose K4M (HPMC) was purchased from The DOW Chemical 
Company, USA. Polyethylene glycol 6000 (PEG 6K) was purchased from Clariant 
GmbH, Germany. Polyvinylpyrrolidone 90F, (Kollidon 90F) (PVP 90F) was provided by 
BASF The Chemical Company, Germany. Polyethylene oxide 8,000,000 (PEO 8M), 
chloramphenicol, polyethylene glycol 4000 (PEG 4K), polyethylene glycol diacrylate 700 
(PEGDA), phenylbis (2,4,6-trimethylbenzoyl) phosphine oxide (BAPO), sodium 
bicarbonate and calcium chloride were purchased from Sigma Aldrich, U.K. Sodium 
chloride was purchased from Fluka Chemie GmbH, Germany. Sodium stearyl fumarate 
(SSF) was purchased from Tokyo Chemical Industry, Japan. Flexible resin was 
purchased from Formlabs Inc, USA. 
 
5.2.2  Methods 
 
5.2.2.1  Hot Melt Extrusion 
Hot melt extrusion was performed using a Process II parallel twin screw extruder 
(Thermo Scientific, USA) with a 2 mm nozzle. 15 g of material was extruded per batch. 
The extrusion parameters were varied, depending on the polymer's melting point or glass 
transition temperature. The extrusion temperature ranged between 50 and 180 °C with 
screw speed of 25 rpm. 
 
5.2.2.2  Preparation of photopolymer solutions 
Seven solutions were prepared based on formulations shown in Table 5.1. The 
formulations all contained 100 g PEGDA, 2 g BAPO and 5 g chloramphenicol. Specific 
formulations also contained one or more of the following materials: 25 mL of H2O and 25 
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g of the specified polymer (PEG 6K or PEG 4K). Each formulation was then printed by 
using a stereolithography 3D-printer. 
 
Table 5.1  Formulation of photopolymer solutions used for 3D-printing mini-tablets. 
Formula 
Name 
Component 
PEGDA BAPO Chl H2O PEG 6K PEG 4K 
Pure 100 g 2 g 5 g 50 mL - - 
P6K1 100 g 2 g 5 g  25 mL 25 g - 
P6K2 100 g 2 g 5 g  - 25 g  - 
P6K3 100 g 2 g 5 g  - 50 g - 
P4K1 100 g 2 g 5 g  25 mL - 25 g  
P4K2 100 g 2 g 5 g  - - 25 g  
* Chl = chloramphenicol 
 
5.2.2.3  3D-printing 
The mini-tablets and production mould were designed using Tinkercad (2015), a 
browser-based 3D design and modelling application, as explained in Chapter 2. The 
design was then saved as an .STL file format and sent to the 3D-printer controller. The 
printer used to print the mini-tablets and mould is Form 1+ high resolution stereo-
lithography printer from Formlabs (USA). The type of material used as printer setting is 
"flexible" with the highest resolution at 0.05 mm, as explained in Chapter 2. 
 
5.2.2.4  Physical characterisation of the 3D-printed mini-tablets 
The weight uniformity, measurement of dimensions, crushing strength, friability and 
moisture uptake methods employed here were described in detail in Chapters 2 and 3. 
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5.2.2.5  Water content 
Water content in the 3D-printed mini-tablets was measured by thermogravimetric 
analysis (TGA). The TGA was equilibrated at 25 °C, heated up to 110 °C at 10 °C/minute 
and held isothermally for 5 minutes. The percentage of water loss then calculated based 
on the measured weight changes. 
 
5.2.2.6  Modulated temperature differential scanning calorimetry 
Modulated temperature differential scanning calorimetry (MTDSC) was performed using 
a DSC Q1000 (TA Instruments, USA) over a temperature range of 25 to 200 °C. The 
method details were described in Chapter 2. 
 
5.2.2.7  Visualisation of the photopolymerisation process 
Solutions prepared based on Table 5.1 were filled into a polystyrene semi-micro cuvette 
and the photopolymerisation processes were recorded using a Leica DM2700M 
microscope (Leica, Germany), a materials microscope with universal LED illumination 
equipped with digital camera. The capture rate of the video was set at the highest 
resolution of 1 frame per second (fps). The time taken for the photopolymerisation 
processes to occur was recorded. Three replicates were performed for each sample. 
 
5.2.2.8  Surface analysis 
The surface of the 3D-printed mini-tablets was evaluated by using SEM and TTM 
techniques as described in Chapters 2 and 3. 
 
5.2.2.9  Drug release profile 
A modified flow-through dissolution apparatus was used to assess the drug release 
profile of the mini-tablets as described in Chapters 2 and 3. The samples were taken 
every hour up to 9 hours. The drug release was then quantified spectrophotometrically at 
278 nm. At the end of the dissolution test, the remnant mini-tablet was placed into a 20 
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mL conical test tube containing 15 mL of STF and stirred with a magnetic stirrer. The 
magnetic stirrer performed the dual functions of stirring the solution while crushing the 
mini-tablet to facilitate drug extraction. The solution was left for 24 hours before being 
spectrophotometrically quantified at 278 nm. At least three replicates were made for 
each formulation. 
 
5.2.2.10  Mathematical modelling for dissolution profile 
Zero order kinetics, first order kinetics and the Korsmeyer-Peppas equation were used 
as mathematical models to determine the dissolution profile statistically. Similarly, the 
difference (f1) and similarity (f2) factors, as proposed by Moore and Flanner (1996), were 
used to evaluate differences between dissolution profiles. These models are described in 
Chapters 2 and 3. 
 
5.2.2.11  Total drug content 
The total drug content in the 3D-printed mini-tablets was determined based on the 
amount of drug that been released during the dissolution testing and the amount of drug 
obtained from the remnant tablets as described above. 
 
5.2.2.12  Correlation between vapour sorption and release profile 
Graphs of percentage drug release against percentage weight change were plotted to 
investigate the correlation between the release profiles and vapour sorption, as 
described in Chapter 3. 
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5.3  RESULTS AND DISCUSSION 
 
5.3.1  Hot Melt Extrusion 
 
The first part of the study was an initial investigation into whether hot melt extrusion 
(HME) extrudates of the necessary polymers could be made, as filaments are required 
for the fused deposition modelling (FDM) 3D-printer to work. This type of 3D-printer 
relies on in-situ melting of the formulation and deposition of a liquid droplet in a pre-
defined location. A filament of the formulation is therefore required in order to provide the 
source of the material and to feed it through the melting and deposition zones of the 
printer. It is not possible to run this type of 3D-printer without a filament of the material 
under test. The polymers chosen for this study were assessed as to whether they could 
be extruded using the HME. If successful, chloramphenicol will be integrated in the 
polymer. The drug-loaded extrudates would then be used to print ocular mini-tablets by 
using the FDM 3D-printer. 
 
5.3.1.1 Pure polymer extrusion 
The HME used in this study has 8 temperature control points along the barrel that can be 
controlled individually. However, all extrusion processes performed in this study used the 
same temperature for all 8 points. Based on data from Chapter 4, polyethylene glycol 
6000 (PEG 6K) has a melting point at 59.30 ± 1.38 °C. As a starting point, 70 °C was 
chosen as the heating temperature for this polymer. This temperature was purposely 
chosen to observe whether extrudates are able to form by heating PEG 6K at a slightly 
higher temperature than its melting point. Molten PEG 6K was observed dripping from 
the exit nozzle of the extruder, hence it can be concluded that this temperature (70 °C) is 
too high a working temperature for PEG 6K and that the molten polymer does not have 
enough time to cool down and harden into extrudates as it goes through the exit nozzle. 
The heating temperature then was decreased to 60 °C, at the high end of the melting 
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point range observed for PEG 6K here. A similar phenomenon to the previous run was 
observed even though the heating temperature is in PEG 6K melting point range. The 
heating temperature was still considered too high for PEG 6K to be extruded properly. 
PEG 6K then was extruded at 55 °C, below the melting point measured here (59.30 ± 
1.38 °C), but within the published melting point range for this polymer of 55 to 60 °C 
(Rowe et al., 2009). Extrudates were obtained at this point as shown in Figure 5.1. The 
extrudate was slightly brittle and could easily be broken into two. There was no visual 
evidence of unmelted material on the outside surface of the extrudate, or on the newly 
created surfaces when the extrudate was snapped into two. 
 
 
Figure 5.1  PEG 6K extrudates prepared at 55 °C. 
 
The heating temperature was further decreased by 5 °C down to 50 °C to observe if PEG 
6K is able to be extruded at temperatures lower than its melting point. Unfortunately, at 
this temperature PEG 6K just moves through the barrel without melting or softening. It 
was therefore decided that 55 °C is the most successful heating temperature to produce 
extrudates of PEG 6K.  
 
The attempts to extrude polyethylene oxide 8,000,000 (PEO 8M), hydroxypropyl 
methylcellulose K4M (HPMC) and polyvinylpyrrolidone 90F (PVP 90F) at temperatures 
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ranging from 55 °C to 180 °C were not successful. This is because these three polymers 
all have very high molecular weights, which means they have high viscosity when in the 
molten state. Polymers with high viscosity are difficult to be extruded and will block the 
die heater, i.e. the exit nozzle. When this happens, it will cause the pressure in the 
extruder to increase and the machine will cease to work once the pressure goes above a 
certain level. Because of that, those three polymers cannot be extruded as they are and 
need an additional plasticiser to decrease the viscosity. These current observations are 
in agreement with previous work in this area (Kolter et al., 2012, Ma et al., 2013, 
Prodduturi et al., 2005). Since PEG 6K is often used in pharmaceutical formulations as a 
plasticiser, binary combinations of each of those three polymers and PEG 6K were 
tested. 
 
5.3.1.2  Combination extrusion 
Each polymer (HPMC, PEO 8M and PVP 90F) was extruded with PEG 6K in the weight 
ratios of 3:1, 1:1 and 1:3 (polymer : PEG 6K). The weighed powders (15 g total batch 
size) were homogenised using a Turbula mixer for 10 minutes. The mixture of PEO 8M 
and PEG 6K was extruded at temperatures between 55 °C and 80 °C, in 5 °C 
increments, using the experience of extruding pure PEG 6K and the published melting 
point of PEO 8M (65 to 70 °C) as a starting point for the temperature selection (Rowe et 
al., 2009). The first mixture that was studied was the 3:1 ratio. However, this combination 
could not be extruded even when the heating temperature exceeded the melting point of 
PEO 8M, due to excessive pressure readings in the barrel of the extruder. According to 
the study by Pinto et al. (2004) on PEO 301 and PEO 303 with molecular weights of 4 
MDa and 7 MDa, respectively, it was not possible to extrude PEO with such high 
molecular weights at 50 % of the total powder weight when combined with propranolol 
hydrochloride and lactose. In their study, PEO could only be extruded at a maximum of 
40 % of the total weight with the presence of water as a plasticiser. The amount of PEO 
in the mixture was then decreased to the ratio of 1:1. At 55 °C, the lowest temperature 
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studied, the mixture was able to be extruded. The appearance of the extrudate was 
similar to that of PEG 6K alone. Closer inspection showed a few unmelted powder 
particles, probably PEO 8M, scattered in the extrudate (Figure 5.2). 
 
 
Figure 5.2  PEO 8M : PEG 6K (1 : 1) extrudate prepared at 55 °C. 
 
In an attempt to reduce the amount of unmelted solid material, the heating temperature 
was increased to 60 °C. At this temperature, extrudates were successfully produced, but 
their surface looked uneven and rough, as shown in Figure 5.3, although there was no 
obvious powder particles as seen with the extrudates formed at 55 °C. The extrudate 
was also fragile and could easily be broken into two. When the processing temperature 
was increased further to 70 °C, the extruder ceased to work because of high pressure 
readings in the barrel. This is probably because the PEO 8M was predominantly molten 
at this temperature, which then significantly increased the viscosity of the mixture to 
above the cut-off point for equipment function. 
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Figure 5.3  PEO 8M : PEG 6K (1 : 1) extrudate produced at 60 °C. 
 
At a process temperature of 80 °C, extrudates could be formed, which is probably due to 
the increased temperature lowering the viscosity sufficiently to allow the equipment to 
function. The extrudate obtained was a bit lumpy and felt it rubbery to touch. The colour 
of the extrudate was also slightly yellowish, unlike previous extrudates, which were 
white, as shown in Figure 5.4. At this point, processing at 55 °C can be considered to 
produce the best extrudate for this specific combination of polymers, based on 
appearance. However, the presence of unmelted PEO 8M in the extrudate indicates that 
the two polymers do not integrate fully with each other, so the product is not ideal. 
 
 
Figure 5.4  PEO 8M : PEG 6K (1 : 1) extrudate produced at 80 °C. 
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The amount of PEO 8M in the mixture was further decreased to a 1:3 ratio with PEG 6K. 
At 55 °C as the processing temperature, the extrudate obtained was similar to the 1:1 
extrudate at the same temperature, with a few unmelted PEO 8M polymer particles being 
observed in the extrudate. A similar phenomena to the 1:1 extrudate was also displayed 
when the temperature increased to 60 °C. However, when the processing temperature 
was increased to 70 °C, a lumpy and rubbery extrudate was obtained. The extrudate 
showed similar appearance to the 1:1 extrudate produced at 80 °C but with a white 
colour instead of yellowish. Molten polymer could also be observed coming out from the 
barrel's top opening, as showed in Figure 5.5, and from the nozzle at the beginning of 
the extrusion. The molten polymer is more likely to be PEG 6K, which has a lower 
melting point than PEO 8M. A similar conclusion as with the 1:1 formulation can be made 
for the 1:3 formulation for the best extrudate, based on the appearance, i.e. a processing 
temperature of 55 °C is best, but some unmixed PEO 8M was still obvious. 
 
  
Figure 5.5  PEO 8M : PEG 6K (1:3) extrudate and melted polymer processed at 80 °C. 
  
Melted 
polymer 
Extrudate 
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For the combinations of HPMC or PVP 90F with PEG 6K, none of the mixtures were 
successfully extruded. The mixtures were heated at 160, 170, 175 and 180 °C. A similar 
scenario was observed for all heating temperatures. Firstly, molten polymer was 
observed coming out of the nozzle, most likely PEG 6K due to its lower melting point. 
Then, the polymer started to block the die heater, which caused the extruder to cease to 
work due to high pressure inside the barrel. The current results therefore agree with the 
findings of Ma et al. (2013) and Kolter et al. (2012), who concluded that HPMC K4M and 
PVP 90F cannot be extruded at high concentrations. 
 
Due to unsuccessful extrusion of the desired polymers except PEG 6K, the idea of using 
extrudates to 3D print the mini-tablets cannot be executed. A different approach was 
therefore investigated using an SLA 3D printer. 
 
5.3.2  3D Design 
 
5.3.2.1  Manufacturing 3D-printed mini-tablets using a 3D-printed mould 
The 3D-printed mini-tablets were designed to be similar in shape with the powder 
compressed mini-tablets discussed in Chapter 3, being cylindrical with 2 mm diameter 
and 2 mm height. However, the cap surfaces of the 3D-printed mini-tablets were kept 
flat, compared to the curved surface of the compressed mini-tablets. This is because the 
flat surfaces design is easier to be 3D-printed than a design with curved top and bottom 
surfaces. By choosing the similar shape, comparison of the properties and behaviour of 
the 3D-printed mini-tablets and the compressed powder mini-tablets discussed in 
Chapter 3 can be made. 
 
One way of making a 3D-printed product using the stereolithography approach is to use 
a mould to hold the initial unpolymerised liquid before the photopolymerisation process 
takes place. The mould determines the overall size and shape of the product, in this 
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case the 3D-printed mini-tablets. Curing occurs through exposure of the unpolymerised 
liquid to UV light of the relevant wavelength through the walls of the translucent mould. 
This approach was investigated initially due to its potential ease of use. Following the 
design of the 3D-printed mini-tablets described above, a complementary mould was also 
designed using the Tinkercad software, as described in Chapter 2, and consisted of 
identical matching top and bottom pieces, which would be joined together to form the 
cavities, into which the unpolymerised liquid would flow. Figure 5.6 illustrates the initial 
design for the mini-tablets moulds, showing a 3 x 3 grid of nine cavities linked together 
by channels to allow the movement of the liquid. Three of these channels were then 
open to the exterior to allow easy input of the unpolymerised liquid. The top and bottom 
moulds were then successfully printed by using flexible resin (Formlabs, USA). 
 
 
Figure 5.6  First mould design for the 3-D printed mini-tablets. 
 
The printed moulds were clipped together and a photopolymer solution made using the 
"Pure" formulation (consisting of PEGDA, BAPO, chloramphenicol and water, Table 5.1) 
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was filled into the mould using a syringe. However, there are flaws with this design of the 
moulds, in that the top and bottom surfaces could not be matched together properly, 
resulting in solution leaking from the gap between the moulds. To overcome these 
problems, a simple solution was attempted - to add a tongue-and-groove functionality to 
the mould (Figure 5.7).  
 
 
Figure 5.7  Optimised mould design for the 3D-printed mini-tablets 
 
By adding a ridge on one side and a hollow on the other side of the moulds, the moulds 
can be interlocked and this action should solve the problems of connection and leakage. 
The moulds were printed, assembled and clipped to hold them together. The "Pure" 
photopolymer solution (as described in Table 5.1) was filled in and exposed to UV-light 
at 365 nm for a certain time to initiate the photopolymerisation process and cure the 
polymer producing a solid product. 
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The effectiveness of the curing process was tested after 5, 15 and 30 minutes. Based on 
visual observation, the solution had not polymerised and still runny within 5 minutes. 
After 15 minutes, most of the solution was polymerised but the moulds were glued 
together and the polymerised mini-tablets broke when the moulds were separated. When 
the solution was left to cure for 30 minutes, the polymerised mini-tablets dried and 
crumbled when removed from the mould. The glueing phenomenon was due to a small 
amount of the formulation leaking out from the channels and forming a thin layer 
between the top and bottom mould. During the curing process, this thin layer was also 
exposed to the UV light and was polymerised, effectively making a solid bridge between 
the top and bottom surfaces of the mould. To attempt to prevent the moulds glueing 
together after the curing process, a layer of lubricant was added to the mould. The 
lubricant was sodium stearyl fumarate (SSF), a water-soluble lubricant generally used in 
conventional powder-based tablet formulations. An aqueous solution of 50 %w/v SSF 
was applied onto the surface of the mould and left to dry. The moulds then were put 
together and filled with the "Pure" polymer solution. After 15 minutes of curing, the 
attempt to split open the moulds was unsuccessful as it was still glued together even with 
a layer of SSF. 
 
At this point, it seemed that it would be difficult, if not impossible, to manufacture 3D-
printed mini-tablets using the mould and UV curing technique. The approach then shifted 
toward printing the mini-tablets directly onto the platform of stereolithography 3D-printer. 
 
5.3.2.2  Manufacturing 3D-printed mini-tablets using the SLA platform method 
 
As it was not possible to use the mould method of casting and curing the mini-tablets, an 
alternative method of printing directly onto the platform of the equipment and creating a 
support was tried. In this case, the support forms part of the design of the product, as 
described in Chapter 2, and once the desired product has been formed, it will need to be 
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separated from the support. As before, the mini-tablets were designed to match as 
closely as possible the compressed powder mini-tablets manufactured in Chapter 3, and 
were cylindrical with a 2 mm diameter and 2 mm height. The top and bottom faces were 
designed to be flat. The support was designed to be a flat base, with "stalks" upon which 
the mini-tablets themselves would be produced. 
 
An initial batch of 60 mini-tablets was printed using the "flexible" resin (Formlabs, USA) 
to evaluate the likely outcome of this process. The 3D-printer settings were "flexible" as 
the material type, "lower" printing resolution (1 mm distance) and 1 mm base thickness 
with support stalks. Figure 5.8 shows a batch of 3D-printed mini-tablets with the support 
as the base. Visually, the shape of these 3D-printed mini-tablets was similar to that of the 
compressed mini-tablets and to the design, indicating that this approach had potential. 
 
 
Figure 5.8  3D-printed mini-tablets prepared from Formlabs (USA) "flexible" resin. 
 
However, it must be remembered that the "flexible" resin (Formlabs, USA) has been 
specifically developed for use within the 3D-printing field for solid objects and is not 
intended to be used as an ingredient in pharmaceutical products. Hence, the further 
experiments investigating the production settings were conducted using a more 
pharmaceutically-relevant formulation. A solution similar to the "Pure" formulation (Table 
5.1) but with only 1 g of BAPO (photoinitiator) was used to optimise the printing settings, 
Chapter 5 
 
195 
as this concentration of 1 % of this photoinitiator with respect to this photopolymer 
(PEGDA) was successfully used in published studies (Wang et al., 2016, Chan et al., 
2010). The settings that were used were "Clear 02" as the material type, "lower" printing 
resolution (1 mm distance) and 1 mm base thickness with support stalks, with a batch 
size of 60 mini-tablets. Although a product was manufactured, the shape of the 3D-
printed product was very poor compared to the design, and the support stalks and the 
mini-tablets cannot be distinguished from each other (Figure 5.9).  
 
 
Figure 5.9  Printed mini-tablets with 1 g of BAPO, "Clear 02" material type, "lower" 
printing resolution (1 mm distance) and 1 mm base thickness with support as settings. 
 
The type of material was then changed to "Flexible" keeping the other parameters the 
same and another batch of mini-tablets cast. The 3D-printed product seems improved 
and of a better shape (Figure 5.10) than the previous setting. However, the shape of 
mini-tablets still cannot be distinguished from the support stalks. 
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Figure 5.10  Printed mini-tablets with 1 g of BAPO, "flexible" material type, "lower" 
printing resolution (1 mm distance) and 1 mm base thickness with support as settings. 
 
The amount of BAPO then was increased to 2 g, following the "Pure" formulation. The 
printing resolution was also increased to "medium" level at 0.1 mm distance in order to 
improve the printing quality. The printed product showed an improvement (Figure 5.11) 
where the shape of mini-tablets can now be distinguished from the support. However, 
the overall shape was still not as good as that of the mini-tablets printed using the 
flexible resin. The attempt to increase the printing resolution to the highest level (0.05 
mm distance) did not result in any noticeable difference compared with the previous 
medium resolution, but the highest printing resolution was kept as default setting for the 
rest of the study. 
 
 
Figure 5.11  3D-printed mini-tablets with 2 g of BAPO, "flexible" material type, "medium" 
printing resolution (0.1 mm distance) and 1 mm base thickness with support as settings.  
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As this approach of using the support was not entirely successful, a further alternative 
approach was tested of printing the mini-tablets directly onto the platform without base or 
support. Recognisable mini-tablets were printed and resembled to some degree the 
compressed powder mini-tablets from Chapter 3 (Figure 5.12). The settings used here, 
i.e. "flexible" as the material type and "highest" printing resolution (0.05 mm), were 
chosen as default settings to 3D-print the mini-tablets. 
 
 
Figure 5.12  Comparison between 3D- printed (left) and compressed powder (right) mini-
tablets. 
 
PEG 6K was incorporated into the formulation to evaluate the effect on the drug release 
profile of mini-tablets of the addition of a water-soluble polymer. In order to keep the 
weight of the formulation constant, 25 g of PEGDA was removed from the formulation 
and replaced with 25 g of PEG 6K. The printing result was not as expected. "Blob"-
shaped mini-tablets with an ill-defined structure were obtained from the printing (Figure 
5.13).  
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Figure 5.13  Blob-shaped mini-tablets. 
 
It is likely that the cause of the poor shape of these mini-tablets is the relative lack of the 
photopolymer PEGDA, which gives the product its overall structure and rigidity once 
polymerised. Therefore, the amount of PEGDA was increased to 87.5 g while the volume 
of water was reduced to 37.5 mL, retaining the 25 g of PEG 6K and maintaining the 
overall formulation batch weight. The "blob"-shaped mini-tablets were still observed but 
the shape was better than the previous attempt. By reinstating the PEGDA content to its 
original value of 100 g and reducing the water volume further to 25 mL, whilst retaining 
the 25 g of PEG 6K and maintaining the overall formulation batch weight, mini-tablets 
similar in appearance to the "Pure" formulation were obtained and were deemed suitable 
for further investigation. This formulation is labelled as P6K1 formulation in Table 5.1. 
 
PEG 6K in the formulation was swapped with HPMC and PVP 90F in order to make a 
comparison of the effect on drug release from the 3D-printed mini-tablets with different 
water-soluble polymers and to mirror the formulations used in Chapter 3. Unfortunately, 
the HPMC formulation coagulated and formed rubbery lumps during the preparation of 
the solution, so could not be cast. Meanwhile, PVP 90F did not dissolve in the PEGDA 
solution, so again mini-tablets could not be printed from this formulation. 
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A batch of 3D printed mini-tablets was prepared using PEG 4K to investigate the effect 
on the dissolution profile of various molecular weights of PEG. PEG 4K was successfully 
dissolved in the photopolymer solution and this was able to be printed into mini-tablets. 
The formulation was labelled as P4K1.  
 
The water was removed from the formulation to evaluate if it has any effect on the 
polymerisation of the solution and/or the mini-tablets dissolution profiles. Both PEG 6K 
and PEG 4K, at 25 g, were dissolved in the solutions and their mini-tablets have decent 
shapes after being printed. PEG 6K and PEG 4K formulations without water were 
labelled as P6K2 and P4K2 respectively. 
 
The amount of PEG 6K and PEG 4K in the formulations was then increased to 50 g. 
PEG 6K dissolved in the photopolymer solution and this as then labelled as P6K3. 
However, some of PEG 4K did not dissolve in the solution. Since PEG 4K is flake-like in 
appearance, it was ground to increase the surface area to help with the dissolution. This 
action improved the dissolution of PEG 4K into the photopolymer solution but there was 
still some undissolved polymer. This mixture was not included in the mini-tablets 
formulation. Although it would be expected that the PEG 4K should dissolve into the 
PEGDA and/or water in the photopolymerisation solution to at least the same extent as 
the PEG 6K as it is chemically identical but with a lower molecular weight, there is an 
issue in that there is only limited time available for the dissolution process to occur 
before photopolymerisation starts. For the formulations with increased low molecular 
weight PEG content, water was removed in order to maintain the same overall 
formulation weight, which will have had the effect of slowing the dissolution process. 
 
Having undertaken the preliminary investigations into likely printable formulations, at this 
point, the six formulations in Table 5.1 were 3D-printed and the mini-tablets analysed as 
described above. 
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5.3.3  Physical Characterisation 
 
Six tests were performed to evaluate the physical properties of the 3D-printed mini-
tablets: weight uniformity, measurement of dimensions, crushing strength, friability, water 
content and water vapour sorption. Table 5.2 summarises five of these physical 
characteristics of the 3D-printed mini-tablets. The details of the studies regarding the 
physical characterisation are discussed in following sections. 
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Table 5.2 Summary of the physical characterisation of the chloramphenicol-loaded 3D-printed mini-tablets (mean ± SD). 
Formula * Weight (mg)  
(n=20) 
Diameter (mm) 
(n=10) 
Thickness (mm) 
(n=10) 
Friability (%) Crushing strength 
(N) (n=10) 
Water Content (%) 
(n=3) 
Pure 5.66 ± 0.53 2.33  0.07 2.04  0.19 n/a 5.71 ± 2.00 8.52 ± 1.65 
P6K1 12.25 ± 0.93 2.58  0.10 2.74  0.11 n/a 24.18 ± 5.72 3.68 ± 0.10 
P6K2 18.84 ± 1.19 2.74  0.11 3.35  0.25 n/a 22.55 ± 2.95 1.70 ± 0.01 
P6K3 25.60 ± 1.48 2.86  0.09 4.12  0.21 n/a 19.79 ± 2.01 0.89 ± 0.02 
P4K1 10.82 ± 0.62 2.53  0.07 2.30  0.20 n/a 20.65 ± 1.67 5.61 ± 0.57 
P4K2 36.76 ± 1.60 2.97  0.09 4.69  0.22 n/a 9.67 ± 1.71 1.75 ± 0.04 
* n/a = not applicable 
* Refer to Table 5.1 for full details of the formulations. 
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5.3.3.1 Weight uniformity 
The weight of the 3D-printed mini-tablets ranged between 5.66 ± 0.53 mg for the "Pure" 
formulation and 36.76 ± 1.60 mg for the P4K2 formulation, as shown in Table 5.2. As 
discussed in Chapter 3 for the compressed powder mini-tablets, although the BP weight 
uniformity specification technically does not apply to products where the individual 
weights are less than 40 mg, the criteria were applied here as product weight variability 
is a good indication of whether the product and process are appropriate and useable 
pharmaceutically. Table 5.3 shows the weight measurements of twenty 3D-printed mini-
tablets randomly chosen from each formulation. Black type denotes tablets that directly 
passed the BP weight uniformity specification (i.e. tablets with weights showing less than 
10 % deviation from the mean), red type denotes tablets that show between 10 and 20 % 
deviation from the mean value, and blue type denotes tablets that show greater than 20 
% deviation from the mean value. 
 
Of the six formulations studied, only P4K2 passed the BP specification directly with all 
3D-printed mini-tablets showing weights with less than 10 % deviation from the mean. 
P4K1 and P6K2 passed when the allowance of two tablets out of 20 showing between 
10 and 20 % deviation from the mean weight was taken into account. The "Pure", P6K1 
and P6K3 mini-tablets all had more than two individual mini-tablet weights that showed 
between 10 and 20 % deviation from the mean values, and the "Pure" formulation has 
one tablet where the deviation from the mean was greater than 20 %. These three 
batches of mini-tablets would not comply with the BP standard for weight variation. 
 
"Pure" 3D-printed mini-tablets have the lowest mean weight of all the mini-tablets 
formulations studied here. The weight of mini-tablets increased substantially with the 
addition of 25 g of low molecular weight PEG and removal of 25 mL water (P6K1 and 
P4K1 mini-tablets), in that the weight was roughly double that of the "Pure" formulation,  
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Table 5.3  Weight uniformity of the chloramphenicol-loaded 3D-printed mini-tablets. 
Mini-
tablets 
Pure* 
(mg) 
P6K1* 
(mg) 
P6K2* 
(mg) 
P6K3* 
(mg) 
P4K1* 
(mg) 
P4K2* 
(mg) 
1 5.77 12.86 18.28 24.03 10.38 36.79 
2 5.92 12.44 19.08 25.79 11.21 39.18 
3 5.86 12.22 17.11 26.75 11.88 36.62 
4 5.24 13.31 18.00 28.20 10.33 37.55 
5 6.86 10.92 21.34 26.99 10.98 34.49 
6 5.97 12.75 18.16 22.64 10.17 35.78 
7 5.25 13.34 18.76 24.70 9.99 37.10 
8 6.04 12.99 19.23 25.46 11.22 36.74 
9 6.21 11.39 19.19 24.64 10.68 34.45 
10 5.33 12.89 20.09 26.90 11.09 35.44 
11 5.48 12.41 17.12 25.12 9.55 35.75 
12 4.74 12.31 18.24 22.99 11.31 35.58 
13 5.49 11.70 19.23 25.79 11.06 39.64 
14 4.96 12.51 18.95 24.73 10.08 35.12 
15 4.98 13.82 17.91 26.10 10.61 34.80 
16 6.57 10.41 18.74 27.80 11.66 37.90 
17 5.65 10.43 21.20 25.37 11.25 37.48 
18 5.82 12.39 18.97 24.64 10.47 38.86 
19 5.69 11.69 20.04 27.23 11.60 39.12 
20 5.39 12.16 17.20 26.08 10.78 36.73 
Mean (mg) 5.66 12.25 18.84 25.60 10.82 36.76 
SD (mg) 0.53 0.93 1.19 1.48 0.62 1.60 
RSD (%) 9.37 7.57 6.29 5.77 5.70 4.36 
* Refer to Table 5.1 for full details of the formulations. 
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and was further increased with the removal of water from the starting formulations 
(P6K2, P6K3 and P4K2 mini-tablets). This may be due in part to the densities of the low 
molecular weight PEGs being higher than that of water. Both PEG 6K and PEG 4K are 
reported to have densities of 1.080 g/cm3 while water density is 1.000 g/cm3 (Rowe et 
al., 2009). If the overall size of the 3D-printed mini-tablets remained the same, an 
increase of roughly 8 % in their weight would be expected if all the water in the 
formulation was replaced by PEG 4K or PEG 6K. However, this argument does not 
directly explain all of the differences in weight observed between the various batches, 
and it must be noted that the heavier mini-tablets were also visibly larger than their 
smaller counterparts, as discussed below. 
 
5.3.3.2  Mini-tablets dimensions 
The diameter and thickness of 10 mini-tablets randomly chosen from each formulation 
were measured, as showed in Table 5.4. The results show that the diameter of the 3D-
printed mini-tablets ranged from 2.33 ± 0.07 mm for the "Pure" formulation to 2.97 ± 0.09 
mm for the P4K2 formulation, while the observed thickness values were between 2.04 ± 
0.19 mm for the "Pure" formulation and 4.69 ± 0.22 mm for the P4K2 formulation. "Pure" 
mini-tablets therefore displayed the lowest values for both the diameter and thickness 
measurements while the P4K2 mini-tablets showed the highest values for both 
measurements, which is consistent with the weight data presented above. Based on the 
mean values and the RSD values (ranging between 2.85 and 3.90 %), the diameters of 
the 3D-printed mini-tablets were reasonably consistent, both between formulations and 
within individual formulations. In all cases, though, the mean value was greater than the 
original design feature of a diameter of 2 mm. The thickness values were much more 
varied than the diameters, both between batches and within a batch, with RSD values 
ranging between 3.90 % and 9.40 %. 
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Table 5.4  Diameter (D) and thickness (T) of chloramphenicol-loaded 3D-printed mini-tablets. 
Mini-tablets Pure* P6K1* P6K2* P6K3* P4K1* P4K2* 
D (mm) T (mm) D (mm) T (mm) D (mm) T (mm) D (mm) T (mm) D (mm) T (mm) D (mm) T (mm) 
1 2.32 1.75 2.45 2.73 2.73 3.47 2.96 3.97 2.49 2.31 2.99 5.05 
2 2.23 1.91 2.66 2.92 2.92 3.23 2.92 3.80 2.70 2.69 2.95 4.46 
3 2.38 2.26 2.37 2.81 2.81 3.60 2.80 4.35 2.48 2.21 2.96 4.47 
4 2.29 1.92 2.63 2.88 2.88 3.73 2.84 4.34 2.59 2.10 2.93 4.80 
5 2.43 2.05 2.59 2.71 2.71 3.53 3.01 3.99 2.53 2.56 2.74 4.51 
6 2.38 2.15 2.61 2.68 2.68 3.51 2.84 4.03 2.47 2.00 3.04 4.48 
7 2.38 1.75 2.56 2.67 2.67 3.03 2.80 4.48 2.46 2.45 2.98 4.91 
8 2.21 2.25 2.70 2.53 2.53 3.41 2.75 4.02 2.53 2.20 3.09 4.88 
9 2.34 2.06 2.69 2.74 2.74 2.99 2.93 4.28 2.45 2.27 2.99 4.84 
10 2.35 2.29 2.53 2.68 2.68 3.02 2.75 3.91 2.56 2.22 3.03 4.45 
Mean (mm) 2.33 2.04 2.58 2.74 2.74 3.35 2.86 4.12 2.53 2.30 2.97 4.69 
SD (mm) 0.07 0.19 0.10 0.11 0.11 0.25 0.09 0.21 0.07 0.20 0.09 0.22 
RSD (%) 2.85 9.40 3.88 3.90 3.90 7.54 2.99 5.21 2.86 8.67 2.99 4.70 
* Refer to Table 5.1 for full details of the formulations. 
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There was a general trend towards increasing thickness and diameter with increasing 
weight, as shown in Figure 5.14. While this in itself may not be surprising (a larger mini-
tablet would be expected to be heavier), it does raise some issues about control during 
the 3D-printing process, as the same mini-tablet design and print parameters were used 
for all batches, and the bulk of the material (PEGDA, BAPO, chloramphenicol) was also 
the same for all six batches. 
 
 
Figure 5.14  The relationship between chloramphenicol-loaded 3D-printed mini-tablet 
weight, thickness and diameter. 
 
5.3.3.3  Crushing strength 
Table 5.5 shows the crushing strength measurements of 10 mini-tablets randomly 
selected from each formulation. The mean crushing strength of the mini-tablets varied 
between 5.71 ± 2.00 N for the "Pure" formulation and 24.18 ± 5.72 N for the P6K1 
formulation. The crushing strength showed a complex relationship with the formulation 
variables, and may also have been influenced by varying weight and shape of the mini-
tablets. Generally, the crushing strength increased with the addition of the low molecular 
weight PEGs, but decreased with the elimination of water from the formulations.  
Diameter
y = 0.0199x + 2.3042
R² = 0.9313
Thickness
y = 0.0904x + 1.5498
R² = 0.9693
0.0
1.0
2.0
3.0
4.0
5.0
6.0
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0
M
in
i-
ta
b
le
t t
h
ic
kn
es
s 
(m
m
) 
o
r 
d
ia
m
et
e
r 
(m
m
)
Mini-tablet weight (mg)
Chapter 5 
 
207 
Table 5.5  Crushing strength of the chloramphenicol-loaded 3D-printed mini-tablets. 
Mini-
tablets 
Pure* 
(N) 
P6K1*  
(N) 
P6K2&  
(N) 
P6K3*  
(N) 
P4K1*  
(N) 
P4K2*  
(N) 
1 5.31 13.81 23.70 19.02 22.50 12.91 
2 3.34 23.09 26.05 17.01 21.39 8.44 
3 4.54 31.86 24.35 19.06 20.18 9.86 
4 4.49 17.16 22.68 23.70 18.91 7.69 
5 6.48 23.29 26.23 18.66 17.26 9.82 
6 6.15 26.20 21.61 21.53 20.35 7.74 
7 4.14 29.59 24.48 21.28 22.75 9.41 
8 9.16 30.52 19.03 20.68 20.14 11.88 
9 8.98 22.29 19.37 17.69 21.76 10.40 
10 4.53 24.01 18.01 19.24 21.28 8.59 
Mean (N) 5.71 24.18 22.55 19.79 20.65 9.67 
SD (N) 2.00 5.72 2.95 2.01 1.67 1.71 
RSD (%) 34.96 23.67 13.07 10.14 8.08 17.69 
* Refer to Table 5.1 for full details of the formulations. 
 
This can be observed from the crushing strength values of "Pure"” mini-tablets compared 
to the matching pairs of P6K1/P6K2 and P4K1/P4K2 mini-tablets (P6K1 and P4K1 both 
contained 25 g of the relevant PEG and 25 mL of water, whereas P6K1 and P4K1 both 
contained 25 g of the relevant PEG and no water). The crushing strength values 
increased from 5.71 ± 2.00 N for "Pure" mini-tablets to 24.18 ± 5.72 N and 20.65 ± 1.67 
N for P6K1 and P4K1 mini-tablets, respectively, and then dropped to 22.55 ± 2.95 N for 
the P6K2 mini-tablets and more dramatically to 9.67 ± 1.71 N for the P4K2 mini-tablets. 
Doubling the amount of PEG 6K in the formulation reduced the crushing strength still 
further. 
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The crushing force is a useful measure to evaluate a specific batch of tablets or mini-
tablets against a pre-defined specification, but it is dependent on the size and shape of 
the material being tested, so for comparative purposes between formulations, the tensile 
strength is a better measure as it accounts for dimensions. The mean tensile strength of 
the mini-tablets was calculated as follows, assuming a perfect cylindrical shape, with the 
data being summarised in Table 5.6: 
 
 σ =   2P  Eq. 5.1 
   πDT 
 
σ = Tensile strength 
P = Fractural loading (crushing strength) 
D = Diameter 
T = Thickness 
 
The calculated values of tensile strength were different for the different batches, 
suggesting a formulation effect on this parameter. There appeared to be a general trend 
towards decreasing tensile strength with increasing weight, as shown in Figure 5.15. 
The one formulation that did not follow this general trend was the "Pure" formulation. 
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Table 5.6  Tensile strength of chloramphenicol-loaded 3D-printed mini-tablets. 
 
Pure* 
(N) 
P6K1*  
(N) 
P6K2*  
(N) 
P6K3*  
(N) 
P4K1*  
(N) 
P4K2*  
(N) 
Mean thickness 
(mm) 
2.04 2.74 3.35 4.12 2.30 4.69 
Mean diameter 
(mm) 
2.33 2.58 2.74 2.86 2.53 2.97 
Mean crushing 
strength (N) 
5.71 24.18 22.55 19.79 20.65 9.67 
Mean tensile 
strength (MPa) 
0.76 2.18 1.56 1.07 2.26 0.44 
* Refer to Table 5.1 for full details of the formulations. 
 
 
Figure 5.15  The relationship between chloramphenicol-loaded 3D-printed mini-tablet 
weight and tensile strength. 
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5.3.3.4  Friability test 
No friability test results were obtained because the mini-tablets stuck to the surface of 
friability tester drum and each other during the test procedure. The test is therefore 
considered invalid for these 3D-printed mini-tablets. There are a few implications of 
stickiness for the 3D-printed product in terms of pharmaceutics and clinical applications. 
A sticky product would be difficult to pack as it may stick on the packaging machine and 
not properly fill in the packet. It may also keep sticking on the patient's finger and may 
not stick onto the eye during the application. A layer of anti-adherent applied after 
processing can possibly be used to overcome the stickiness of the mini-tablets. 
However, it may interfere with the friability test results as the weight changes measured 
might be coming from the loss of dust associated with the anti-adherent layer.  
Alternatively, it may be possible to incorporate an anti-adherent into the printing 
formulation. 
 
5.3.3.5  Water content 
The water content of the 3D-printed mini-tablets was assessed after manufacture by 
TGA. "Pure" mini-tablets showed the highest water content of all the formulations. This 
would be expected due to the high quantity of water used in the “Pure” formulation. 
Meanwhile, P6K3, P6K2 and P4K2 mini-tablets showed low levels of water content, 
again expected as no water was added to these formulations. The water found in these 
mini-tablets could have arisen from low amounts of adsorbed water in the formulation 
ingredients or absorption from the atmosphere after manufacture. P6K1 and P4K1 
showed intermediate levels of water in the final mini-tablets, as expected from the 
intermediate levels of water in the initial formulation. 
 
These results therefore seem logically to be following the amount of water added into the 
formulation. However, closer inspection found that the amounts of water in the mini-
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tablets are lower than the initial percentage of water in the formulation, as shown in 
Table 5.7. It can be concluded that there is water loss during the printing process. 
 
Table 5.7  Comparison of the water content in the initial (pre-printing) formulation and 
the chloramphenicol-loaded 3D-printed mini-tablets (mean ± SD, n=3). 
Formula* Water content in 
formulation (%) 
Water content in the 
mini-tablets (%) 
Pure 31.85 8.52 ± 1.65 
P6K1 15.92 3.68 ± 0.10 
P6K2 0 1.70 ± 0.01 
P6K3 0 0.89 ± 0.02 
P4K1 15.92 5.61 ± 0.57 
P4K2 0 1.75 ± 0.04 
* Refer to Table 5.1 for full details of the formulations. 
 
5.3.3.6  Vapour sorption 
The moisture uptake tests were performed over 24 hours at a relative humidity level of 
95.0 ± 1.0 %, the highest humidity level that can be acquired by the DVS equipment. The 
percentage weight changes were plotted against time as shown in Figure 5.16 to 
evaluate the vapour sorption of each mini-tablet formulation. 
 
“Pure” mini-tablets showed the lowest changes in weight, roughly 30 % only at 
equilibrium, which was reached after approximately 5 hours. The rate of moisture uptake 
over the first 4 hours was highest for the “Pure” formulation and the P4K1 formulation. 
P6K3 mini-tablets displayed the highest weight changes; slightly above 50 % at 
equilibrium. The rest of mini-tablets showed similar intermediate values of around 35 to 
40 %. 
 
Chapter 5 
 
212 
 
 
 
Figure 5.16  Moisture uptake of the chloramphenicol-loaded 3D-printed mini-tablets* (mean ± SD, n=3) 
* Refer to Table 5.1 for full details of the formulations. 
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From the graph, it can be concluded that by adding low molecular weight PEG polymers 
in the formulations, the mini-tablets can retain more vapour/water. P6K1, P6K2 and 
P6K3 all showed a lower initial rate of moisture uptake than the “Pure” formulation and a 
longer time until equilibrium was reached (approximately 15 hours for P6K1 and P6K2 
and 20 hours for P6K3). The equilibrium moisture increased with increasing PEG 6K 
content, to approximately 37 to 40 % for P6K1 and P6K2, which initially contained 25 g 
of PEG 6K, and to approximately 51 % for P6K3, which initially contained 50 g of PEG 
6K. There was limited effect of the initial presence of water in the formulations in that 
P6K1 and P6K2 showed very similar responses throughout this part of the study. P4K1 
and P4K2 showed different initial rates of moisture uptake, but both showed similar 
equilibrium values of moisture content to P6K1 and P6K2, suggesting that the final 
moisture content is dependent on the added quantity of PEG in the initial formulation. 
There did not seem to be a relationship between residual moisture content in the mini-
tablets and water vapour uptake in the DVS study. 
 
5.3.4  MTDSC 
 
MTDSC was used to try to assess whether the polymer existed in an amorphous, 
crystalline or semi-crystalline state in the 3D-printed mini-tablets and in which form the 
drug was present. The raw materials were therefore assessed as well as the final 
products. Figure 5.17 shows the MTDSC profile of chloramphenicol, following a heat-
cool-heat cycle. Chloramphenicol demonstrates a melting point of 149.22 ± 1.32 °C and 
a glass transition temperature (Tg) of 32.68 ± 0.34 °C. PEG 4K and PEG 6K showed 
melting points of 60.71 ± 0.50 and 59.30 ± 1.38 °C °C, respectively, but no obvious Tg in 
the temperature range studied. Figure 5.18 shows the MTDSC profiles of PEG 6K and 
PEG 4K. PEGDA and BAPO were not studied by MTDSC as raw materials, as they 
would not exist in this same state after the photopolymerisation process.  
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Figure 5.17  A representative MTDSC trace of chloramphenicol. 
 
 
 
Figure 5.18  Representative MTDSC traces of PEG 6K and PEG 4K. 
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Figures 5.19 and 5.20 show MTDSC profiles of all mini-tablets. Table 5.8 shows a 
summary of the MTDSC behaviour of chloramphenicol, the low molecular weight PEGs 
and the 3D-printed mini-tablets. 
 
 
Figure 5.19  Representative MTDSC profiles of "Pure", P4K1 and P4K2 mini-tablets. 
 
 
Figure 5.20  Representative MTDSC profiles of P6K1, P6K2 and P6K3 mini-tablets. 
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Table 5.8  Summary of the thermal behaviour of the drug, excipients and 
chloramphenicol-loaded 3D-printed mini-tablets (n=3). 
Compound* Melting Temperature (°C) 
(mean  SD) 
Glass Transition Temperature 
(°C) (mean  SD) 
Chloramphenicol 149.22 ± 1.32 32.68 ± 0.34 
PEG 6K 59.30 ± 1.38 n/o 
PEG 4K 60.71 ± 0.50 n/o 
Pure 55.39 ± 1.91 n/o 
P6K1 51.79 ± 1.62 n/o 
P6K2 55.40 ± 1.82 n/o 
P6K3 57.17 ± 2.09 n/o 
P4K1 51.01 ± 5.11 n/o 
P4K2 58.38 ± 1.20 n/o 
* n/o = not observed 
* Refer to Table 5.1 for full details of the formulations. 
 
Based on the MTDSC results, the presence of the low molecular weight PEGs and water 
in the formulations influenced the melting temperature of the 3D-printed mini-tablets. The 
“Pure” mini-tablets melting temperature was 57.50 ± 1.85 °C, while the P6K1 and P4K1 
mini-tablets (the original formulations contained 25 g of the relevant PEG and 25 mL of 
water) displayed melting points which were approximately 4 °C lower, at circa 53 °C. In 
comparison to the P6K1 and P4K1 formulations, the melting point of the 3D-printed mini-
tablets increased after water was removed from the formulations (P6K2 and P4K2) to be 
more similar to the "Pure" formulation. 
 
There was no evidence of a melting peak or a glass transition attributed to 
chloramphenicol in the 3D-printed mini-tablets. There are several possible explanations 
for this. If chloramphenicol was present in the amorphous state, it may not be easily 
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detectable as the glass transition is relatively small and may be lost in the MTDSC 
baseline. However, in the temperature region that chloramphenicol's glass transition 
would be expected, the baseline was expanded to allow easier visualisation and no glass 
transition was observed. Hence, it is unlikely that the chloramphenicol is present in the 
amorphous state. If chloramphenicol is present in the crystalline state, then it would be 
expected to show a melting point, but if all other components had melted whilst 
chloramphenicol was still solid, then it would probably dissolve into the molten liquid, 
rather than remain as a solid. In this case, a melting peak would not be observed. 
Finally, the drug may exist in micro- or nano- crystalline deposits, which would have 
been as difficult to detect as the macro-crystalline system would be. Similarly, a separate 
melting peak was not observed for either PEG 4K or PEG 6K, but as their melting points 
are so similar to that of the "Pure" mini-tablets, which don't contain either of the low 
molecular weight PEGs, then it would be expected for the mixed systems that a broad, 
combined melting endotherm would be expected. 
 
5.3.5  Observation of the photopolymerisation process 
 
The photopolymerisation processes were monitored using a light microscope equipped 
with a digital camera. The times for the polymerisation processes to occur have been 
recorded based on visual observation, as shown in Table 5.9. The endpoint of the 
photopolymerisation process was determined as when the solution ceased to “move” 
because of its change in state from liquid to solid. Three replicates were performed for 
each formulation. All formulations used for mini-tablet production were studied, along 
with a "Pure" formulation without water, in order to determine if the water content 
affected the photopolymerisation process directly. 
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Table 5.9  Polymerisation length of time process (n=3). 
Formula* Time (minutes)  
(mean ± SD) 
Pure 13.99 ± 1.55 
Pure without H2O 6.59 ± 1.16 
P6K1 1.58 ± 0.18 
P6K2 1.63 ± 0.28 
P6K3 1.60 ± 0.20 
P4K1 4.14 ± 0.47 
P4K2 1.28 ± 0.23 
* Refer to Table 5.1 for full details of the formulations. 
 
The light intensity that was used to observe and polymerise the solution was different, 
depend on the individual solution. The light intensity had to be adjusted in this way to 
allow the light to pass through the solution so the polymerisation process could be 
observed. “Pure”, “Pure” without water and P4K1 formulation were translucent solutions, 
so the light intensity used was level 2. Meanwhile, the rest of the formulations displayed 
cloudy solutions under the microscope, although they were clear visually to the naked 
eye, so the light intensity had to be increased to level 8. Based on the observed results, 
the polymerisation was faster with the reduction (P4K1, circa 4 minutes) or total absence 
("Pure" without water, circa 6.5 minutes) of water from the initial formulation ("Pure", 
circa 14 minutes). This is probably because the addition of water in the formulation 
diluted the PEGDA and BAPO solution. However, the addition of PEG 4K also 
decreased the polymerisation time (P4K1 compared to the "Pure" formulation). 
 
All solutions observed with the higher light intensity showed very similar polymerisation 
times, which is probably a reflection of the light intensity used rather than as a result of 
formulation changes. According to Nomoto et al. (1994), generally for 
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photopolymerisation processes, the higher the light intensity, the faster the curing 
process. There was an obvious difference between the matched pair of P4K1 and P4K2 
formulations: P4K1 was polymerised after approximately 4 minutes, noticeably slower 
than the P4K2 formulation which required approximately 75 seconds. However, this is 
more likely to be attributable to the different light intensities used rather than a 
formulation difference. This investigation was somewhat inconclusive, due to the need to 
vary the light intensity in order to study the photopolymerisation process. However, it 
should be noted that during the actual 3D-printing process of the mini-tablets, the light 
intensity was kept constant for all formulations. 
 
5.3.6 Surface analysis 
 
The surface images of mini-tablets were captured using SEM. Figure 5.21 shows the 
collective SEM images of mini-tablets. All the 3D-printed mini-tablets had an uneven and 
rough surface, with the "Pure" mini-tablets showing the most regular surface. The P6K1 
and P4K1 mini-tablets look similar with small spikes covering the surface. P6K2, P6K3 
and P4K2 mini-tablets have the roughest surface. There are a few lumps that can be 
observed on P6K2 and P6K3 mini-tablets surfaces and a large crater on the surface of 
the P4K2 mini-tablets. It was initially intended to study the surface of the 3D-printed mini-
tablets with transition temperature microscopy (TTM) to assess the distribution of 
materials across the surface, in the same manner as had been conducted for the 
compressed powder mini-tablets. However, the tip of the TTM probe stuck to the mini-
tablet's sticky surface during the analysis, and broke. Therefore, the TTM study was 
halted, as it was apparent that the 3D-printed mini-tablets are too sticky and their 
surfaces are too rough for the delicate (and expensive) TTM probes to cope with. 
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Figure 5.21  SEM images of the chloramphenicol-loaded 3D-printed mini-tablets. Scale 
bar = 100 µm. 
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5.3.7  Drug release profile 
The drug release profiles from the 3D-printed mini-tablets were obtained using the same 
dissolution test as for the compressed powder mini-tablets in Chapter 3. The same flow-
through dissolution apparatus was used, with STF as the dissolution medium. Samples 
were taken hourly within a 9-hour total time frame and the drug content quantified 
spectrophotometrically at 278 nm. The amount of drug remaining undissolved at this 
point was quantified as described earlier in this Chapter and was used to determine the 
% released at each timepoint. Figure 5.22 shows the drug release profiles for all six 3D-
printed mini-tablet batches. 
 
“Pure” and P6K1 mini-tablets showed the lowest percentage drug release at the end of 9 
hours of dissolution test, with both formulations showing approximately 47 % release at 9 
hours. The two formulations based on PEG 4K showed the highest total drug release, 
with circa 80 % release at 9 hours. The Pure formulation showed a different dissolution 
profile to the others, with an initial fast release rate for the first three hours, then 
appearing to plateau after 7 hours. All the other batches continued to release drug 
throughout the full 9 hours of the dissolution test and the differences between them were 
related to speed and extent of drug release rather than the dissolution profile shape. 
 
PEG 4K and PEG 6K were added to the formulation in order to act as pore formers in the 
insoluble PEGDA/BAPO matrix. In the dissolution experiment, it was expected that the 
low molecular weight PEGs would dissolve into the STF, creating pores through which 
the STF could move, dissolving the drug in situ and allowing the drug to diffuse out into 
the bulk fluid for detection. As PEG 4K has a lower molecular weight than PEG 6K, it 
would be expected to dissolve faster itself, thus promoting a faster general release rate 
of the drug. On the other hand, the pores formed by the heavier PEG 6K would be 
expected to be larger, so would promote greater drug release. 
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Figure 5.22  Drug release profiles of the chloramphenicol-loaded 3D-printed mini-tablets (mean ± SD, n=3)  
* Refer to Table 5.1 for full details of the formulations. 
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From Figure 5.22, it is obvious that the presence of PEG 4K in the formulation (P4K1 
and P4K2) did lead to substantially enhanced drug dissolution at all timepoints compared 
to the "Pure" formulation. However, there was no apparent difference in the drug release 
profiles of P4K1 and P4K2, except at 1 hour where P4K2 showed a higher amount 
released than P4K1, suggesting that the presence or absence of water in the initial 
formulation mix had no significant effect on the behaviour of the 3D-printed mini-tablets. 
A different relationship was observed for the PEG 6K formulations in comparison to the 
"Pure" formulation. P6K1 (25 g of PEG 6K and 25 mL of water) showed a slower but 
steadier drug release than the "Pure" formulation, which was not expected. Removing 
the water from the initial formulation (P6K2) increased the rate and extent of drug 
release compared to both the "Pure" mini-tablets and the P6K1 mini-tablets. Increasing 
the PEG 6K content further (P6K3) seemed to have a detrimental effect on the rate and 
extent of drug release. 
 
5.3.7.1  Mathematical modelling for dissolution profile 
 
The dissolution profiles were modelled mathematically in the same manner as the 
compressed powder mini-tablets discussed in Chapter 3. Table 5.10 shows the 
coefficient of determination (r2), the release rate constants (k0, k1 and kKP), and the 
diffusional exponent (n) values for the release profiles of the 3D-printed mini-tablets. 
Green values indicated the best fitting model. 
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Table 5.10  Mathematical fitting parameters for the dissolution profiles from the chloramphenicol-loaded 3D-printed mini-tablets. 
 
Mini-tablet* Zero Order First Order Korsmeyer-Peppas 
r2 k0 r2 k1 r2 kKP n 
Pure 0.5674 6.6996 0.7110 0.0880 0.9022 17.29 0.5110 
P6K1 0.8881 6.0679 0.9951 0.0780 0.9728 10.07 0.7468 
P6K2 0.8819 9.7524 0.9963 0.1610 0.9870 18.21 0.6791 
P6K3 0.8803 8.6215 0.9807 0.1296 0.9788 15.05 0.7180 
P4K1 0.7876 11.0900 0.9788 0.2041 0.9580 22.46 0.6406 
P4K2 0.6852 10.7420 0.9536 0.1890 0.9890 28.75 0.4820 
* Refer to Table 5.1 for full details of the formulations. 
 
 
 
 
Chapter 5 
 
225 
As expected from visual inspection of the dissolution profiles, none of the formulations 
showed a good fit to the zero order model. The "Pure" mini-tablets fitted best to the 
Korsmeyer-Peppas model, although as the r2 value was only 0.9022, this was not a 
perfect fit. The P6K1, P6K2, P6K3 and P4K1 formulations were best fitted to a first-
order process if all data points were included. If only the data up to approximately 60 % 
drug release were included, then these formulations were best fitted to the Korsmeyer-
Peppas model. P4K2 fitted best with the Korsmeyer-Peppas model irrespective of 
whether the full or truncated data set was used. In each case where the Korsmeyer-
Peppas model was used, the exponent n took values between 0.5 and 1, suggesting 
an "anomalous" drug release profile. In such cases, there are multiple factors 
governing the release pattern, such as polymer relaxation and diffusion, as suggested 
by Peppas et al (1989). For the formulations studied here, the governing factors are 
likely to be dissolution of the added low molecular weight PEG, diffusion of the drug 
throughout the pores created by the dissolution of the PEG, and a degree of swelling 
that may occur with the insoluble PEGDA/BAPO matrix on prolonged exposure to 
aqueous fluid. 
 
The dissolution profiles of the 3D-printed mini-tablets were compared pair-wise using 
the f1 difference and f2 similarity factors. These results are summarised in Table 5.11, 
with green text indicating that the two formulations have similar dissolution profiles and 
red text indicating that the profiles are dissimilar. As expected, the two formulations 
based on PEG 4K were deemed to be similar in this exercise. The P6K2 and P6K3 
mini-tablets were similar in their profiles, but both were deemed to be different to the 
P6K1 profile. The "Pure" formulation was similar only to the P6K1 formulation. 
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Table 5.11  Difference (f1) and similarity (f2) factors for the dissolution profiles of 
chloramphenicol-loaded 3D-printed mini-tablets. 
 Pure P6K1 P6K2 P6K3 P4K1 P4K2 
Pure  
f1 = 14 
f2 = 60 
f1 = 28 
f2 = 38 
f1 = 19 
f2 = 47 
f1 = 38 
f2 = 27 
f1 = 37 
f2 = 32 
P6K1 
f1 = 14 
f2 = 60 
 
f1 = 38 
f2 = 34 
f1 = 30 
f2 = 42 
f1 = 47 
f2 = 27 
f1 = 46 
f2 = 28 
P6K2 
f1 = 28 
f2 = 38 
f1 = 38 
f2 = 34 
 
f1 = 12 
f2 = 59 
f1 = 14 
f2 = 53 
f1 = 13 
f2 = 55 
P6K3 
f1 = 19 
f2 = 47 
f1 = 30 
f2 = 42 
f1 = 12 
f2 = 59 
 
f1 = 24 
f2 = 41 
f1 = 23 
f2 = 43 
P4K1 
f1 = 38 
f2 = 27 
f1 = 47 
f2 = 27 
f1 = 14 
f2 = 53 
f1 = 24 
f2 = 41 
 
f1 = 5 
f2 = 70 
P4K2 
f1 = 37 
f2 = 32 
f1 = 46 
f2 = 28 
f1 = 13 
f2 = 55 
f1 = 23 
f2 = 43 
f1 = 5 
f2 = 70 
 
* Refer to Table 5.1 for full details of the formulations. 
 
5.3.7.2  Drug loading 
All the 3D-printed mini-tablets showed higher than expected drug content, as shows in 
Table 5.12. The results obtained ranged from 113 to 129 % of expected. According to 
BP specifications, the formulations would be considered uniform if not more than 1 
individual drug content value were outside the limit of 85 to 115 % and none outside 70 
to 130 % of the average content. However, this specification relates to data for 10 
tablets tested where in this case, they were only being done with 3 tablets. The red 
type indicates the values that deviated outside the range of 85 to 115 % but within the 
70 to 130 % range compared to the average for both the actual content and drug 
loading. Blue type indicates the values that deviated outside of the range of 70 to 130 
%. Based on the results, Pure, P6K2, P4K1 and P4K2 mini-tablets passed the BP 
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specifications. Meanwhile, P6K1 and P6K3 showed more than 1 value that is outside 
the 70 to 130% range which mean they fail the test. 
 
Table 5.12  Chloramphenicol loading in the 3D-printed mini-tablets compared to the 
chloramphenicol amount in the formulation (n=3). 
Polymer Tablet 
weight 
(µg) 
Drug 
content 
(µg) 
Mean 
(µg) 
SD (µg) Drug 
content 
(%) 
Mean 
(%) 
SD (%) 
Pure 5.71 0.24 0.22 0.02 4.20 3.83 
(3.18) 
0.33 
 5.68 0.21   3.70  
 5.57 0.20   3.59  
P6K1 11.00 0.44 0.47 0.08 4.00 3.90 
(3.18) 
0.83 
 13.24 0.40   3.02  
 11.99 0.56   4.67  
P6K2 19.95 0.94 0.91 0.03 4.71 4.81 
(3.79) 
0.14 
 18.13 0.90   4.96  
 18.72 0.89   4.75  
P6K3 27.10 1.30 1.05 0.26 4.80 4.12 
(3.18) 
0.69 
 23.14 0.79   3.41  
 25.60 1.06   4.14  
P4K1 9.15 0.34 0.36 0.03 3.72 3.62 
(3.18) 
0.11 
 9.99 0.35   3.50  
 10.71 0.39   3.64  
P4K2 35.15 1.73 1.74 0.12 4.92 4.59 
(3.79) 
0.40 
 39.05 1.62   4.15  
 39.51 1.86   4.71  
* Refer to Table 5.1 for full details of the formulations. 
** Values in () showed the percentage of chloramphenicol based on the formulations. 
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The high drug loading is highly possibly due to the water loss during the printing 
process as mentioned previously. Since the amount of water in the final mini-tablets 
was reduced compared to the starting formulation, the percentage of drug content 
based on the formulation would have changed to compensate. However, there is no 
easy correlation between the water content measured in the mini-tablets and the drug 
content calculated here, so there this cannot explain fully the discrepancy. 
 
5.3.7.3  Correlation between vapour sorption and release profile 
 
As with the compressed powder mini-tablets, the dissolution profiles and the water 
sorption profiles look similar and hence a correlation between the two was investigated. 
Figure 5.23 shows the correlation graphs between these two profiles for the six 
formulations of 3D-printed mini-tablets. All the formulations showed a good correlation 
between the water uptake and drug release, although there were some subtle 
differences between the batches. Those batches with added PEG 6K (i.e. P6K1, P6K2, 
and P6K3) appeared to show a linear relationship between drug release and water 
uptake, beginning at the start of the experiment, with limited differences between these 
three batches. This probably reflects the pore formation in the 3D-printed mini-tablets 
which occurs due to the dissolution of the low molecular weight PEG. The two batches 
based on PEG 4K (P4K1 and P4K2) also showed a linear relationship between drug 
release and water uptake, but were different in whether they showed a lag time or not. 
The "Pure" mini-tablet formulation appeared to show drug release occurring before any 
water uptake started, but a linear relationship thereafter. All the graphs showed p 
values lower than 0.0001. These indicate that there are significant correlation between 
two profiles since the p value is smaller than 0.05 (Seltman, 2015). 
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Figure 5.23  Correlation between drug release profile and vapour sorption of the 
 chloramphenicol-loaded 3D-printed mini-tablets.  
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5.4  GENERAL DISCUSSION 
 
The current study was an initial investigation into whether various 3D printing 
techniques could be used to prepare mini-tablets suitable for a range of purposes, 
specifically here for ocular drug delivery. Recently, a 3D-printed tablet product 
(Spritam from Aprecia Pharmaceuticals) has been granted marketing approval by 
FDA. The tablets were printed using a solid, free-form fabrication (SFF) technique. This 
technique creates a 3D object by printing fluid droplets using the drop-on-demand print 
head into selected areas of deposited layers of powder. A few layers were printed to 
produce the tablets (Yoo et al., 2015).  
 
In this study, two different types of 3D-printers with different printing techniques were 
used. It was not possible to use the more common fused deposition model (FDM) of 
3D-printing (similar to the SFF technique used to manufacture the Spritam tablets) as 
this requires a filament of the relevant formulation to be manufactured to use as a stock 
material for the actual printing process. Unfortunately, the polymers initially selected for 
investigation, to match the compressed powder mini-tablets studied earlier, could not 
be extruded to make a suitable filament. The focus of the study then switched to 
stereolithography techniques for 3D-printing, using a base material which could be 
photopolymerised by exposure to light. PEGDA was chosen as the photopolymerisable 
substrate, as it has been used before successfully to produce 3D-printed material, 
albeit not for pharmaceutical use (Hockaday et al., 2012, Ovsianikov et al., 2010). Its 
chemistry is well understood and therefore it provided a platform upon which to build a 
formulation strategy. As well as investigating the ability of the stereolithography 
approach for manufacturing mini-tablets, by adjusting the level of low molecular weight 
polymeric additives in the base formulation, the effect of these on the behaviour of the 
product could be evaluated. The design process for the mini-tablets was simple and 
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straightforward, using freely-available software to design the size and shape of the 
mini-tablets and to guide the 3D-printing process. Production of the mini-tablets was 
not as straightforward as their design, in that it was not possible to cast the mini-tablets 
using a mould system, due to leakage and the photopolymerised material acting as a 
glue between the mould surfaces and the mini-tablets, preventing them being released 
from the mould at the end of the photopolymerisation period. It was also not possible to 
3D-print the mini-tablets using a scaffold structure, as was the original intention and 
possible with the "flexible" resin manufactured by Formlabs (USA) for use as a design 
trial material and hence the mini-tablets were 3D-printed directly onto the platform of 
the 3D-printer. 
 
Six batches of mini-tablets were 3D-printed, varying the formulation in terms of added 
low molecular weight polymer and water, and characterising their physical and drug 
release behaviour. The mini-tablets showed quite substantial differences in their 
physical dimensions (thickness and diameter) and weight, indicating that the control 
parameters of the 3D-printing process need investigating to determine how to ensure 
that the product matches the design. The weight variability of the 3D-printed mini-
tablets was not as good as would be hoped, with only three of the six batches passing 
the BP weight uniformity specification. Fine-tuning the production control parameters of 
the 3D-printing process would be expected to have a direct beneficial effect on this 
quality control aspect. During the 3D-printing process, water was lost from the 
formulation, and understanding this evaporation process in more detail may also help 
to design formulations and 3D-printing processes which will lead to higher quality and 
more reproducible products. 
 
As a potential drug delivery vehicle, it is important to understand and characterise the 
drug release behaviour of the 3D-printed mini-tablets. The dissolution profiles could be 
modelled using either first-order kinetics or the Korsmeyer-Peppas equation. In the 
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latter case, the release exponent (n) indicated that the release profile was 
"anomalous". In some respects, this is to be expected, as the 3D-printed mini-tablets 
are not water-soluble, so will not erode in the same way as the compressed powder 
mini-tablets did, so drug dissolution will be reliant on diffusion of the dissolution 
medium (in this case STF) into the bulk of the mini-tablet by diffusion through pores 
either naturally occurring or created by dissolution of water-soluble additives such as 
the low molecular weight PEGs. The linear relationship between water vapour uptake 
and drug release suggests that movement of water and hydration of the mini-tablet is 
important in controlling the drug release pattern. It was interesting to note that the 
"Pure" formulation appeared to reach a dissolution plateau after 7 hours testing and 
circa 47 % drug release. This may be a reflection of the internal structure of these mini-
tablets, such as pore size and tortuosity, and warrants further investigation to fully 
understand the factors which determine this plateau effect. Addition of PEG 4K or PEG 
6K generally increased the dissolution rate, except for the P6K1 formulation, which 
unexpectedly showed an initial slower rate than the "Pure" formulation. All formulations 
with additives shown a drug release profile which was incomplete but still ongoing 
when the dissolution experiment was terminated after 9 hours. Further studies into how 
to control the drug release behaviour with alternative additives would be useful. Ideally, 
a slower and more zero-order release rate would be required for treatment with a non-
biodegradable drug delivery device, such as these mini-tablets. Alternatively, a 
biodegradable drug delivery device would be ideal and would require the patient only to 
insert it and not to have to remove it at the end of its useful life. 
 
Table 5.13 below summarises whether the 3D-printed mini-tablet batches would pass 
the initial target specifications presented in Chapter 1 and whether they would be 
considered for further development. 
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Table 5.13  Summary of the analytical tests of the 3D-printed mini-tablets in comparison to the initial target values. 
Attribute Target Pure P6K1 P6K2 P6K3 P4K1 P4K2 
Drug content 5 % w/w 
= 0.5 mg 
No No No No No No 
 Meets BP 
specifications for 
content 
uniformity 
Yes Yes Yes Yes Yes No 
Weight 10 mg No No No No Yes No 
 Meets BP 
specifications for 
weight uniformity 
No No Yes No Yes Yes 
Hardness 5 to 15 N No No No No No Yes 
Thickness 2 mm Yes No No No No No 
Diameter 2 mm No No No No No No 
Friability Meets BP 
specifications for 
friability 
N/A N/A N/A N/A N/A N/A 
Dissolution profile Zero order No No No No No No 
 24 hours release, 
i.e. 4.17 % per 
No Possibly No Possibly No No 
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hour 
Development 
potential 
 Possibly Possibly Possibly Possibly Possibly Possibly 
Comments  For all formulations: 
- Dissolution profile needs to be altered and extended. 
- Factors controlling the final drug loading need to be investigated (e.g. evaporation of water). 
- Factors controlling the size and shape of the product need to be investigated (e.g. laser strength). 
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5.5  CONCLUSIONS 
 
Based on the results of this investigative study, it can be concluded that it is plausible to 
use specific 3D-printing techniques to manufacture mini-tablets, such as 
stereolithography, although there is much work to be done to fully understand the 3D-
printing process and the factors which govern product quality. The drug release rate was 
altered by the presence of water-soluble additives, suggesting that the basic framework 
of PEGDA/BAPO could be used as a basis for much formulation design work in order to 
tailor the drug release rate to that desired to treat the particular disease state under 
study. 
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Design and Manufacture of Customised Ocular Inserts and Corresponding Flow-
through Dissolution Apparatus Using 3D-printing Techniques 
 
6.1  INTRODUCTION 
 
The possibility of using 3D-printing techniques to manufacture mini-tablets for ocular 
treatment was studied and discussed in Chapter 5. Since the shape of the samples 
produced with these techniques can easily be reconfigured, it is a good idea to broaden 
the current studies towards using different shapes and hence different drug delivery 
methods. Thus, ocular inserts were made using the 3D-printing technique. 
 
Ocular inserts are one of the drug delivery methods that have been used in ocular 
treatment but are less commonly used than eye drops. The inserts can be either soluble 
(erodible) or insoluble. Insoluble inserts would be expected to give a controllable, pre-
determined rate of drug release, possibly with zero-order kinetics. The disadvantage of 
insoluble inserts is the need for removal from the eye once the drug is fully dissolved 
(Saettone and Salminen, 1995). Despite this disadvantage, insoluble inserts are one of 
the most effective ways of providing ocular treatment. This is because inserts increase 
the overall local drug bioavailability and efficiency due to prolongation of contact time 
and controlled drug release. The inserts can also reduce the potential drug systemic 
adverse effects and administration frequency (Rawas-Qalaji and Williams, 2012). 
 
There are a few studies published on erodible inserts. Most of these inserts are in the 
form of compressed tablets (Di Colo et al., 2001, Di Colo et al., 2002) and mini-tablets 
(El-Gawad et al., 2012, Weyenberg et al., 2006, Weyenberg et al., 2004, Weyenberg et 
al., 2003, Weyenberg et al., 2005, Bozdag et al., 2010, Ceulemans et al., 2001). These 
inserts would absorb water when in contact with tear fluid and then form a gel into which 
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the drug would dissolve and diffuse through in order to provide a slow release profile. 
The quoted studies were mostly focused on investigating the release profiles of the 
inserts by manipulating the composition of the excipients, particle sizes and compression 
forces. The inserts used in these studies would normally be intended to be placed at the 
eye conjunctival fornix or cul-de-sac. 
 
Bioerodible inserts were also studied by several researchers. Aburahma and Mahmoud 
(2011) studied bioerodible inserts manufactured using a film-casting method. These 
inserts were tested to treat glaucoma in rabbits' eyes after being placed in the cul-de-
sac. A more invasive insert, known as the OphthaCoil, was developed using a short coil 
of thin stainless steel wire as the device core which was coated with bioerodible drug-
loaded hydrogel and then inserted into the fornix. However, the coil needed to be 
removed once the hydrogel was completely dissolved (Pijls et al., 2007, Pijls et al., 
2005). 
 
Although several studies have been performed on the formulation of ocular inserts, none 
of the inserts were customised based on the shape of the patient's eye or used 3D-
printing techniques in their manufacture. In this chapter, ocular inserts resembling scleral 
shields were designed based on actual human data, i.e. the shape of a subject's eye, 
and manufactured using a 3D-printing technique. The flow-through dissolution apparatus 
used in Chapters 3 and 5 could not be used here as the insert was too large to fit into 
the dissolution chamber. Hence, a customised flow-through dissolution cell was 
designed for these inserts and produced using the same 3D-printing technique. The drug 
release profiles from the inserts were studied and compared with the profiles from the 
3D-printed mini-tablets generated in Chapter 5.  
 
The same 3D-printing formulations were used in this part of the study as before, in order 
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to enable comparisons with the previous Chapter.  Additionally, a starting point of ocular 
coverage of the inserts was selected, of 1/8th of the eye's surface, in order to assess 
whether or not the SLA approach of 3D-printing these shaped inserts is feasible.  As this 
is an exploratory study into the feasibility of producing such an insert, the weight of the 
insert cannot be predicted at the outset and hence the actual drug content is also not 
directly predictable.  However, compliance with BP specifications for weight uniformity 
and drug content uniformity would be required. 
 
The target product profile of the chloramphenicol-loaded 3D-printed inserts is given in 
Table 6.1 below.   
 
Table 6.1  Ideal product profile of the chloramphenicol-loaded 3D-printed inserts. 
Attribute Specification detail 
Drug content 5.0 % w/w 
Meets BP specifications for content uniformity 
Weight Meets BP specifications for weight uniformity 
Dimensions Crescent-shaped 
Height, width and depth: to cover 1/8th of the eye surface  
Thickness 1 mm 
Dissolution profile Zero order over 5 days, i.e. 20 % per day, or 0.83 % per 
hour 
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6.2  METHODOLOGY 
 
6.2.1  Materials 
 
Polyethylene glycol 6000 (PEG 6K) was provided by Clariant GmbH, Germany. 
Chloramphenicol, polyethylene glycol 4000 (PEG 4K), polyethylene glycol diacrylate 700 
(PEGDA), phenylbis (2,4,6-trimethylbenzoyl) phosphine oxide (BAPO), sodium 
bicarbonate and calcium chloride were purchased from Sigma Aldrich, U.K. Sodium 
chloride was obtained from Fluka Chemie GmbH, Germany. Flexible resin was 
purchased from Formlabs Inc (USA). Polylactic acid (PLA) 1.75 mm white filament was 
purchased from 3DFilaPrint, UK. 
 
6.2.2  Methods 
 
6.2.2.1  Preparation of photopolymer solutions 
Three photopolymer solutions were prepared matching the formulations used in Chapter 
5, as shown in Table 6.2. The formulations generally contained 100 g of PEGDA, 2 g of 
BAPO, 5 g of chloramphenicol (Chl) and 25 mL of water. Specific formulations also 
contained 25 g of a low molecular weight polymer or an additional 25 mL of water. These 
solutions were used to manufacture the ocular inserts. 
 
Table 6.2  List of polymer solutions used for manufacturing the ocular inserts. 
Name Component 
PEGDA BAPO Chl H2O PEG 6K PEG 4K 
Pure 100 g 2 g 5 g 50 mL - - 
P6K1 100 g 2 g 5 g 25 mL 25 g - 
P4K1 100 g 2 g 5 g 25 mL - 25 g 
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6.2.2.2  3D-printing 
 
6.2.2.2.1  Magnetic resonance imaging 
A Magnetic Resonance Imaging (MRI) image was provided by a colleague in the UCL 
School of Pharmacy, based on his own head scan. The colleague gave permission for 
his MRI scan to be used in this project.  The MRI image obtained was in several 2D 
images, called slices. These images were analysed by using InVesalius (2016), a free 
software that generates 3D images based on the MRI slices, as described in Chapter 2. 
 
6.2.2.2.2  3D design 
Following analysis of the shape of the eye from the MRI scan, a matching ocular insert 
was designed using Tinkercad (2015), a free browser-based 3D design and modelling 
application. The design processes were the same as used for the 3D-printed mini-tablets 
and were explained in Chapter 2. The model designs were saved in .STL file format and 
then uploaded to the 3D-printers for the printing process. The design for the flow-through 
dissolution cell was finalised after the shape of the inserts had been defined, using the 
design processes described above. 
 
6.2.2.2.3  3D-printing 
For the printing process two different 3D-printers were used. A fused deposition 
modelling (FDM) MakerBot Mini Replicator printer (MakerBot, USA) was used to print the 
prototype design of the customised flow-through dissolution cell and a stereolithography 
apparatus (SLA) FormLabs 1+ printer (Formlabs, USA) was used to print the finalised 
design. For the ocular inserts, only the SLA printer was used. The printing settings used 
were similar to those used to 3D-print the mini-tablets in Chapter 5. Fifteen inserts 
printed for each batch. 
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6.2.2.3  Physical characterisation of the inserts 
 
6.2.2.3.1  Weight uniformity 
Ten ocular inserts were chosen randomly and weighed individually. The mean and 
standard deviation were calculated based on the data obtained. 
 
6.2.2.3.2  Surface area 
In order to determine the surface areas of ocular inserts, ten inserts from each 
formulation were selected randomly. The height, width and depth of the inserts were 
measured using a digital calliper (Mitotoyo, Japan). The STL format files for the ocular 
inserts from Section 6.2.2.2.3 were uploaded to Netfabb (2016). This software can be 
used to edit, repair and analyse STL format files. The surface areas of the inserts were 
calculated using this software, by editing the inserts dimensions based on the 
measurements, as explained in Chapter 2. 
 
6.2.2.3.3  Thickness swelling test 
Three inserts were chosen randomly from each formulation. The thickness of the inserts 
were measured using a digital calliper (Mitotoyo, Japan). Each insert was placed into a 
20 mL sample tube containing 10 mL simulated tear fluid (STF). The samples were left 
for one hour before the thickness was re-measured. The mean and standard deviation of 
the percentage thickness swelling were calculated based on the data obtained. 
 
6.2.2.4.  Drug release profile 
The customised flow-through dissolution apparatus was used to assess the drug release 
profile of the ocular inserts. The 3D-printed dissolution apparatus made in section 
6.2.2.2.2 was attached to a peristaltic pump with the dissolution medium flowing through 
at a rate of 50 µL/min to be consistent with the dissolution method used in Chapter 5. In 
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this study, STF was used as the dissolution medium. STF consists of sodium 
bicarbonate 0.2 % w/w, calcium chloride 0.008 %w/w and sodium chloride 0.67 %w/w at 
pH 7.4, based on the STF formulation suggested by Marques et al. (2011). Samples 
were taken every hour up to 9 hours and then at 24, 48, 72 and 96 hours. The drug 
content in the samples was quantified spectrophotometrically at 278 nm, as in the 
analysis of the mini-tablets in Chapters 3 and 5. The remnant ocular inserts then were 
crushed and dissolved in STF with the amount of drug remaining being quantified as 
above. Three replicates were performed for each formulation. 
 
6.2.2.4.1  Mathematical modelling of the dissolution profile 
Zero order kinetics, first order kinetics and the Korsmeyer-Peppas equation were used 
as mathematical models to determine the dissolution profiles of the 3D-printed ocular 
inserts statistically. Similarly, the difference (f1) and similarity (f2) factors, as proposed by 
Moore and Flanner (1996), were used to evaluate any differences between the 
dissolution profiles of the 3D-printed ocular inserts and the corresponding 3D-printed 
mini-tablets. These models are described in Chapter 2, 3 and 5. 
 
  
Chapter 6 
 
245 
 
6.3  RESULTS AND DISCUSSION 
 
6.3.1  Measurement of eye dimensions 
 
The inserts and the customised flow-through dissolution cell were designed based on 
MRI images. Figure 6.1 shows selected MRI images from three different angles based 
on human axial, sagittal and coronal planes. The axial, or transverse, images are 
horizontal slices through the body, beginning at the bottom and moving through to the 
top of the body. The sagittal images are vertical slices through the body, beginning at the 
left hand side and moving to the right hand side. Finally, the coronal images are vertical 
slices through the body, beginning at the front and moving to the back of the body. 
 
The dimensions of the eye were measured by using InVesalius (2016) as described 
above. In particular, as the eye is a three-dimensional structure, measurements in the x, 
y and z directions are all required. Here, the x axis reflects the horizontal distance across 
the eye from left to right and is obtained from the axial and coronal images. The y axis 
reflects the vertical distance across the eye from bottom to top and is obtained from the 
sagittal and coronal images. The z axis reflects the horizontal distance across the eye 
from front to back and is obtained from the sagittal and axial images. This is summarised 
in Figure 6.2. There are three different colours of lines drawn on the MRI images in 
Figure 6.1, representing the measurements in the three dimensions and utilising the 
colour scheme shown in Figure 6.2. 
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Anatomical plane MRI image 
Axial 
 
Sagittal 
 
Coronal 
 
 
Figure 6.1  MRI images from the three different anatomical planes. 
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Figure 6.2  The x-, y- and z-axes of the eye. 
 
Figure 6.1 shows the MRI slices at the point where the maximum dimensions of the eye 
in all three directions can be measured. Table 6.3 shows the triplicate measurements of 
each of these lines, with the global mean (i.e. the mean value summarising all the 
readings from both the relevant MRI slices) of the maximum dimensions of the eye being 
shown in Table 6.4. 
 
Table 6.3  Line measurements on each anatomical plane of the MRI images in Figure 
6.1. 
Reading 
Axial (mm) Sagittal (mm) Coronal (mm) 
x-axis z-axis z-axis y-axis x-axis y-axis 
1 26.72 19.80 19.50 22.99 26.79 21.73 
2 26.16 20.66 19.98 22.15 26.07 21.04 
3 25.49 20.64 19.84 22.17 25.38 20.99 
Mean 26.12 20.37 19.77 22.44 26.08 21.25 
STD 0.62 0.49 0.25 0.48 0.71 0.41 
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Table 6.4  Measurement of the eye's maximum dimensions, taken from the MRI images 
in Figure 6.1 (n=3). 
Axis Length (mm) (mean ± SD) 
x-axis 26.10 ± 0.59 
y-axis 21.85 ± 0.48 
z-axis 20.07 ± 0.76 
 
According to Bekerman et al. (2014), the dimensions of the eye in healthy human adults 
range between 20.9 and 27.1 mm for the coronal axis, 20.5 mm and 26.4 mm for the 
sagittal axis and 19.9 mm and 26.2 mm for the axial axis when measured across the 
external surface of the sclera. The study could not find any significant difference in eye 
dimensions between subjects of different gender, age or race, or between left and right 
eyes in the same subject. 
 
The coronal, sagittal and axial measurements mentioned in their study are equivalent to 
the x-, y- and z-axis measurements generated here. Based on these results, the eye 
dimensions measured from the current MRI scans were overall within the range for 
normal adult humans. However, the x-axis measurement was near to the higher end of 
the normal range while for the y-axis and the z-axis, the measurements were close to the 
lower end of the range, suggesting that the subject of the current study had eyes that 
were more elongated (x-axis), flatter (y-axis) and narrower (z-axis) than the "average" 
adult human. 
 
6.3.2  Design and 3D-printing of the Ocular Inserts 
 
The ocular inserts were designed based on the MRI images discussed above and to 
mimic the shape and structure of the subject's eye. The administration of these would 
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into eye "sac" between the bulbar conjunctiva and palpebral conjunctiva (Figure 6.3). 
This will allow the insert to be relatively easily inserted and removed from the eye after 
the treatment is accomplished. The shape chosen for the inserts was crescent-shape, as 
it fits well with the eye shape and can easily be placed in the sac, which make it an ideal 
shape for the inserts. The inserts also need to be thin since there is not much gap 
between the eye lid and eye surface. The dimensions of the ocular inserts were 
designed based on the measurements of this particular patient's eye. In this study, the 
inserts' dimensions were chosen as 8.30 mm height (y-axis), 24.80 mm width (x-axis), 
7.22 mm depth (z-axis) and 1.00 mm thickness with surface area (including the top and 
bottom surfaces) of 4.72 cm2. The inserts as designed would cover roughly 1/8th of the 
whole eye surface area. Figure 6.4 illustrates the design and measurements of the 
ocular insert. 
 
 
Figure 6.3  Anatomy of bulbar conjunctiva and palpebral conjunctiva. 
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Figure 6.4  3D image of the design of the ocular inserts with 8.30 mm height, 24.80 mm 
width, 7.22 mm depth and 1.00 mm thickness. 
 
A similar approach was taken to the refining the manufacturing process of the 3D-printed 
ocular inserts as was used for the 3D-printed mini-tablets in Chapter 5. Initial 
experimentation was performed using the flexible resin (Formlabs, USA) to assess 
whether the procedure was viable or not, and these inserts are described as "model" 
inserts to distinguish them from the inserts that were later 3D-printed using the 
photopolymer formulations listed in Table 6.2, which are denoted "sample" inserts. 
 
The model inserts were originally designed to be 3D-printed with a support, so a 
prototype was printed using the SLA printer using the following settings: "flexible" 
material type, "highest" printing resolution (0.05 mm distance) and 1 mm base thickness 
with support. This was successful when the flexible resin (Formlabs, USA) was used. 
However, due to the problems faced when attempting to 3D-print the PEGDA-based 
mini-tablets with supports in Chapter 5, it was decided to try to print the model inserts 
directly onto the platform surface, using the same material type and printing resolution 
settings. Again, this was successful for the flexible resin-based inserts. Figure 6.5 shows 
an image of the model inserts 3D-printed both with and without support. In both cases, 
the model insert closely resembled the design specification, giving confidence that this 
approach of preparing inserts was viable. 
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Figure 6.5  3D-printed model ocular insert with support (left) and without support (right). 
 
Following the procedure used with the 3D-printed mini-tablets in Chapter 5, all the 
sample inserts were printed directly onto the platform surface, using the three 
formulations listed in Table 6.2 and the same settings as for the model inserts. Figure 
6.6 shows images of representative sample inserts from the three formulations. To the 
naked eye, the sample inserts looked similar overall to the model inserts, but the sample 
inserts seemed thicker than the model inserts, even though they were printed using the 
same settings and design. This observation is discussed in more detail later in this 
Chapter. 
 
The 3D-printed "Pure" inserts were yellowish in colour. The shape seemed uniform for 
the whole batch of 15 inserts, the texture was slightly flexible and the surface was 
smooth and sticky. P6K1 inserts were paler in colour than the "Pure" inserts. Again, the 
texture of the P6K1 inserts was slightly flexible with a smooth surface and the shape 
seemed uniform for the whole batch. However, their surfaces were covered with a thin 
layer of white powder, possibly PEG 6K. The powder was easily removed by wiping it off 
with a tissue and instantly dissolved when in contact with water. The occurrence of a 
layer of white powder was not observed with the corresponding 3D-printed mini-tablets 
from Chapter 5. For the P4K1 formulation, the inserts were beige in colour and 
displayed similar texture and uniformity to the P6K1 inserts. All inserts were similar in 
colour to the 3D-printed mini-tablets with the same formulations from Chapter 5.  
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Figure 6.6  Images of (a) "Pure", (b) P6K1 and (c) P4K1 chloramphenicol-loaded 3D-
printed inserts from three different angles.  
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6.3.3  Design and 3D-printing of the customised flow-through dissolution cell 
 
Normally, dissolution studies are performed using either a conventional large-volume 
dissolution bath or a flow-through dissolution apparatus. However, these dissolution 
methods do not necessarily represent the actual dissolution process which is likely to 
take place on the surface of the human eye. There are a few factors that can affect the 
dissolution profiles on the human eye such as the composition of the tear fluid, flow rate 
and eye shape. Previous dissolution methods, for example the flow-through apparatus 
with a small sample chamber, were able to mimic the tear fluid composition and have an 
appropriately low flow rate but could not replicate the eye shape. The eye shape is 
crucial in ocular treatment with inserts, since everyone has different eye shape and size 
and it would be expected that contact between the insert and the surface of the eye 
would be necessary for dissolution to occur.  There is the additional factor of size of the 
inserts, in that the inserts studied here are too large for the flow through cell using for the 
mini-tablets. 
 
The customised flow-through dissolution cell was designed based on the measurement 
of eye dimensions and the size of the ocular insert. The shape of the eye was 
reconstructed by using Tinkercad software. The first prototype design of the dissolution 
cell consisted of an upper and a lower part, which would then be assembled by screwing 
the two parts together using bolts and nuts, as indicated in Figure 6.7. 
 
In the lower part, the 3D shape of the eye was re-created using the full x-axis and y-axis 
dimensions and approximately half the z-axis dimension. This was because the insert 
would be placed only over approximately 1/8th of the eye, rather than totally surrounding 
the eye, and the local dissolution of the drug from the insert was the important factor to 
study. The "eye" part of the design stands proud of the flat surface of the mould. 
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Surrounding this is an evenly-sized raised ridge, which would allow interlocking with the 
top part of the dissolution cell. The upper part itself was effectively a mirror image of the 
lower part, consisting of an eye-shaped hollow and a surrounding channel into which the 
ridge on the lower part would fit. Once assembled, there would be a 2 mm gap between 
the upper and lower parts of the cell. This 2 mm gap was to allow the insert (design 
thickness 1 mm) to be placed inside the dissolution cell with sufficient space to allow the 
dissolution medium to pass over the inserts. The design of the lower part of the 
dissolution cell included a small horizontal channel from the exterior to the 2 mm gap to 
enable the dissolution fluid to be pumped in one side and collected on the other. 
 
 
Figure 6.7  The first prototype of the customised flow-through dissolution cell consisted 
of upper (red) and lower (blue) parts. 
 
The dissolution cell prototypes were printed using the FDM printer with a polylactic acid 
(PLA) filament because it is more cost effective compared to the SLA printer. However, a 
significant problem associated with this approach was discovered after the two 
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components of the dissolution cell were printed. Following the design, the lower part was 
built with a ridge to fit with the recess in the upper part and seal the dissolution cell with 
the aim of preventing leakage of the dissolution medium during the dissolution process. 
Unfortunately, the upper part did not fit with the lower part, so therefore the cell could not 
be sealed, as shown in Figure 6.8.  
 
During the 3D-printing process, the PLA filament undergoes heating and melting at the 
point where the deposition of the polymer onto the mould occurs. It is actually droplets of 
liquid that are deposited, which then solidify and build up the 3D construct. If there is any 
movement of liquid away from the exact deposition site, this will result in a broadening of 
the element being printed and the product not being an exact match to the original 
design. In the present case, the issue will be exacerbated as two 3D-printed surfaces 
need to interact for the dissolution cell to seal correctly. It is likely that the ridge on the 
lower part of the cell will expand to be wider than it should be and the recess in the top 
part will be narrower than it should be as material on its edges will expand into this 
space. Only a small amount of movement in either or both of the parts would be 
sufficient to prevent the ridge and recess interlocking and cause the dissolution cell to 
leak. 
 
 
Figure 6.8  (a) 3D-printed lower (left hand side) and upper (right hand side) parts of the 
customised dissolution cell prototype and (b) both parts when put together. 
Chapter 6 
 
256 
 
 
Obviously, the two components of the dissolution cell need to fit properly in order to 
prevent the dissolution medium from leaking during the experiment. To attempt to 
overcome this problem, the ridge was removed from the design of the lower part of the 
cell, leaving it flat in this zone. The top part of the cell was kept the same with the recess, 
but this was now to be filled with a rubber O-ring, so that when the two parts of the cell 
were affixed to each other, the O-ring would form the seal between the two surfaces and 
preventing dissolution fluid loss. Figure 6.9 shows the two components separately and 
sealed together to make the dissolution cell. 
 
 
Figure 6.9  (a) 3D-printed lower (left hand side) and upper (right hand side) parts of the 
dissolution cell prototype with the rubber ring and without ridge or recess and (b) the 
successfully assembled prototype with bolts and nuts. 
 
The design without the ridge was chosen as the final design for the dissolution cell and 
printed using the SLA printer with flexible resin (Formlabs Inc., USA). The SLA printer 
was used to print the final design because this printer is capable of printing the product 
more accurately, based on the design measurement from the 3D software. The flexible 
resin was used to provide a translucent dissolution cell, so that the dissolution 
experiment could be monitored visually. Two metal tubes with 1 mm inner diameter were 
attached and glued to the dissolution medium inlet and outlet. These were to make it 
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easier to connect the dissolution cell to the peristaltic pump and to collect the dissolution 
samples. Figure 6.10 shows the final 3D-printed customised dissolution cell ready 
before use. The dissolution medium inlet and outlet were positioned across the eye 
shape to mimic the tear flow in human eye which is excreted from the tear duct and then 
spread across the eye surface. 
 
 
Figure 6.10  (a) The lower (top) and upper (bottom) parts of the final 3D-printed 
customised dissolution cell and (b) the successfully assembled prototype with bolts and 
nuts. 
 
6.3.4  Physical characterisation of the 3D-printed ocular inserts 
 
6.3.4.1  Weight Uniformity 
The weight uniformity of the inserts was measured by individually weighing ten inserts 
that were randomly chosen. The mean and standard deviation of the readings were then 
calculated, as shown in Table 6.5. Although these inserts would not necessarily be 
subject to the BP weight uniformity guidelines, and the batch size of 15 inserts is lower 
than the 20 units that are required for the BP analysis, the general specification for this 
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attribute was applied to assess the manufacturing reproducibility of the inserts. As the 
inserts are greater than 250 mg in weight, 5 % deviation from the mean is used as the 
criterion for assessing whether the batch met the BP specifications or not. In Table 6.5, 
black type denotes inserts that directly passed the BP weight uniformity specification (i.e. 
inserts with weights showing less than 5 % deviation from the mean), red type denotes 
inserts that show between 5 and 10 % deviation from the mean value, and blue type 
denotes inserts that show greater than 10 % deviation from the mean value. 
 
Table 6.5  Weight uniformity data for chloramphenicol-loaded 3D-printed ocular inserts. 
 Insert Pure* 
(mg) 
P6K1* 
(mg) 
P4K1* 
(mg) 
1 540.53 497.71 539.89 
2 494.94 516.82 553.62 
3 479.48 537.63 619.78 
4 500.34 519.19 511.56 
5 492.20 502.23 634.67 
6 434.46 477.25 613.84 
7 519.83 490.47 624.88 
8 446.27 502.15 568.41 
9 475.25 507.27 575.04 
10 431.20 517.67 545.89 
Mean 481.45 506.84 578.76 
SD 35.95 16.96 42.20 
RSD (%) 7.47 3.35 7.29 
* Refer to Table 6.2 for full details of the formulations. 
 
The "Pure" formulation and the P6K1 formulation were not statistically significantly 
different in weight, but the P4K1 formulation was statistically significantly different 
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(p<0.05) to both of the other formulations. The 3D-printed mini-tablets studied in Chapter 
5 also showed differences in weight between formulations, in that the "Pure" formulation 
was significantly lower in weight than all other formulations, and the P6K1 and P4K1 3D-
printed mini-tablets were significantly different (p<0.05) to each other. However, in that 
case the P6K1 3D-printed mini-tablets were heavier than the P4K1 3D-printed mini-
tablets, whereas for the 3D-printed ocular inserts, the relationship was inversed. 
 
Based on the summary values, the P6K1 formulation was the most reproducible in terms 
of weight with an RSD value of 3.35 %. Both the "Pure" formulation and the P4K1 
showed similar higher variability (RSD values of 7.47 % and 7.29 %, respectively), 
although the actual weights were quite dissimilar between the batches. Using the BP 
weight uniformity specifications as a guide, only the P6K1 inserts would pass, and only 
then if the "2 out 20 showing deviation between 5 and 10 % of the mean" could be taken 
to be "2 out of 10". Both the "Pure" and the P4K1 inserts would fail this specification. 
 
The slightly higher weights of individual inserts, and hence the high variability, may have 
been caused, at least in part, by the excessive areas that look like a "skirt" around the 
inserts, as shown in Figure 6.11. This "skirt" was a by-product created during the curing 
process of the inserts. After the 3D-printing process was complete, the platform was 
lifted from the formulation solution in the resin tank. One or more droplets of the 
formulation solution were adsorbed to the surface of the inserts. During the curing 
process, these residues were photopolymerised and cured, creating the "skirt". 
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Figure 6.11  The "skirt" around the inserts 
 
6.3.4.2  Dimensions 
The ocular inserts were crescent-shaped, close to being a quarter-sphere. Since the 
inserts' shape was irregular, it is difficult to calculate the surface area using standard 
surface area (cubic, sphere, pyramid etc.) formulae. Because of that, Netfabb software 
was used to determine the surface area of the inserts. To use the software, the height, 
width and depth of the 3D-printed inserts need to be measured. A digital calliper was 
used for that purpose. The inserts' dimensions on the software were then re-adjusted 
using these readings and the surface areas were then calculated, as summarised in 
Table 6.6.  
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Table 6.6  Summary of the design parameters and actual dimensional data for 
chloramphenicol-loaded 3D-printed ocular inserts (mean  SD) (n=10). 
Inserts Height (mm) Width (mm) Depth (mm) Surface area 
(cm²) 
Design 8.30 24.80 7.22 4.72 
Pure* 8.32 ± 0.16 22.59 ± 0.26 6.72 ± 0.20 4.22 ± 0.09 
P6K1* 8.71 ± 0.38 26.13 ± 0.30 8.16 ± 0.09 5.43 ± 0.13 
P4K1* 8.01 ± 0.36 23.80 ± 0.28 8.23 ± 0.43 4.80 ± 0.18 
* Refer to Table 6.2 for full details of the formulations. 
 
Based on the results, the P4K1 inserts were the closest to the design in term of the 
mean surface area and width. Meanwhile, the mean values of the height and depth of 
the "Pure" inserts were the closest to the design, as shown in green type in Table 6.6. 
P6K1 inserts displayed higher mean values for all measurements and calculated surface 
area, indicating the P6K1 inserts were printed larger than the model.  
 
Tables 6.7, 6.8 and 6.9 show the individual dimensional data for ten inserts from each of 
the three different batches. Overall, the "Pure" formulation was the most consistent, with 
very low RSD values for all measurements. Both the P6K1 and P4K1 inserts showed 
much more variability in the height dimension and the P4K1 inserts also showed higher 
variability in the depth dimension. 
 
Overall, it was apparent that the inserts had not been 3D-printed exactly as the original 
design. This is probably due to the printing settings used to manufacture the inserts, in 
that the pre-installed printing settings on the software were meant for commercialised 
resin specifically developed for 3D-printing, e.g. the flexible resin used in the prototyping 
exercise. However, the settings chosen for this study was the best settings possible for 
these formulations, as discussed in Chapter 5 for the 3D-printed mini-tablets. This is an 
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area which needs some attention if this technology is to be used successfully for 
pharmaceutical products. 
 
Table 6.7  Measured dimensions and calculated surface areas of chloramphenicol-
loaded 3D-printed "Pure"* inserts. 
Insert Height (mm) Width (mm) Depth (mm) Surface area 
(cm²) 
1 8.42 21.98 6.82 4.18 
2 8.28 22.57 6.82 4.23 
3 7.98 22.86 6.46 4.06 
4 8.55 22.47 6.93 4.34 
5 8.26 22.38 6.89 4.21 
6 8.38 22.72 6.87 4.30 
7 8.30 22.78 6.55 4.18 
8 8.28 22.79 6.88 4.28 
9 8.54 22.71 6.62 4.28 
10 8.24 22.65 6.40 4.10 
Mean 8.32 22.59 6.72 4.22 
SD 0.16 0.26 0.20 0.09 
RSD (%) 1.92 1.15 2.98 2.13 
* Refer to Table 6.2 for full details of the formulations. 
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Table 6.8  Measured dimensions and calculated surface areas of chloramphenicol-
loaded 3D-printed P6K1* inserts. 
Insert Height (mm) Width (mm) Depth (mm) Surface area 
(cm²) 
1 8.97 26.66 8.26 5.66 
2 8.41 26.27 8.13 5.33 
3 9.37 25.56 8.03 5.53 
4 8.15 26.08 8.27 5.25 
5 9.16 25.89 8.08 5.53 
6 8.84 26.00 8.19 5.46 
7 8.51 26.00 8.13 5.32 
8 8.50 26.39 8.27 5.43 
9 8.72 26.17 8.23 5.46 
10 8.46 26.24 8.04 5.31 
Mean 8.71 26.13 8.16 5.43 
SD 0.38 0.30 0.09 0.13 
RSD (%) 4.36 1.15 1.10 2.39 
* Refer to Table 6.2 for full details of the formulations. 
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Table 6.9  Measured dimensions and calculated surface areas of chloramphenicol-
loaded 3D-printed P4K1* inserts. 
Insert Height (mm) Width (mm) Depth (mm) Surface area 
(cm²) 
1 7.63 23.50 7.76 4.46 
2 7.59 24.04 8.47 4.77 
3 7.85 24.29 8.35 4.86 
4 8.22 23.64 7.72 4.67 
5 7.93 23.62 8.56 4.85 
6 8.53 23.47 8.53 5.02 
7 8.02 23.66 7.55 4.55 
8 7.88 23.88 8.61 4.89 
9 7.81 24.17 8.73 4.96 
10 8.67 23.71 7.98 4.93 
Mean 8.01 23.80 8.23 4.80 
SD 0.36 0.28 0.43 0.18 
RSD (%) 4.49 1.18 5.22 3.75 
* Refer to Table 6.2 for full details of the formulations. 
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6.3.5  Drug release profile 
The dissolution studies on the inserts could not be conducted using the same flow-
through dissolution system as used in Chapters 3 and 5, because the inserts were too 
large to fit into the 200 µL chamber. Hence, a flow-through cell based on the shape of 
the subject's eye was designed and manufactured as described earlier in this Chapter. 
The remainder of the experimental set-up was the same as used previously, i.e. it was 
simply that the sample casket that was connected to the peristaltic pump was replaced 
with the 3D-printed customised dissolution cell. The inserts were placed and sealed 
inside the dissolution cell, as shown in Figure 6.12. The cell was sealed to ensure that 
the dissolution medium did not leak during the test. The dissolution cells were 
translucent, which made it possible to observe the sample inside. 
 
 
Figure 6.12  Sample placement inside the 3D-printed customised dissolution cell. (a) 
The insert was placed on the lower part and (b) the two parts were held together by bolts 
and nuts. 
 
The complete dissolution system was assembled as shown in Figure 6.13. The 
dissolution medium was kept at 34.0 ± 1.0 °C to mimic the temperature of normal human 
eye which is 34.0 ± 0.5 °C (Fujishima et al., 1996). The medium then was pumped 
through the dissolution cell using the peristaltic pump at the rate of 50 µL/minute. This 
rate was chosen in order to obtain sufficient amount of sample to be analysed using a 
UV/Vis spectrophotometer at 278 nm and to provide a comparison to the dissolution data 
Inserts Inserts 
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generated in Chapters 3 and 5. The sample was collected at the dissolution cell outlet 
using a 15 mL vial, every hour up to 9 hours and then at 24, 48, 72 and 96 hours. 
 
 
Figure 6.13  Customised ocular flow-through dissolution apparatus. 
 
The data obtained from the dissolution tests were plotted graphically as percentage of 
drug release against time, as shown in Figure 6.14. Three replicates were generated for 
each formulation.  
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Figure 6.14  Drug release profile from chlorampenicol-loaded "Pure", P4K1 and P6K1 
inserts (n=3). 
 
Based on Figure 15, all formulations displayed slow release profiles, but there were 
some obvious differences between the three formulations. The rank order of release was 
"Pure" (slowest rate and lowest total % drug released), P4K1 (intermediate rate but 
complete drug release), P6K1 (fastest rate and complete drug release). 
 
The "Pure" inserts released the drug up to the 72 hours timepoint before the release 
profile started to plateau. Over the first 9 hours the "Pure" inserts released only circa 20 
% of the drug. There then appeared to be a slight disconnect between the results for the 
inserts at 9 hours and 24 hours, i.e. the profile is not completely smooth, which is 
probably a consequence of the long-time gap (overnight) between these samples. Drug 
release continued after 24 hours until a plateau was reached at circa 65 % drug release 
at 72 hours. 
 
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70 80 90 100
%
 D
ru
g 
re
le
as
e
Time (Hour)
Pure P6K1 P4K1
Chapter 6 
 
268 
 
Similar behaviour was observed with the P4K1 inserts, in that over the first 9 hours of the 
study only circa 20 % of the drug was released. Again, there was a disconnect between 
the results at 9 hours and 24 hours, but drug release continued thereafter until the drug 
was completely released after 96 hours. 
 
Meanwhile, the P6K1 inserts released the drug at a higher rate than the other 
formulations up to 24 hours, before the release rate started to slow down significantly. 
Drug release from these inserts was essentially complete after 72 hours of the 
dissolution test. 
 
6.3.5.1  Mathematical modelling of the drug release profiles 
As discussed in Chapters 3 and 5 for the compressed powder and 3D-printed mini-
tablets, three mathematical models of release kinetics were used to evaluate the drug 
release profiles: first order kinetics, zero order kinetics and the Korsmeyer-Peppas 
equation. For the first and zero order kinetics, data were analysed up to approximately 
85 % of release profile. Meanwhile, for the Korsmeyer-Peppas analysis, the values were 
analysed up to approximately 60 % of the fractional release. In case of the release profile 
plateauing before reaching the 100 %, the values were analysed up to the point before it 
plateaued. Table 6.10 shows the coefficient of determination (r2), release rate constant 
((k0, k1 and kKP)) and the diffusional exponent (n) values for the release profiles of the 
3D-printed ocular inserts. Green values indicated the best fitting model. Table 6.11 
shows a similar analysis but using data from the first 9 hours of the experiment only, in 
order to facilitate comparison with the 3D-printed mini-tablets, discussed later in this 
Chapter. 
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Table 6.10  Mathematical modelling parameters for drug release from chloramphenicol-loaded 3D-printed ocular inserts - full profile. 
Mini-tablet Zero Order First Order Korsmeyer-Peppas 
r2 k0 r2 k1 r2 kKP n 
Pure* 0.8688 1.4945 0.9581 0.0215 0.9869 4.1678 0.7032 
P6K1* 0.6006 4.3318 0.9805 0.0748 0.9982 14.7008 0.5406 
P4K1* 0.9311 1.9898 0.9874 0.0384 0.9717 4.3017 0.768 
* Refer to Table 6.2 for full details of the formulations. 
 
Table 6.11  Mathematical modelling parameters for drug release from chloramphenicol-loaded 3D-printed ocular inserts - 9 hours only. 
Mini-tablet Zero Order First Order Korsmeyer-Peppas 
r2 k0 r2 k1 r2 kKP n 
Pure* 0.8966 2.2454 0.9242 0.0243 0.9992 4.5136 0.633 
P6K1* 0.7962 6.1315 0.9086 0.0788 0.9970 14.7567 0.5373 
P4K1* 0.8962 2.5444 0.9261 0.0279 0.9950 4.8477 0.665 
* Refer to Table 6.2 for full details of the formulations 
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Over the full dissolution profile, the "Pure" and P6K1 inserts were best modelled with 
the Korsmeyer-Peppas equation, with n values of 0.7032 and 0.5406, respectively. 
This values indicate an "anomalous" mechanism of dissolution, whereby multiple 
factors are involved in the controlling the drug release pattern. The dissolution profile of 
the P4K1 inserts was best fitted with a first order profile. Although it is obvious from 
Figure 6.15, that the drug release profiles are different, this was confirmed by 
examination of the similarity factors (f2) which were < 50 for all paired comparisons. 
 
When only the first 9 hours of the dissolution profile were considered, all three 
formulations showed excellent fitting to the Korsmeyer-Peppas equation, with r2  
0.9950, and n values of 0.6330, 0.5373 and 0.665 for the "Pure", P6K1 and P4K1 
inserts, respectively, indicating an "anomalous" control process. In this timeframe, the 
"Pure" and P4K1 inserts had similar dissolution profiles (f2 = 85) whereas the P6K1 
inserts still showed f2 < 50 for comparisons with the other inserts. 
 
6.3.5.2  Comparison between the 3D-printed mini-tablets and 3D-printed ocular inserts 
The drug release profiles of matched pairs of 3D-printed mini-tablets and ocular inserts 
were compared in order to investigate if their different size and shapes played essential 
roles in their release profiles, since both the ocular inserts and mini-tablets were 3D-
printed using the same formulations. The comparison was performed over the first 9 
hours only, as this was the duration of the release testing for the 3-D printed mini-
tablets and the timepoints at which the dissolution samples were taken were the same 
for both the 3-D printed mini-tablets and the 3D-printed ocular inserts. 
 
Figures 6.15, 6.16 and 6.17 compare the drug release profiles of the two product 
types for the "Pure", P6K1 and P4K1 formulations, respectively. 
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Figure 6.15  Drug release profiles from the chloramphenicol-loaded "Pure" 
formulations (n=3). 
 
The drug release from the "Pure" 3D-printed mini-tablets appeared to plateau after 7 
hours, with only minimal drug release being observed thereafter. The inserts showed a 
similar type of profile, but the time taken to reach the plateau was much longer at 72 
hours. Both product types showed incomplete dissolution, with circa 20 % and 65 % 
drug release for the inserts at 9 hours and 96 hours respectively, and circa 47 % drug 
release for the mini-tablets at 9 hours. The two drug release profiles were clearly 
different over the first 9 hours, reinforced by examination of the f1 and f2 difference and 
similarity factors, as summarised in Table 6.12. These results suggest that the 
dimensions and surface area of the product may play a role in controlling the 
dissolution rate for this particular formulation. 
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Meanwhile, the profiles of the P6K1 inserts and mini-tablets were very similar and 
overlapped from the 3 hour timepoint to the 9 hour timepoint, when the dissolution 
experiment for the mini-tablets was terminated. Given these profiles, it would be 
expected that the mini-tablet would have continued to release the drug until complete 
release was observed, rather than plateauing as was the case with the "Pure" 
formulation. The inserts' profile over this 9-hour period fitted better to the Korsmeyer-
Peppas equation (anomalous dissolution), whereas the mini-tablets' profile fitted better 
to first-order kinetics, which is probably a consequence of the slight differences at the 
very early timepoints (1 hour and 2 hours). For the P6K1 formulation, therefore, it 
would appear that there was little effect of the product dimensions on the release 
profile. The f1 and f2 difference and similarity factors, as summarised in Table 6.12, 
support this conclusion. 
 
 
Figure 6.16  Drug release profiles from the chloramphenicol-loaded P6K1 formulation 
(n=3). 
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The behaviour of the P4K1 products displayed a similar pattern to that of the "Pure" 
products, in that there was a substantial difference between the drug release profiles of 
the inserts and the mini-tablets, with that of the inserts being significantly slower than 
the mini-tablets over the first 9 hours. The P4K1 mini-tablets had released circa 80 % 
of the drug at 9 hours when the experiment was terminated, and would be expected to 
show complete drug release at longer time periods. The P4K1 inserts had only 
released circa 20 % of the drug at 9 hours, although complete drug release was 
observed at 96 hours. Evaluation of the f1 and f2 difference and similarity factors (Table 
6.12), confirm that the profiles are dissimilar. Similarly to the "Pure" formulation, it 
would appear that there was an effect of the product dimensions for this particular 
formulation. 
 
 
Figure 6. 17  Drug release profiles from the chloramphenicol-loaded P4K1 formulations 
(n=3). 
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Table 6.12  Difference and similarity factors between chloramphenicol-loaded ocular 
inserts and 3D-printed mini-tablets. 
Formulation Difference Factor (f1) Similarity Factor (f2) 
Pure* 68 29 
P6K1* 5 80 
P4K1* 77 15 
* Refer to Table 6.2 for full details of the formulations. 
 
6.3.5.3  Evaluation of the thickness and swelling behaviour of the 3D-printed ocular 
inserts 
The dissolution behaviour of the 3D-printed inserts was unexpected, particularly when 
compared to the 3D-printed mini-tablets of the same formulation, and hence was 
investigated further. One possibility is that the physical dimensions of the inserts 
resulted in contact with both the upper and lower surfaces of the dissolution cell, 
preventing the dissolution medium flowing easily across the surface of the insert and 
reducing the amount of drug dissolved. The gap between the lower and upper parts of 
the dissolution cell when they were put together was 2 mm and the design thickness of 
the inserts was 1 mm, hence there should have been plenty of clearance. However, if 
the thickness of the insert was greater than 2 mm, it would be expected that contact to 
both surfaces would arise. Therefore, the central thickness of ten randomly-selected 
inserts was measured to investigate this issue, and the results are presented in Table 
6.13. 
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Table 6.13  The thickness values of the chloramphenicol-loaded 3D-printed ocular 
inserts. 
Reading Pure* P6K1* P4K1* 
1 2.64 1.78 1.88 
2 2.44 1.80 2.36 
3 1.80 1.60 1.74 
4 2.47 1.88 2.18 
5 2.48 1.80 2.35 
6 1.70 1.75 2.41 
7 1.83 1.90 1.97 
8 1.83 1.73 1.74 
9 2.33 1.78 1.85 
10 1.85 1.82 1.78 
Mean 2.14 1.78 2.03 
SD 0.36 0.08 0.27 
RSD (%) 16.82 4.49 13.30 
* Refer to Table 6.2 for full details of the formulations. 
 
It can be seen immediately from Table 6.14 that all of the inserts were significantly 
thicker than the design specification of 1 mm. The values of insert thickness that were 
lower than 2 mm (the width of the gap in the dissolution cell design) are highlighted in 
green while red is used for values equal to or higher than 2 mm. The mean thickness of 
the "Pure" inserts was 2.14 ± 0.36 mm, with a large range of individual values from 
1.70 mm to 2.64 mm. Closer inspection showed that the thickness values seemed to 
fall into two groups, with half of the readings being much higher than 2 mm and the 
other half being much lower than 2 mm. When these two subsets of data are analysed 
separately, the variability within each subset is much lower, with the means, SD and 
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RSD values being 1.80 mm, 0.06 mm and 3.32 % for those inserts thinner than 2mm, 
and 2.47 mm, 0.11 mm and 4.50 % for those inserts thicker than 2 mm, respectively.  
These two subsets of thickness data were shown to be statistically significant (p < 
0.001). 
 
A similar pattern was displayed by the P4K1 inserts. The mean thickness was 2.03 ± 
0.27 mm, with a range of individual values between 1.74 mm and 2.41 mm. Four of the 
readings were much higher than 2 mm and 6 readings were much below 2 mm.  When 
these two subsets of data are analysed separately, the variability within each subset is 
much lower, with the means, SD and RSD values being 1.83 mm, 0.09 mm and 4.97 % 
for those inserts thinner than 2mm, and 2.33 mm, 0.10 mm and 4.31 % for those 
inserts thicker than 2 mm, respectively.  These two subsets of thickness data were also 
shown to be statistically significant (p < 0.001). 
 
Meanwhile, all the P6K1 inserts had thickness readings that were lower than 2 mm, 
with a mean of 1.78 ± 0.08 mm and a range of 1.60 mm to 1.90 mm. The RSD value 
for the thickness of the P6K1 inserts was 4.49 %, similar to the RSD values of the 
subsets of data for the other two formulations discussed above. 
 
If the thickness values of all 10 of the P6K1 inserts are compared to the values of the 
thinner "Pure" and P4K1 inserts, then there is no significant differences (p > 0.1) 
between them. Examination of the weight variability data in Table 6.5 shows that the 
P6K1 inserts are more consistent in weight than the "Pure" or P4K1 inserts, which may 
be related to the variability in the thickness data. Together, this suggests the 3D-
printing process was reasonably well controlled in terms of product thickness, but that 
there was a systematic issue causing some thicker inserts to be printed and an 
underpinning issue that even the "thin" inserts are almost twice as thick as the design 
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specification of 1 mm. This warrants further investigation. 
 
With respect to the dissolution studies on the inserts using the customised dissolution 
cell, since all the P6K1 inserts had thickness values that were less than 2 mm, it would 
be expected that the dissolution medium would be able to flow across the inserts in the 
manner intended and that the "correct" dissolution profile would be obtained. If the 
inserts are greater than 2 mm in thickness, it would be expected that the dissolution 
cell could not be closed. However, such a problem was not identified during the 
dissolution experiments on the "Pure" and P4K1 inserts, possibly in part because the 
inserts are slightly flexible and may have deformed sufficiently to allow the dissolution 
cell components to be screwed together. Additionally, the possibility of choosing for the 
dissolution tests the inserts that were thinner than 2 mm was roughly 50 %, so it is 
possible that all dissolution experiments were conducted on "thin" inserts. 
 
However, based on the drug release profiles, both the "Pure" and P4K1 inserts showed 
slower release rates than the mini-tablets of the same formulations from Chapter 5, 
whereas the P6K1 inserts and mini-tablets gave the same drug release profiles. 
Overall, the error bars for the inserts' dissolution data were small, indicating all 
replicates displayed similar results, suggesting that the inserts studied in each batch 
were of similar thickness. A plausible explanation of why the "Pure" and P4K1 inserts 
behaved differently is these inserts swelled during the dissolution test. To investigate 
this, three inserts from each formulation were chosen randomly. The thickness of the 
inserts was measured with a digital calliper before the test. The inserts then were 
placed into a 20 mL tube sample containing 10 mL of STF and were completely 
submerged. The thickness of the inserts was re-measured after one hour. Table 6.14 
shows the readings for all the inserts. 
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Based on these results, the "Pure" and P4K1 inserts had significantly swollen after one 
hour of soaking, with thickness increments of 14.29 ± 1.46 % and 7.83 ± 1.22 %, 
respectively. However, for P6K1 inserts, a very small percentage increment was 
displayed by only one of the samples, with no change being observed for the other two 
inserts tested. This increment is so small that it is likely to be insignificant 
experimentally. Therefore, even if the "Pure" and P4K1 inserts chosen for the 
dissolution test were thinner than 2 mm, it is likely that they would swell more than 2 
mm within one hour of the dissolution test. This would then result in the insert pushing 
against both the top and bottom of the dissolution cell gap and reducing the flow of 
dissolution fluid across its surfaces, with a consequent decrease in the amount of drug 
that could be dissolved from the inserts. The dissolution profile measured would be 
slower than would normally be expected. As the dissolution chamber used for the mini-
tablets had a volume of 200 µL (equivalent to 200 mm3), and the 3D-printed mini-
tablets had a maximum calculated volume of circa 35 mm3, any swelling during the test 
is unlikely to have a significant effect on the results, such that a "true" dissolution profile 
would be measured. 
 
Table 6.14  The thickness and swelling data of chloramphenicol-loaded 3D-printed 
ocular inserts. 
Inserts Initial (mm) Final (mm) Difference (%) Mean  SD of 
the difference 
(%) 
Pure* 2.42 2.77 14.46 14.29 ± 1.46 
1.98 2.29 15.66 
2.43 2.74 12.76 
P6K1* 1.60 1.60 0.00 0.37 ± 0.64 
1.80 1.82 1.11 
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1.77 1.77 0.00 
P4K1* 1.80 1.95 8.33 7.83 ± 1.22 
2.33 2.48 6.44 
1.95 2.12 8.72 
* Refer to Table 6.2 for full details of the formulations. 
 
 
Taken together, these results provide an explanation of why the dissolution rates for 
both the "Pure" and P4K1 inserts were slower than the mini-tablets from the same 
formulations. Since the P6K1 inserts did not swell and the thickness of the inserts were 
less than 2 mm, a "true" dissolution profile could be obtained. The drug release for the 
inserts and mini-tablets from P6K1 formulation showed identical profiles. Perhaps 
surprisingly, this is to be expected as the surface area to volume ratios are 
approximately the same for the two product types. 
 
6.3.5.4  Content uniformity 
According to BP specifications, the formulations would be considered uniform if not 
more than 1 individual drug content value were outside the limit of 85 to 115 % and 
none outside 70 to 130 % of the average content. However, these specifications were 
for 10 dosages while in this study, only 3 dosages were used. Table 6.15 shows the 
content uniformity for the ocular inserts. All formulations were between 85 and 115 % 
which complied the BP standards. The percentage of drug in the inserts were similar 
with the percentage of drug content in Chapter 5 from the same formulations.  
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Table 6.15  Content uniformity for the ocular inserts. 
Polymer Weight 
(µg) 
(Mean ± 
SD) 
Drug 
content 
(µg) 
Mean 
(µg) 
SD (µg) Drug 
content 
(%) 
Mean 
(%) 
SD (%) 
Pure 481.45 ± 
35.95 
18.53 18.29 0.28 3.85 3.80 0.06 
 18.37   3.82   
 17.98   3.73   
P6K1 506.84 ± 
16.96 
19.54 19.79 0.25 3.86 3.91 0.05 
 20.03   3.95   
 19.81   3.91   
P4K1 578.76 ± 
42.20 
21.40 21.07 0.30 3.70 3.64 0.05 
 20.98   3.62   
 20.83   3.60   
* Refer to Table 6.2 for full details of the formulations. 
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6.4  GENERAL DISCUSSION 
 
In this Chapter, the potential of 3D-printing to manufacture customised ocular inserts 
and corresponding flow-through dissolution cells was investigated. A colleague in the 
UCL School of Pharmacy kindly gave permission for an MRI scan of his head to be 
used as a basis for designing a customised ocular insert specifically for one individual. 
The MRI data were analysed with InVesalius (2016) in order to recreate the shape of 
this individual's eye. Following analysis of the dimensions of the eye, Tinkercad 
software was used to design an ocular insert to match the shape of the eye, the same 
software having been used to design the 3D-printed mini-tablets studied in Chapter 5. 
 
As observed in Chapter 5, it was possible to 3D-print the prototype ocular inserts using 
flexible resin (Formlabs, USA), either with a support or directly onto the platform. Such 
model inserts showed a good correlation to the initial design of the inserts. Three 
formulations based on PEGDA and used to 3D-print mini-tablets in Chapter 5 were 
selected to create the sample ocular inserts for analysis: "Pure", with no added low 
molecular weight PEG, and P6K1 and P4K1, where an equal amount of low molecular 
weight PEG (6000 or 4000) is added to the formulation. It was possible to 3D-print 
these ocular inserts directly onto the platform, i.e. without a support. However, as seen 
with the 3D-printed mini-tablets, the 3D-printed ocular inserts were larger than the initial 
design in all four dimensions (height, width, depth and thickness), with an inconsistent 
effect of varying the formulation on each of these parameters, i.e. the rank order of the 
variation from the design measurement was not the same for each parameter. Of 
particular concern, the thickness of even the thinnest ocular insert was almost twice 
that of the design (1 mm). Interestingly, and perhaps worryingly, the "Pure" and P4K1 
inserts seemed to fall into two groups when the thickness was evaluated, with the 
variability within each group being reasonable, whereas the P6K1 inserts were 
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consistently "thin". 
 
The difference in 3D-printing behaviour of the model and sample inserts in most likely 
due to the fact that the 3D-printer is designed to be used with commercially-available 
(from the same company) resins and all the printing parameters are set up to maximise 
printing efficiency with those materials. The 3D-printer is not optimised to be used with 
the PEGDA-based formulations studied here, and the settings used to 3D-print the 
mini-tablets and inserts were the best possible under the circumstances. This aspect of 
the 3D-printing control needs to be investigated further and improved (or at least 
understood), as it is vital for pharmaceutical products that the final product is identical 
to the design and the products are consistent in appearance and performance. A high 
degree of product variability, such as was seen with the thickness of the inserts, is 
unacceptable pharmaceutically. 
 
A customised flow-through dissolution cell was successfully developed, matching both 
the subject's eye and the ocular insert. Such a dissolution cell was necessary as the 
ocular insert was too large to fit into the dissolution chamber used to assess the drug 
release profile of the mini-tablets in Chapters 3 and 5. This dissolution cell was 
manufactured using the flexible resin (Formlabs, USA) to maximise the efficiency of 
printing. An additional advantage is that this resin is translucent, so it is possible to 
observe the insert in situ once placed in the dissolution cell and to monitor the 
dissolution experiment. 
 
Dissolution studies on the 3D-printed ocular inserts suggested that the drug release 
pattern is governed by the Korsmeyer-Peppas equation, with values of the exponent n 
suggesting "anomalous" diffusion. "Anomalous" kinetics indicate that there is more than 
one factor governing the release of the drug from the product. In the case of the 
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inserts, this is likely to be a combination of diffusion of water into pores within the insert 
matrix to dissolve the drug, dissolution of the low molecular weight PEG from the matrix 
creating more pores, and the continual flow of dissolution medium across the surface of 
the insert. The actual dissolution results were unexpected and further investigation 
suggested that some of the inserts absorbed water during the initial stage of the 
dissolution experiment, swelling to a such a degree that they made contact with both 
the top and bottom surfaces of the dissolution cell, which resulted in lower contact 
between the insert and the dissolution fluid and hence lower total dissolution than 
would be expected. The P6K1 inserts were consistently thinner than the other two 
batches and also did not swell when submerged in STF, leading to a "correct" 
dissolution profile being observed. Overall, the dissolution profile from the P6K1 inserts 
was essentially indistinguishable from that of its counterpart mini-tablets, probably as 
ultimately the surface area to volume ratios are similar for the two product shapes. The 
P4K1 and P6K1 inserts swelled significantly during the 1 hour STF submersion test, so 
even if "thin" inserts were selected for the dissolution test, they would have swollen 
during the test, making the results inconclusive. Hence, it was not surprising that the 
inserts of these two formulations showed different dissolution behaviour to the 
equivalent mini-tablets. 
 
Table 6.16 below summarises whether the 3D-printed ocular inserts would pass the 
initial target specifications presented earlier in this Chapter and whether they would be 
considered for further development. 
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Table 6.16  Summary of the analytical tests of the chloramphenicol-loaded 3D-printed 
ocular inserts in comparison to the initial target values. 
 
Attribute Target Pure P6K1 P4K1 
Drug content 5.0 % w/w No No No 
 Meets BP 
specifications for 
content uniformity 
Yes Yes Yes 
Weight Meets BP 
specifications for 
weight uniformity 
No Yes No 
Dimensions Height Yes No No 
 Width No No Yes 
 Depth Yes No No 
 Thickness 1 mm No No No 
Dissolution 
profile 
Zero order No No No 
5 days release, i.e. 
20 % per day 
   
Development 
potential 
 Possibly Possibly Possibly 
Comments  For all formulations: 
 
Dissolution profile needs to be altered and 
extended 
 
Factors controlling the final drug loading 
need to be investigated (e.g. evaporation 
of water). 
 
Factors controlling the size and shape of 
the product need to be investigated (e.g. 
laser strength). 
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6. 5  CONCLUSIONS 
 
This Chapter used the novel approach of combining MRI scans and 3D-printing to 
design, manufacture and test customised ocular inserts with a matching customised 
flow-through dissolution cell. Overall, it can be concluded that this approach was 
successful, in that both the inserts and the dissolution cell were 3D-printed. Some issues 
were identified, such as the difference in the product's dimensions compared to the 
design specification, which are related to the control of the 3D-printer and choice of 
formulation, and which need to be overcome if this technology is to be developed further 
for pharmaceutical use. 
 
 
  
 
  
 
Chapter 7 
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Overall Discussion, Conclusions and Future Work 
 
7.1  Concluding Remarks 
 
The work in this thesis covers the general area of ocular formulation. In particular, it 
includes a study into some of the manufacture and characterisation issues related to 
"normal", compressed powder mini-tablets. Additionally, the novel approach of 3-D 
printing mini-tablets and customised ocular inserts was investigated, along with the 
development of matching customised dissolution cell. From the data presented in this 
thesis, this novel approach shows promising results although further work is required to 
fully exploit this technology. 
 
The particle size distribution of the powders is significant for the manufacture of tablets 
generally and is especially important for mini-tablets. One initial finding for the 
manufacturing process was that the lowering cam on the tablet press needs to be 
removed when very small tablets are being produced. The lowering cam is a feature on 
the Riva Piccola press and exists to pull down the lower punch slightly after die filling to 
prevent loss of powder from the surface of the die during rotation. However, due to the 
design of the underside of the mini-tablet dies, this can result in loss of powder through 
the small gap between the die and the punch. It is recommended, therefore, that the 
design of very small tablet dies and the presence of a lowering cam on a tablet press are 
considered together when developing a manufacturing process for mini-tablets. 
 
In Chapter 3, the effect of particle size on the physical characteristics of the compressed 
powder mini-tablets and the drug release profiles were investigated. Mini-tablets could 
be manufactured from both particle size distributions of all polymers studied, although 
PVP 90F gave very weak mini-tablets and would not be recommended as the bulk 
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component in a mini-tablet formulation. There were some subtleties in the properties of 
the mini-tablets between the two particle size distributions, such as the crushing strength 
results, but these could probably be manipulated by changing the compression 
parameters - in this study they were kept constant to reduce the number of experimental 
parameters. All mini-tablets showed similarity in the drug release profiles between the 
two sieve fractions except PEO 8M. A direct linear correlation between water sorption 
and drug release profiles was observed once dissolution had commenced.  There were 
some subtle differences at the start of the process between formulations based on the 
different polymers, due to the time required for the polymer to show sufficient levels of 
hydration before the drug release started.  
 
At least 85 % of drug was released within 9 hours of dissolution test except PEO 8M 
125-180 µm, which showed a slower release profile. HPMC, PEG 6K and PVP 90F mini-
tablets were best described either first order kinetics or Korsmeyer-Peppas, since the 
correlation values (r2) were similar. Meanwhile, PEO 8M mini-tablets were best described 
by zero order kinetics.  In conclusion, with the exception of PEG 8M, the particle size 
distribution of the bulk polymer did not seem to have a serious effect on the 
characteristics and behaviour of the mini-tablets, as long as it was kept within the overall 
range of 125 to 250 µm. 
 
The work performed in this chapter examined the role of powder particle size in the 
behaviour of mini-tablet formulations, which has not been explored in the literature 
previously, and has highlighted some areas for consideration for other workers in this 
field in terms of the range of particle sizes recommended to be used for mini-tablet 
development. As the intention was not to fully define one ideal formulation and 
manufacturing process, but to compare how different polymers affected the behaviour of 
the mini-tablets, the specific compaction parameters used were kept constant throughout 
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the study to allow for easier comparison. This has left some room for some improvement 
in the production of specific formulations. Table 3.14 summarised the development 
potential of the formulations studied. Particular areas of concern were the tablet weight 
and by extension the drug content within the mini-tablets, although it has to be noted that 
the majority of mini-tablet batches met the BP specifications for uniformity of weight and 
content (when assessed in comparison to the mean values rather than the target 
values). The dissolution profiles of the PEG 6K-based and PVP-based mini-tablets were 
zero-order as required, but the drug release did not extend for the intended 24 hours.  It 
is possible that experimentation with different (higher) molecular weights of these 
polymers, or a suitable mixture of them, may prolong the release profile and this should 
be investigated further. The HPMC-based formulation probably needs additives in order 
to make it give a zero-order drug release profile. 
 
Examining the correlation between water sorption using DVS and drug release is a novel 
approach to the characterisation of prolonged-release mini-tablets and has not been 
reported in the literature before. This may give some insights into the mechanisms of 
drug release from the various formulations of mini-tablets and is likely to be more 
representative of an in vivo situation as the mini-tablet is stationary in the DVS, as would 
be the case once inserted in to the ocular pocket. This technique may also be a useful 
approach to predicting drug release under different physiological conditions. For 
example, where a patient suffers from dry eye conditions or a reduced generation of tear 
fluid, there may be a prolonged initial hydration period with the HPMC-type mini-tablets 
with no drug release and possibly a slower release rate thereafter, whereas with the 
PEG-type formulations, it may be expected that the delay in the initiation of drug release 
would be shorter or even negligible, although a slower release profile may be seen due 
to the relative lack of tear fluid. This could easily be investigated using the DVS system 
as the humidity of the chamber is easily varied and controlled. Similarly, the correlation 
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between drug release and water sorption profiles may give insights into how a 
formulation may be manipulated to improve the dissolution rate, for example adding pore 
formers (such as NaCl) may be expected to change the behaviour of the HMPC-type 
formulations but not that of the PEG-type formulations. 
 
Following on the irregular results obtained in Transition Temperature Microscopy (TTM) 
in Chapter 3, further study was undertaken in Chapter 4 to assess the ability of TTM to 
cope with surfaces of varying smoothness. Mono-component mini-tablets of three 
different polymers (HPMC, PEG 6K and PVP 90F) with two sieve fractions (125-180 µm 
and 180-250 µm) were prepared by compression. PEG 6K mini-tablets had very smooth 
surfaces as seen on scanning electron microscopy (SEM) images, due to some surface 
melting during the compression process, itself due to the low melting point of PEG 6K 
(circa 60 C). The TTM images for PEG 6K mini-tablets were consistent, with a sensible 
value for the melting point being observed. Mini-tablets of HPMC and PVP 90F showed 
rough surfaces and inconsistent TTM data, with a range of transition temperatures being 
displayed.  
 
These inconsistent results are thought to be due to inconsistent contact of the probe with 
the sample's surface. If the probe makes contact directly with a particle, the results are 
reliable. If, however, the probe lands on the edge of a particle or in the gap between 
particles, the results are inconsistent. This is compounded by the software applying a 
variable analysis to such data. It is recommended that all probe deflection graphs are 
examined individually in a TTM map, rather than relying on the software to provide the 
interpretation of the results. It is also recommended that the surface of the sample be 
examined closely before a TTM mapping experiment is started, to ensure that 
measurement is viable. Unfortunately, with the current experimental set-up, it is not 
possible to generate a topology map of the sample before acquiring the transition map, 
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although this would be the obvious solution to this problem, allowing the probe to be 
positioned during on a particle rather than at its edge or in a gap between particles. This 
investigation was undertaken to attempt to explain the unexpected results from the initial 
TTM studies in Chapter 2 and to continue the work conducted in the research group on 
the utility of the TTM technique for complex pharmaceutical systems. The overall aim of 
the development work on TTM is to allow it to be applied to sample surfaces, generating 
extra information that cannot easily be obtained from the analysis of whole samples, 
such as whether there is a surface excess of any specific component or in which 
physical state a material exists. This information is complementary to that obtained from 
the whole tablet, averaging studies and may help interpret dissolution and stability data. 
 
Unconventional methods of manufacturing mini-tablets using 3D-printing techniques 
were studied in Chapter 5. The first attempt of manufacturing 3D-printed mini-tablets 
was by combining hot melt extrusion (HME) with fused deposition modelling (FDM) 3D-
printing, as a polymer-based filament (acquired from the HME) is required for the FDM 
process to work. Attempts were made to extrude HPMC, PEG 6K, PEO 8M and PVP 
90F based on their transition temperatures. However, only PEG 6K was able to be 
extruded. The attempts to integrate PEG 6K in other polymers as a plasticiser showed 
minimal success with PEO 8M, but no success with HPMC and PVP 90F. Due to 
unsuccessful extrusion of the desired polymers except PEG 6K, the idea of using 
extrudates to 3D print the mini-tablets cannot be executed and hence this approach was 
abandoned. This work was conducted with the intention of expanding the range of 
polymers demonstrated to be useable for FDM printing, as only a very limited range of 
polymers have been used in the past, most studies utilising PLGA as the carrier polymer 
due to its suitable melting and setting properties. The polymers studied in this work were 
all pharmaceutically acceptable and have been used for many years in a range of 
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pharmaceutical products. However, as demonstrated here, this was not possible with 
these specific polymers and further materials should be investigated for their potential. 
 
The alternative approach of stereolithography (SLA) was investigated, whereby a 
photopolymerisation process is used to "cure" a monomer solution into a polymer which 
can take on and maintain a pre-designed 3D shape. The photopolymer used here was 
PEGDA, as it has been used successfully previously, albeit for non-pharmaceutical use. 
Initially, the use of a casting mould to provide the 3D shape was investigated. Mini-
tablets moulds were designed using Tinkercad software based on the mini-tablets shape 
from Chapter 3 and 3D-printed using an SLA printer and used to cast the mini-tablets. 
Unfortunately, this approach was not successfully, as the light-induced curing process for 
the mini-tablets resulted in the moulds and mini-tablets being glued together. 
 
The photopolymer was then printed directly on the platform using SLA printer. The 
printing settings were optimised along with the photopolymer formulations. The final 
settings were set to print the mini-tablets directly on the platform without support and 
using flexible as material type at the highest resolution. The mini-tablets formulations 
were based on PEGDA as photopolymer, BAPO as photoinitiator and chloramphenicol 
as a model drug with addition of PEG 6K, PEG 4K and/or water. Based on the physical 
characterisations, the mini-tablets showed quite substantial differences in their physical 
dimensions and weight in which only three of the six batches passing the BP weight 
uniformity specification. The drug release profiles indicated that the mini-tablets better fit 
either first order kinetics or Korsmeyer-Peppas equation. In the latter case, the release 
exponent (n) indicated that the release profile was "anomalous". Addition of the low 
molecular weight PEGs as pore formers increased the drug dissolution rate from the 3D-
printed mini-tablets. The linear relationship between water vapour uptake and drug 
Chapter 7 
 
293 
 
release suggests that movement of water and hydration of the mini-tablet is important in 
controlling the drug release pattern. 
 
The implications of the work presented in Chapter 5 are that the novel approach of using 
SLA 3D-printing of mini-tablets has potential, but there are several areas which require 
further investigation. Table 5.13 summarises the performance of the 3D-printed mini-
tablets against the pre-determined performance indicators.  As can be seen, the product 
did not behave quite as intended.  The variability in the physical characteristics of the 
3D-printed mini-tablets such as weight, thickness and diameter, are concerning, as these 
will result in differences in drug loading and hence therapeutic effect, and also potentially 
the drug release profile. This variability was seen both between formulations and, more 
worryingly, within a batch of the same formulation. The most likely cause of this is the 
printing settings used, which are optimised for the use of commercial resins, rather than 
the photopolymer used here, so this is an area of obvious future work. However, even if 
the print settings are not completely optimised, it would be expected that the 
reproducibility of the product, especially within a batch, would be better than was 
observed. There is probably a lower "limit of production" in terms of the size of an article 
that can be printed reproducibly using the SLA 3D-printing technique and it is likely that 
the 2 mm diameter and thickness mini-tablets are below this lower limit of production 
leading to the variability seen in mini-tablet dimensions and hence weight and drug 
content. It is worth noting at this point that the vast majority of 3D-printing activities 
reported in both scientific studies and more artistic-based studies concern larger 
structures, and not small products the size of mini-tablets. There are no published 
studies (September 2016, Web of Science) on 3D-printing of mini-tablets. The factors 
governing the deposition of the material at each layering stage need to fully understood 
in order to assess whether this SLA method really is appropriate for the production of 
mini-tablets. 
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The drug release profile from the 3D-printed mini-tablets was interesting in that the 
"pure" formulation, i.e. the one that contained only the structuring polymer and not the 
pore formers, showed a maximum drug release of approximately 47 % and appeared to 
reach a plateau after about 6 hours. Conversely, the formulations with the pore formers 
showed much higher drug release, which was still ongoing when the experiment was 
terminated after 9 hours. The data for the "pure" formulation were unexpected in that full 
drug dissolution would be expected over time, even if the profile was very slow, rather 
than the obvious plateauing that was observed here. This suggests that the internal 
micro-structure of the mini-tablet is controlling the movement of the water into the mini-
tablet and the drug (in solution) out of the mini-tablet. In these experiments, 
approximately half of the drug was being retained within the tablet matrix, suggesting 
that there was some impedance to the movement of the water into the mini-tablet.  
Factors such as pore size and pore tortuosity need to be investigated further to fully 
understand this process, and additional experimental investigations as to whether there 
is indeed a dry part of the mini-tablet during the dissolution process need to be 
undertaken. 
 
A limited number of experimental variables were explored in this work and it would be 
useful in future to extend this work to include different pore formers and different drugs, if 
the same structuring polymer system is used and to try to improve the intra-batch 
reproducibility and to understand the factors that affect that process. One major issue is 
the use of the PEGDA / BAPO system. This was chosed deliberately as it has been used 
in the literature for SLA 3D-printing and this was a proof-of-principle investigation into 
whether it is possible to 3D-print mini-tablets. The concept was proven to be sound, in 
that recognisable mini-tablets were produced, which showed some pharmaceutical 
functionality.  However, PEGDA is not biodegradable so would not be suitable for use in 
a real-life situation, as the mini-tablet ghost would need to be removed at the end of its 
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therapeutic life.  An immediate need to take the field further is to develop a photo-
polymerisable biodegradable polymer which can then be used to provide the mechanical 
construct for the mini-tablets. Similarly, the BAPO used here as a photo-polymerisation 
photo-initiator should be replaced with a more biocompatible compound. If a suitable 
polymer and initiator system can be developed, then there is great potential for the use 
of 3D-printed mini-tablets, both for ocular use and more general pharmaceutical use, if 
the reproducibility issues discussed earlier are overcome. 
 
Chapter 6 extended the study from Chapter 5 by developing customised ocular inserts 
based on an individual subject's eye. The dimensions of subject's eye were measured 
based on an MRI image supplied with permission by the subject. Inserts, similar to 
scleral shields, were designed using Tinkercad software based on these dimensions to 
specifically cover approximately 1/8th of the external surface of the eye. This use of an 
MRI scan to develop a customised 3D-printed pharmaceutical product is a really exciting 
development in personal therapy and has many potential applications other than the one 
explored here. To date, there have been no literature reports (September 2016, Web of 
Science) on using MRI scans in this manner. The actual process of analysing the MRI 
data files and generating the image to be printed is relatively straightforward and uses 
freely-available software. 
 
Three formulations ("Pure", P6K1 and P4K1) from Chapter 5 were 3D-printed into 
inserts using an SLA printer based on settings used in that chapter. Table 6.16 
summarises the performance of the 3D-printed ocular inserts against the pre-determined 
performance indicators. All the 3D-printed ocular inserts showed dimensions that were 
larger than the initial design with an inconsistent effect of varying the formulation on each 
of the parameters. Again, this is most probably because the 3D printer is designed for 
commercially-available resins rather than the photopolymer and formulations used here 
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and again suggests that this is an area for further work. As discussed before with the 3D-
printed mini-tablets, this issue of consistency of printing requires further work before the 
technology can be fully developed towards a useful pharmaceutical product.  
Additionally, the biocompatibility of the polymer and initiator needs to be improved. 
However, if a biodegradable polymer is developed, this is likely to have an effect on the 
rate and extent of drug release and this would need extensive investigation. 
 
Since the flow-through dissolution apparatus used in Chapters 3 and 5 could not be 
used here due to the inserts' shape and size, a customised dissolution cell was designed 
based specifically on the subject's eye shape and individualised insert shape. This was 
relatively easy to design and 3D-print. Using the customised dissolution cell and the 
same control parameters as in Chapter 3 and 5 (flow rate, dissolution fluid, etc.) the 
dissolution profile of the inserts was studied over 96 hours. During the dissolution 
process, it became apparent that the inserts swelled during the test. This swelling was 
compounded by the fact that the inserts were thicker than the design, so after swelling 
they contacted both surfaces of the dissolution cell resulting in unusually slow dissolution 
profiles being generated. The dissolution profiles of each inserts fit better with 
Korsmeyer-Peppas equation, with values of the exponent n suggesting "anomalous" 
diffusion. 3D-printed mini-tablets and inserts prepared from the P6K1 formulation 
showed identical profiles, whereas the inserts made from the "Pure" and P4K1 
formulation showed slower profiles than the 3D-printed mini-tablet counterparts, but this 
is probably a consequence of the swelling behaviour of the inserts in the dissolution cell. 
 
The use of the individual's MRI scan to develop firstly a personalised drug delivery 
device and secondly a matching personalised dissolution chamber is very exciting and 
has not been reported before. Typically, drug release profiles from solid ocular 
formulations are obtained using a flow-through cell similar to that described in the BP 
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2016 as Apparatus IV. The BP 2016 method, however, is a general method applicable to 
all solid products and the volume of the cell is in the order of 8 mL with a minimum flow 
rate of the dissolution fluid of 4 mL/minute.  This is not very representative of the in vivo 
ocular situation, so systems based on Apparatus IV but with smaller chambers and lower 
flow rates have been used, such as the one used here in Chapters 3 and 5 for the mini-
tablets (courtesy of Professor Steve Brocchini). Additionally, Hou et al. (2014) have 
developed a system for use with intra-vitreal inserts based on the volume of the vitreous 
humour and the vitreal fluid turnover rate in rabbits.  Awwad et al. (2015) have proposed 
a novel two compartment system which also considers the flow of fluid from the posterior 
section of the eye to the anterior section and have suggested that this may be used to 
aid in initial drug pharmacokinetic studies. Such systems give a reasonably good first-
line approach to the in vivo case for both anterior segment application of a small 
medicated product (e.g. mini-tablets) and in-dwelling posterior segment products (e.g. 
small inserts), as in both cases the pharmaceutical product is essentially stationary but 
surrounded by ocular fluid and with only limited fluid flow across its surface. However, 
none of these systems are suitable for assessing the drug release behaviour of larger in-
dwelling products such as the ocular inserts resembling scleral shields produced in this 
work, as there are too large to fit into the dissolution chambers. Additionally, in the in vivo 
situation, these inserts would have limited room for movement or for fluid to flow across 
their surfaces, so simply covering the insert with an appropriate dissolution medium, as 
has been used in the past for the study of medicated contact lenses, would not be a 
good method.  Hence, the 3D-printed personalised dissolution chamber used here is a 
step forward in the development of rationally-designed dissolution methodology. More 
work is obviously required to fully validate this approach, including examining a range of 
products of different dimensions, loaded with various drugs and varying the flow rate of 
the dissolution medium. Ultimately, comparisons to in vivo release studies would be 
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required to fully establish this type of system as a tool to be used in routine product 
development. 
 
Overall, the work presented in Chapter 6 suggest that there is great potential for the use 
of 3D-printed personalised pharmaceutical products. Here, ocular inserts were studied 
based on the MRI image of an individual subject, but the same approach could be taken 
for any device where personalisation would be useful. Additionally, the MRI images were 
used to design an individualised dissolution cell for use with the customised ocular 
inserts and constructed using 3D-printing techniques. Again, the same approach could 
be taken to the development of customised analytical equipment for all devices. 
 
However, there are some drawbacks to the 3D-printing approaches. FDM requires a 
filament to be produced initially, which reduces the number and type of polymers that 
can be used to prepare the final product. The SLA approach is useful but requires much 
further study into the control systems used to ensure that the correct product is made 
reproducibly. Small changes in product dimensions may not be serious in some 
applications, but pharmaceutical products have very tight specifications and a 
requirement for high consistency, and hence the level of reproducibility seen here is not 
sufficient. PEGDA and BAPO are not the most pharmaceutically-acceptable 
photopolymer and photoinitiator, so an area of future work would be to develop more 
pharmaceutically-acceptable compounds. 
 
Summarising as a whole the work presented in this thesis, it can be concluded that mini-
tablets are more easily produced using conventional tabletting technology rather than the 
SLA 3D-printing technique, as the compressed powder mini-tablets were more uniform 
and reproducible than the 3D-printing ones. However, conventional tabletting has been 
used for several decades whereas 3D-printing is still in its infancy and there is a lot of 
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development work required.  This thesis has highlighted that precision 3D-printing is 
challenging and that there may very well be a lower limit of size of product or detail that 
can be printed using the SLA technique.  Even using the FDM technique to prepare the 
customised dissolution cell highlighted some issues in terms of how the molten material 
spread during deposition, leading to the same concerns about precision. 
 
The most original part of the thesis was the use of the MRI head scan to allow the 
development of a personalised ocular insert (scleral shield) and matching customised 
dissolution chamber.  This work demonstrated that this was indeed possible with easily 
available software and equipment and opens the way to future developments in this 
area. 
 
7.2  Future Work 
 
Based on the studies conducted in this thesis, some areas that would benefit from further 
investigation are listed below.  
 
1.  The TTM technique could be developed by investigating how the probe penetrates 
through gaps in a sample's surface and what effect this has on the results generated. 
The hypothesis behind this is that the results obtained in Chapter 4 could be 
explained if the probe did not make adequate contact with the samples' surface.  A 
TTM based on larger probes would be useful as well, as this may help in eliminating 
the variability inherent in using the nano probes on uneven surfaces, as it would be 
expected to be less sensitive to particle and gap dimensions. Here the rationale is 
that a larger probe would lead to more "averaging" of the measured results, albeit still 
on a sub-micron level.  Ultimately, for TTM to be useful as an analytical technique, 
the results need to be reliable and accurate.  If so, TTM can give a measure of the 
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drug and excipients distribution across the sample's surface. Taken together with the 
bulk analytical content uniformity and dissolution results, this could help understand a 
product's performance, particularly for systems which have a high surface area to 
volume ratio such as mini-tablets. 
 
2. The quality of 3D-printed samples printed using the SLA printer needs to be 
improved, in terms of the closeness of the match to the original design and the 
reproducibility within and between batches. An intensive study on the 3D-printer 
settings for each individual formulation may help elucidate the level of control 
possible with the current commercial printers. Improving the understanding of the 
factors controlling the 3D-printing process will lead to better products and may help in 
the rational design of SLA 3D-printed products, e.g. by reducing the amount of fine 
detail needed on a product. 
 
3. Further studies into how to control the drug release behaviour of the 3D-printed 
products with alternative additives would be useful. Ideally, a slower and more zero-
order release rate would be required for treatment with a non-biodegradable drug 
delivery device, such as the mini-tablets. The hypothesis here is that the water-
soluble pore formers will dissolve from the insoluble matrix, leading to ingress of 
water and hence drug dissolution. Varying the levels of these pore formers will allow 
different release rates to be designed. 
 
4. A biodegradable drug delivery device would be ideal and would require the patient 
only to insert it and not to have to remove it at the end of its useful life. A 
biodegradable and biocompatible photo-polymer and photo-initiator would both be 
required to make a fully biodegradable drug delivery device.  Such chemical, if 
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developed, would need to be tested for general and ocular toxicity before being used 
in a clinical situation. 
 
5. An investigation into patient perspectives regarding ocular treatments in general and 
mini-tablets and inserts in particular would be required.  Most of the published work 
on ocular therapy has considered the technical aspects, rather than the patient 
aspects, and it is well known that people are squeamish about their eyes, so may be 
less willing to accept novel ocular devices than novel systems intended for other 
routes of administration. Patients' opinions on the shape, size and feel of the 
samples as well as their general willing ness to use them would be very useful in 
taking this field further. 
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